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Cystic fibrosis (CF) is a highly prevalent autosomal recessive disorder caused by mutations in
the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The main phenotype
of clinical significance is the development of chronic lung infections which is the cause of
morbidity and mortality in 95% of patients. The processes by which CF lung disease occurs
are however, poorly understood.
In the last 5 years there has been considerable interest in gene therapy as a form of treatment
for CF. Gene therapy is a method of therapeutic intervention in which a functional copy of a
gene is inserted into a cell to replace or complement a non-functional gene. One area of
growing importance in this field is that of the kinetics of target tissues; in the case of CF
gene therapy, the lung epithelium. By understanding the kinetics of the lung epithelium more
efficient methods of gene therapy can be envisaged, especially if epithelial progenitor cells or
cells expressing CFTR could be targeted.
This thesis aimed to investigate the cellular kinetics of the trachea including that of the
submucosal glands. Submucosal glands produce mucus and antimicrobial agents onto the
epithelial surface and are thought to be implicated in the occurrence of the abnormal mucus
and pathology, which are characteristics of the CF lung. In addition, this thesis aimed to
explore methods of liposome somatic gene therapy, which may prove, in the future, to be
useful in the targeting of progenitor cell populations.
The suitability of the mouse to act as the animal model for these studies was examined. The
mouse showed high similarity to the human with respect to pulmonary pathology and
anatomy implicated in CF pathophysiology. This included epithelial cell types and the
structure and functionality of submucosal glands. Some differences were also observed
including epithelial cell type frequency and a restricted submucosal gland distribution.
v
The spatial distribution of murine submucosal glands was found to be significantly affected
by both genetic background and cftr expression. These data suggested that cftr may play a
developmental role and that genes which act as modifiers of submucosal gland distribution
may exist. This study led to the development of a model which outlined a possible misnomer
in the traditional interpretation of single point electrophysiology measurements as a means to
measuring CF phenotype in the mouse.
Submucosal glands were found to be the major site of cftr expression in the mouse trachea
(an observation similar to that previously reported in humans). Reduced cftr expression in
this region may have the consequence of raising chloride concentrations in the airway surface
fluid. In this thesis, data are presented showing that both the human and mouse homologue of
the p-defensin-1 peptide shows a selective salt dependent antimicrobial activity. This may in
part explain the higher susceptibility to colonisation by certain bacteria in the CF lung.
In the search for possible progenitor cell populations in the mouse trachea, studies were
conducted into the development of the submucosal glands and the kinetics of the tracheal
epithelium in steady state and after damage. Through the study of aggregation chimaeric
mice, evidence is presented to suggest that mouse submucosal glands are clonally derived
from a single progenitor cell.
In the mouse tracheal epithelium, basal cells were found to be the epithelial cell type with
greatest proliferative capacity. Furthermore, a discrete niche of cells exhibiting stem cell
characteristics were found in the submucosal gland ciliated duct. These cells were observed
to be proliferative in times of stress to produce migratory transit amplifying cells which act to
repopulate and maintain the local epithelium.
Experiments were conducted using liposome mediated gene therapy to approach the issue of
targeting the tracheal progenitor cell populations. Although positive results for tissue
transfection were obtained, the levels were disappointingly low.
This thesis concludes that firstly, the mouse provides a useful animal model in which to study
human tracheal kinetics and secondly, cells of high proliferative capacity displaying stem cell
characteristics exist in the tracheal epithelium. The targeting of these progenitor cells may be
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A Short Guide for the Reader
This thesis investigates the kinetics of the tissues of the mouse trachea and begins to
explore possible means by which progenitor cell populations could be targeted for
phenotypic correction by gene therapy.
At this time, the technology of aerosolised somatic gene therapy, as a method of
treatment of the lung phenotypes associated with cystic fibrosis, is still in its infancy.
Yet even once the technology is improved so that it can be marketed as a useful
therapeutic drug, this particular strategy of therapy may still be considered imperfect.
Due to the steady turnover of cells in the lung such treatment would require frequent
dose delivery and furthermore, pulmonary tissues considered to be important in the
development of CF lung disease may not be accessible to aerosolised methods of
gene therapy delivery.
The submucosal glands are the prime example for this argument. There are many
pieces of albeit circumstantial evidence which links these glands with the
development of the abnormal pathology observed in CF patients yet their complex
structure, and mucus efflux makes them inaccessible to aerosolised gene therapy
drugs. One way to overcome these issues (and indeed, the aim of this thesis) is to
target pulmonary progenitor cell populations. Genotypic correction of these cells
could perhaps lead to the correction of cell types beyond those accessible by current
aerosolisation techniques and reduce the requirement for frequent dosing.
A considerable amount of data has been published concerning the kinetics of the
smaller airway epithelium and the alveoli. The method by which cellular renewal and
repair occurs in the larger airways is still unclear. Therefore, this thesis focused on
two different, though structurally connected, tissues: the tracheal epithelium and
submucosal glands.
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The mouse was chosen as a candidate for use as the animal model for this research
primarily for the in-house expertise concerning this animal and the availability of the
many different transgenically produced mice which are deficient in the normal
expression of the CF gene.
In particular, the biology of murine submucosal glands, with their strong link with
the development of CF lung disease in humans was examined. This work is
presented in chapter 2. Chapter 3 extends and broadens this work by investigating
variation in submucosal gland biology and distribution in mice of varying genotype
and genetic background.
Chapter 4 examines the currently popular theory of P-defensin inactivation. This
theory describes the presence of abnormal pulmonary secretions arising from the
submucosal glands. This leads to the inactivation of one of the many anti-microbial
proteins present in the human and mouse lung and may explain (in part at least) why
the CF lung is more susceptible to bacterial colonisation than non-CF lungs.
The submucosal gland story is continued in chapter 5 but with an eye towards the
developmental kinetics of the gland. These experiments aim to explain the
developmental kinetics of the submucosal glands with view to identifying and
developing systems by which progenitor cell populations could be corrected by gene
therapy.
Chapter 6 leaves the world of submucosal glands briefly and is involved in the
current methods for gene therapy delivery to the mature mouse trachea. Chapter 7
returns to the big question of whether there are progenitor cell populations in the
tissues of the trachea? If there are, in what direction should research continue to
fulfil the original aim of targeting these cells for gene therapy correction?
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Each chapter is preceded with an introduction that describes the pertinent research
and conclusions in the particular field and also describes the specific experimental
aims of the studies undertaken. To begin with, however, a general introduction to
CF.
Historical Perspectives of Cystic Fibrosis
Prior to the 1930's it was not known why children who had died of lung disease also
commonly presented with intestinal blockages and fibrosis of the pancreatic acini.
However, since its original classification (and naming as a consequence ofpancreatic
pathology) by Dorothy Anderson in the late 1930's (Anderson, 1938) much has been
learnt about cystic fibrosis (CF). By the end of the 1940's, CF was known to be was
caused by the inheritance of two copies of a dysfunctional gene but it was not until
1989 that the CF gene, the Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR), was identified (Riordan, 1989). CFTR is a chloride channel, which
primarily operates in regulating the ionic composition of cellular secretions and the
cell's neighbouring environment. When CFTR does not function normally, the
disease CF occurs and a wide range of tissues are affected. The complications that
arise lead, most commonly, to the death of the individual by pulmonary failure at a
median age of 29 years.
The chances of a cystic fibrosis patient being born to white parents in the UK are
about 1 in 2000. In Black populations, this figure is approximately 1 in 17000 and in
Oriental populations about 1 in 90000 (Stern, 1986). CF is caused by the inheritance
of two copies of a recessive mutation of the CFTR gene. Thus, the frequency of 1 in
22 Caucasians in the UK being "carriers" (heterozygous) of a CFTR mutation puts
CF into the unwanted position of the most common autosomal recessive disorder in
Northern Europe. The high prevalence of the disease if reflected in the number of CF
researchers, scientists and clinicians. CF patients would perhaps be comforted to
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know that the ratio of US CF patients to delegates at the 1997 North American CF
Conference was approximately 30:1.
Improving techniques for the care of CF patients and the treatment of their symptoms
has led to an incredible increase in the median survival age of CF patients from
about 1 year in 1938 to 12 years in 1970 and 29 years in 1998 (Davis, 1996). As this
survival curve altered its position, the patients' requirements for the care and
treatment have also changed. Care of CF patients has grown beyond the exclusively
speciality of paediatric doctors into the requirement of practical care and support for
adult patients.
Although CF diagnosis is now possible through molecular identification of CFTR
mutations in the new-bom patient, diagnosis still occurs most commonly through
more traditional means. The clinical features go to make the classic CF "diagnostic
triad" are a high chloride concentration in the sweat (as determined by Gibson and
Coke's method from the 1940's (Gibson and Coke, 1959)), chronic pulmonary
disease of appropriate character and/or pancreatic insufficiency and/or a sibling or
first cousin with CF (Davis, 1984).
There can be considerable variation in the symptoms presented. About 80% of CF
patients present with pancreatic insufficiency although nearly all present with
abnormal chloride concentrations in the sweat. It is estimated that only about 0.1%
of patients with typical CF lung disease have normal sweat chloride concentrations
(Davis, 1980).However when the complete triad is present, CF exists as a unique
disease.
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The Search For The CF Gene
The discovery of the gene whose dysfunction causes CF was only made possible
through the development of a technique called "positional cloning". This technique
is based on chromosomal position of the gene rather than knowledge of the defective
protein. This technique was especially useful since searches for chromosomal
alterations in CF patients (which would have provided some structure to the hunt)
proved unsuccessful. Linkage studies took the search onto Chromosome 7 and then
further to the region of 7cen-q22 (White, 1985). CpG islands were used as markers
to reduce the search site and to enable the methods of "chromosome walking" and
"chromosome jumping" to be used. These provide the means for covering large areas
of a candidate region for markers. The Riordan group eventually identified the CF
locus and found a gene which was evolutionary conserved between several
mammalian species (Riordan, 1989). This gene was able to fulfil the three key
criteria for the "CF" gene: firstly, its locus is situated on the correct chromosomal
region; secondly, the expression pattern was found to be consistent with the tissues
affected in the disease and thirdly, a mutation in this gene was found that only occurs
in CF patients (Rommens, 1989). As a consequence of preliminary cDNA data (and
not for ease of acronym pronunciation) the gene was called the Cystic Fibrosis
Transmembrane Conductance Regulator gene (CFTR). The CFTR gene is composed
27 exons encompasses about 250 kilobases of DNA in addition to the CFTR
promoter region of which little is understood (Vuillaumier, 1997, Verlingue, 1998,
Denamur and Chehab, 1995).
The Mutations Of CFTR
At this time over 800 different mutations in CFTR have been identified. Of these,
one mutation stands out from the rest as a result of its high prevalence. The AF508
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mutation is caused by a 3 pair deletion of a phenyalanine codon on exon 10. Over
68% of CF patients have this mutation (Kerem, 1989, Tsui, 1992). The remaining
mutations represent the complete range of possible genetic mutations although
appear to be more highly localised to particular genomic regions including the two
nucleotide binding domains. Furthermore, these mutations occur in the regions
conserved across species suggesting evolutionary functional homology.
The different mutations bring about dysfunction of CFTR activity in a number of
different ways and a corresponding selection of severity of phenotype. Mutations in
CFTR can be categorised as those resulting in :
1: Defective CFTR translation: unstable CFTR mRNA (usually caused by the
presence of new stop codons) is produced which results in the production of
shortened protein which quickly degrades in the cytoplasm.
2: Alternate splice sites: stable but shortened mRNA leading to the production of
shortened protein
3: Defective post translation processing of CFTR: CFTR protein is produced but is
not properly glycosylated and as a consequence is not correctly localised in the
apical membrane. However, often the CFTR is potentially functional if only it could
reach the membrane. Such is the case in AF508 (Cheng, 1990). By reducing the
temperature of AF508 expressing cells in vitro, some normal CFTR activity can be
rescued (Drumm, 1991). This finding has led to considerable amount of research
which aims to correctly localise AF508 CFTR as a means of therapeutic correction.
4: Defective ion channel activity: CFTR is correctly localised to the apical
membrane but does not function correctly. Mutations resulting in only partial
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reduction of CFTR activity are often of this class and are associated with mild CF
phenotypes as those who will not go to develop fatal lung disease.
Prenatal and postnatal screening
The discovery of the CF gene opened the doors for the development of genetic
screening for CF offering informed reproductive decisions to be made by those at
risk. With the possibility of prenatal diagnosis, parents would have the knowledge to
prepare for having a CF child or infact, give them the right to terminate that
pregnancy. Additionally, the screening of new born babies could result in treatments
starting sooner, leading to improved health.
It is now possible to test for CF at the pre-implantation stage. Although this
technique carries with it great financial costs as well as only a 10% success rate for
implantation, it can provide parents with the opportunity to choose against having a
CF child without the ordeal of a possible termination later in term. At this time, the
procedure of pre-implantation selection is not in general practice (Davis, 1996).
It should be noted that the high number of possible CFTR mutations increases the
complexities of screening. Screening is most commonly conducted using PCR for
specific mutations so some degree of rationalisation must take place as it would be
both costly and inefficient to test for all 800+ mutations (see
http://www.uwcm.ac.uk/uwcm/mg/search/120584.html). What most commonly
occurs is that an individual is screened for the 5 most common mutations affecting
individuals from that particular ethnic background. Such tests have an accuracy level
of around 98%. High as this may seem, it also means that about 1 in 50 screens
results in false results. This accuracy level is further decreased in multi-racial
communities in which the frequencies of CFTR mutations are unknown. It is hoped
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that with the advent of the DNA-chip that all possible mutations could be screened
for and thereby increase the accuracy of such tests.
Heterozygote Advantage And Population Genetics
CF is highly prevalent in Caucasian populations and less so in African or Asian
populations. In such genetic scenarios the question often posed is,"Why is there such
a high frequency of a gene which when inherited homozygously causes a fatal
condition?". Basic evolutionary arguments point the finger at there being a personal
selectable advantage in being a heterozygote ("carrier"). Sickle Cell anaemia is the
classic example of such a scenario in which heterozygotes have a reduced
susceptibility to malarial infection whilst homozygotes suffer a potentially from
potentially lethal anaemia.
Numerous arguments of such structure have been made for CF carriers. It has been
suggested that CF carriers have a resistance to the effects of diarrhoea, of asthma, of
salmonella infection and even breast cancer. Of these choices, there is most evidence
to support the diarrhoea argument. In a study into this theory, cholera toxin was
administered to "CF" mice (mice with reduced cftr expression), CF heterozygous
mice and wildtype mice and the chloride and water secretions from the gut
epithelium measured. Mice lacking cftr protein did not secrete fluid in response to
this stimulus but heterozygotes secreted about 50% of the normal fluid and chloride
ion (Gabriel, 1994). This finding is in contrast with the study by the Cuthbert group
(1995) who examined the hypothesis by measuring electrogenic chloride secretion in
gut epithelia of normal and heterozygous CF mice. They found no evidence to
support the genetic advantage hypothesis in ileal or colonic epithelia of the null CF
mouse has been found, at least for acute responses. The Gabriel model is surprising
as CF acts as a recessive condition. This reduction in fluid loss, it is argued, may
protect them from death from cholera. It is therefore surprising that there is not a
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proportional link between CF prevalence in certain ethnic groups and the history of
cholera.
Does the high prevalence of these mutations and in particular AF508 provide
pointers, in any way, towards the historical origins of CF? By just taking AF508 as
the model, it is possible to generate a map of AF508 frequency through Europe (The
CF Consortium, 1990). The results is a map resembling a gradient of frequency from
low values (30%) in the Southeast rising to higher values (88%) in the Northwest.
The pattern suggests that the spread of the CF gene may have accompanied the early
migrating farmers from the Middle East and the diffusion of the gene being favoured
by whatever selective advantage exists.
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CFTR Is A Chloride Channel: The Biochemistry Of CFTR
The CFTR gene encodes a protein ion channel which functions in controlling the
passage of chloride ions through the membranes of epithelial cells. In order for
CFTR to exist as a channel which is both selective for chloride ions and which is
also regulatory, a number of distinct protein domains must exist. Indeed, on the basis
of amino acid sequence, CFTR was predicted to be composed of two membrane
spanning domains (called TM1 and TM2) which are each composed of 6
transmembrane segments. Each domain is associated with a nucleotide binding
domains (NBD-1 and NBD-2). See figure 1.0.1. In addition, CFTR protein contains a
intracellular hydrophilic regulatory or "R" domain.
The structure of CFTR is similar to members of the ABC (ATP-binding cassette)
family of proteins. Family members are found to be highly conserved through
evolution acting in the transportation of a wide variety of compounds (Davis, 1996).
One significant difference in CFTR is that other ABC proteins lack the R domain.
The similarities between CFTR and the ABC family suggested to researchers that
CFTR may also resemble members of this family structurally and also in behaviour.
The first, sixth and twelfth transmembrane segments have been identified as forming
the core of the channel (Anderson, 1991). The regulation of CFTR activity is
regulated by means of the two NBD domains and the "R" domain. CFTR channels in
a membrane patch open in response to applications of PKA and ATP to the
intracellular side. The NBD-1 domains act as the lock through which hydrolysis of
ATP can open the CFTR channel (Anderson, 1991). However, the "lock" will only
work if the "R" domain is sufficiently phosphorylated by PKA. Deletion of the R
domain renders the channel unable to close (Rich, 1991) and the addition of excess
un-phosphorylated R domain peptides to the intracellular side of the channel results
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in the closure of the channel (Ma, 1996). The process of closing the channel is
regulated by hydrolysis of ATP at NBD-2 and the de-phosphorylation of the R
domain.
It is important to comment that CFTR may have other roles beyond the channelling
of chloride ions. CFTR is likely to also transport ATP, water and possibly small
solutes (Reisin, 1994). The implications of this may be far reaching as the
extracellular transportation of ATP stimulates the activity of another channel called
the Outwardly Rectifying Chloride Channel (ORCC) which has many of the
physiological properties of CFTR (Egan, 1992). The observation of increased
sodium reabsorption in the CF airways led to the discovery of the Epithelial Sodium
Channel (ENaC)(Stutts, 1995). When CFTR was expressed in vitro, ENaC channel
activity is reduced and its regulation by cAMP is altered from stimulation in the
absence of CFTR to inhibition in its presence. These finding have been found to
have profound implications on the understanding of electrophysiology data and in
therapeutic concepts for the treatment of CF. It is therefore puzzling that when the
defective CFTR is replaced through methods of gene therapy in CF tissues that the
sodium defect is not corrected (Boucher, 1996). Furthermore in diseases associated
with defective ENaC expression, abnormal mucus rheology is noted without the




Predicted Secondary Structure Of The CFTR Protein
Extracellular
CFTR is composed of two membrane spanning domains (TM-1 and TM-2) each composed of
6 transmembrane segments. Regulation of CFTR channel activity is controlled through ATP
hydrolysis by the Nucleotide Binding Domains (NBD-1 and NBD-2) and the phosphorylation of
the Regulatory "R" domain .
Clinical Aspects Of CF
CF manifests itself in the development of a wide range of symptoms affecting a
number of different organs. The severity of symptoms can be highly variable
depending on the CFTR mutation, health care, environment and also on the
individuals genetic makeup. The success in treating the different symptoms of each
organ is variable.
Sweat Duct Abnormality
During a particularly hot New York summer in 1949, the diSant' Agnese group
(1953) observed that an abnormally large number of infants presenting symptoms of
heat prostration (occurrence of salt crystals on the skin) also had CF. It was
subsequently discovered that mutations in CFTR has the effects of causing a 5 fold
increase in the normal chloride concentrations in the sweat ducts. This is due to an
inability of the salt duct to properly reabsorb NaCl from the sweat before it is
released through the duct (Quinton, 1996).
Beyond the increased susceptibility to heat prostration, this defect does not
apparently lead to any further clinical complication.
Reduced Fertility In CF Patients
CF leads to a reduced fertility in women and a high frequency of infertility in men.
In the women, the lack of functional CFTR leads to a reduction in the water content
of cervical mucus in the uterine cervix (Kopito, 1973). The abnormality would
appear to be highly localised to the region of the cervix and this is reflected in the
success of artificial insemination procedures which place sperm beyond this region.
CF Male infertility results not from a lack of mature and fertile sperm but due to the
blocking or absence of the vas deferens. Male infertility may be bypassed through
the removal of sperm from the testes and artificial insemination of the partner
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(Raeymaekers, 1995). Any artificial insemination treatment using CF sperm or egg
obviously results in the passing of copies of the faulty gene to the child. However,
there is little increased risk to the women with CF during pregnancy (assuming good
pulmonary health)(Huang, 1987). With screening of both partners now available and
the possibility of pre-implantation screening, there is a good prognosis for CF
patients who want to start a family.
Pancreatic Insufficiency In CF
Many patients present with pancreatic insufficiency (PI) at the time of diagnosis
(80%) or go on to develop PI (95%) later in their lives (Davis, 1980). Either way, PI
leads to an reduced ability to digest food. The physiology of this defect is discussed
in chapter 4. If left unchecked, PI results in the failure to put on weight (although CF
patients have a characteristic voracious appetite), greasy stools and colicky pain after
eating (Davis, 1996). CF patients taking up to 100 pancreatic enzyme pills a day to
compensate for PI are not unheard of. Further complicating this issue is the high rate
of anorexia in patients with active lung inflammation. About 1 % of patients with CF
additionally require insulin injections with the frequency of such incidences increase
with age of the CF population.
Improvements in the field of nutrition and the welfare of CF patients have also
contributed to the increased survival of CF patients. The CF diet is now liberal, high
in calories and often with added vitamins and salt (to replace that loss through
sweating) (Ramsey, 1992).
Blockages In The Intestines
The exchange of water across the membranes of the intestine is associated with the
exchange of chloride ions. Therefore, in CF, when the CFTR chloride channel is
inoperative there is a significant reduction in the secretion of water into the gut
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(Raeymaekers, 1995). This leads to the sludging of intestinal contents and the
development of intestinal blockages ("meconium ileus equivalent" which occurs in
neonates or "distal intestinal obstruction syndrome" which can occur postnatally
(Park, 1981)). These blockages occur in between 10 and 15% of new-bom babies
and can be treated surgically (Stem, 1986).
Liver Disease
Liver disease is the second most common cause of mortality in CF patients although
its occurrence is not inevitable (FitzSimmons, 1993). CFTR is normally expressed in
the epithelial lining of the biliary ductules where it acts to maintain the water and
electrolyte content of bile. In the non CF ductules, the secretion of chloride leads to
the passive secretion of water (Davis, 1996). When CFTR is dysfunctional, the
biliary ductules can become blocked which can lead to obstmctive cirrhosis and
bleeding. The most common method of treatment for this situation is liver
transplantation.
Related to the abnormal secretions, CF patients are more susceptible to the
development of gallstones (a prevalence of about 15% in young CF adults)(Stern,
1986). Treatment for CF gallstones is similar to that for non-CF patients although
there is a stronger argument for surgery of asymptomatic gallstone in CF patients, as
surgical risk will increase as the pulmonary health of the individual decreases.
Lung Disease In CF Patients
Although lung disease is the major cause of death in CF patients, the precise
aetiology of CF lung disease is still poorly understood (Davidson, 1998). The
development of CF lung disease begins shortly after birth and is characterised in the
chronic bacterial colonisation of the lung and the presence of excessive and
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abnormal mucus which leads on to the development of bronchial and glandular
obstruction. An ongoing massive inflammatory response ultimately results in the
severe bronchiectasis and finally respiratory failure (Davis, 1996).
It is likely that CF lung disease develops through a multi-step cascade. Though even
this statement is subject to argument since the logical progression of abnormal
mucus to bacterial infection to inflammatory response to abnormal histology does
not seem to operate in the CF patient. Instead, the first signs of CF lung disease are
histological (dilation of submucosal glands) (Madden, 1991) and indeed studies in
CF infants detected raised levels of inflammatory markers (EL-8 and neutrophils)
without any corresponding evidence for infection (Armstrong, 1995).
Treatment For CF Lung Disease
The treatment of CF lung disease is largely based on interrupting the disease-forming
cascade which eventually manifests in the destruction of the lung. Such a framework
for clinical intervention is displayed in figure 1.0.2.
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Figure 1.0.2
Therapeutic Strategies For Treating CF Lung Disease:
Breaking The Chain Of Events
CF gene therapy is discussed more fully in chapter 6.
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Clearance Of Excessive Mucous Build Up
Treatment of CF lung disease has improved steadily over the last 50 years with
methods of therapy now available to tackle each part of the lung disease jigsaw,
albeit to varying degrees of success. The build up of excess mucus is most commonly
treated by extensive programmes of chest physiotherapy or more mechanical
methods such as the Flutter devise which has been shown to raise four times as much
mucus as traditional physiotherapy and does not require a partner (Konstan, 1995).
Associated with these methods is the use of bronchiodilators such as P-adrenergic
agonists and cholinergic blockers that act to dilate the small airways.
In tandem to these methods, mucolytics are often used. Mucolytics are chemicals
which aim to digest the DNA and/or the protein components of the CF lung mucus
which are largely to blame for the mucus viscoelasticity. Early mucolytics, such as
bovine pancreatic DNase, were found to be bronchial irritants and have unpleasant
side effects (Raskin, 1968). More recently a large double-blind trial was undertaken
to study the effect of recombinant human DNase ("dornase alpha") (Shak, 1990).
The results were very positive and in the first year of commercial release of dornase
alpha, more than 40% of the CF population in the US (over the age of 5) received the
drug (Davis, 1996).
Controlling CF Lung Infections
The battle against bacterial colonisation in the CF lung has been largely waged
through the use of antibiotics. Although the antibiotics often fail to completely clear
bacterial infections (especially P. aeruginosa which appears virtually impossible to
eradicate) there is little doubt that their use has contributed to the increased survival
of CF patients. Courses of antibiotics are usually administered in intermittently in
response to a sudden decrease in lung activity or health.
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As an alternative to antibiotics, the concept of immunisation against specific bacteria
through vaccination has been explored. Clinical trials, such as those using a vaccine
directed against P. aeruginosa, have been largely disappointing and may even have
predisposed some patients to more severe disease once P. aeruginosa infection
occurred (Langford, 1984, Pennington, 1975).
Controlling Lung Inflammation
Inflammation is a significant cause of damage to the CF lung. Raised levels of
neutrophils are noted in the CF lung even in infancy thus the structure of any
programme of anti-inflammatory therapy would most likely begin in infancy and
continue indefinitely. There are a number of ant-inflammatory drugs available used
in the treatment of CF.
The use of corticosteroids in the treatment of CF patients has had a controversial
history. In two large scale trials, recruiting over 300 CF patients, corticosteroids
were found to lead to an immediate increase in pulmonary function and fewer
admissions into hospital (Donati, 1987, Auerbach, 1985). However, in both cases,
follow up studies (4-6 years) showed strong evidence that the treatment led to side
effects which included growth retardation, glucose abnormalities, osteoporosis and
the formation of cataracts (Rosenstein, 1991).
Non steroidal inflammatory drugs (such as ibuprofen) generally have fewer side
effects than their steroidal counterparts. Used in high concentrations, they were
shown to have specific activity against neutrophils making them a possible candidate
for use in CF (Konstan, 1990). This hunch was shown to be correct in a 4 year trial
conducted on CF patients over 5 years of age with mild lung disease (Konstan,
1991). Test patients (as compared to those who received placebo) had significantly
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less decline in pulmonary function, maintained their normal body weight and had
fewer hospitalisation. Most importantly, there was no development of side effects as
noted in the corticosteroid trials.
Lung Transplantation
CF patients with end-stage lung disease often attempt to find a donor lung. This
procedure is fraught with uncertainty and is over shadowed by a low long term
survival rate : 15% death rate in the first year and 33% in the second year (Davis,
1996). Deaths during the first few months after transplantation are predominantly as
a consequence of bacterial infection probably resulting from native bacteria residing
in the upper trachea (Egan, 1992). However, for many CF patients, the increased
quality of life resulting from a lung transplantation can be considerable.
Unfortunately, at this time a global sparcity of donor organs. Some patients have to
wait for over 2 years for a donor organ during which time their pulmonary health








The aim of this chapter was to examine the biology of the murine submucosal gland.
Submucosal glands are thought to be important in the development of CF lung
disease in humans but have been up to now, poorly characterised in the mouse. The
experiments in this chapter address the suitability of the mouse as a model for human
pulmonary airways.
Mouse Models Of Cystic Fibrosis
There are many technological and practical reasons why the mouse, as opposed to
other mammals, should be used as an experimental model for genetic and clinical
studies. Mice are small in size and have a short reproductive cycle thus making them
economical to house and quick to generate data. As a consequence, they have been
used for over a century for experimentation (Erickson, 1996).
Traditionally mouse mutants have been generated through radiation treatment of
animals or by breeding naturally found mutants. These techniques have however,
always relied on chance or randomness. With the advent of molecular genetics, the
possibility of generating mice with mutations of choice has become reality and in the
last decade the field of mouse genetics has seen a rapid change with the production
of transgenic mice now commonplace.
The extrapolation of data from Mus musculus to Homo sapiens (which is often the
purpose of clinically orientated genetic studies) must not be blind to anatomical,
development or pathological differences between species. Yet, reporting the
pathological variation arising from the species difference is often of great
importance in highlighting critical steps in the disease pathogenesis. The margin of
similarity between what we perceive to be important in the pathogenesis of a
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particular disease is likely to be an ever changing one as research both in the human
condition and in the mouse grows and becomes more comprehensive. The study of
the CF mouse is such an example.
There is no known naturally occurring animal model for CF (Dorin, 1996b) however
a number of murine models of transgenic CF have now been generated. (Snouwaert,
1992, Dorin, 1992a, Rozmahel, 1996, O'Neal, 1993, Zeiher, 1995). A CF mouse is
defined as a mouse with reduced CFTR expression and not necessarily a reflection
on its phenotype. There are essentially two ways to generate the CF mice. Firstly,
Insertional Gene Targeting which aims to introduce a fragment of foreign DNA
which will disrupt the normal functioning of the target gene. Secondly, gene
replacement, which relies on a double reciprocal recombination which will delete a
vital segment of the target gene (Dorin, 1996b). One of the first CF mice to be
reported was that of the Dorin group (1992a). This mouse was developed at the
Medical Research Council's Human Genetics Unit in Edinburgh and is therefore
gains the designated abbreviation of Cftrtm,HGU ("tml" refers to, "transgenic mouse
number 1"). The strategy devised was to disrupt the normal read through of exon 10
of the mouse CFTR homologue in embryonic stem cells. A 3.5kb fragment of DNA
which was isogenic with areas of intron 9 and exon 10 was cloned into a vector
carrying the neomycin resistant gene. The vector was linearised and electroporated
into an E14 embryonal stem cell line. Correctly targeted clones were determined by
antibiotic resistance and Southern blot and cells were injected from a clone into
C57BL/6 blastocysts, which were transferred to pseudopregnant albino female mice.
Male chimaeric offspring were bred with MF1 females to test for germline
transmission. Offspring from these matings were genotyped by southern blot for
presence of the transgene. As the transgene was successfully shown to be present in
chimaeric germ cells, the chimaeric mice were further bred to produce wildtype
animals and heterozygous and homozygous animals which carried the transgene
(Dorin, 1992b, Dorin 1992a).
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The CftrfmIHGU mouse, unlike many of the other CF mice, is not however, a complete
cftr "null" ("null" meaning that 0% of wildtype cftr is expressed). Animals homozygous
for the cftr transgene were found to express between 5 and 10% of wildtype levels of
cftr as a results of aberrant splicing and exon skipping (Dorin, 1994). Interestingly,
the CftrpnIBay mouse which was also generated by Insertional targeting but this time
targeting exon 3 does not show this same "leaky" expression of cftr (O'Neal, 1993).
It is considered that the efficiency of aberrant splicing in the exon 3 region of the cftr
gene may be low compared to the exon 10 region (Dorin, 1996b). A summary of CF
mouse models is given in figure 2.0.1.
CF affects the normal functioning of many organs in the human patient including the
sweat gland duct, the pancreas, the lung, the gut and the reproductive tract. The
phenotypes of these tissues in the CF mouse models have been discussed extensively
elsewhere (Dorin, 1996b, Dickinson, 1995). The most significant phenotype
affecting survival in the CF mouse "null" models (see figure 2.0.1) is the occurrence
of gut blockages which cause the majority of mice to die perinatally (Dorin, 1994).
This phenotype is similar to meconium ileus which occurs in -20% of new-bom CF
patients. This high perinatal death rate was originally feared to hamper further
experimentation until the finding that by feeding the mice a liquid diet could prolong
their life. Interestingly, it was found that the positioning of CFTR in its normal
physiological crypts position was not entirely necessary for the correct functioning
of the gut. When CFTR was expressed on the villi of the mouse intestine (CFTR is
normally expressed in the crypts) it was found to be sufficient to prevent the mouses'
reduced survival rates (Zhou, 1994). The Cftr,mIHGU mouse also shows overt
histological changes in the gut, but less than 10% die of meconium ileus or
equivalent. In addition to the phenotypes seen in the human, the Cftr,mIUNC null
mouse was found to show abnormal incisor enamel (Wright, 1996).
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Table 2.0.1
Transgenic Mouse models for CF
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One of the most fundamental phenotypes which can be studied in the CF mouse is
that of chloride ion transport activity. Dorin (1992a) reported electrophysiological
dysfunction in the respiratory and gastrointestinal tracts in the cftrpn,HGU mouse. A
variety of tissues were incubated with forskolin and zardaverine in the presence of
amiloride and the potential difference (p.d.) across the tissues measured. P.d.
measurements were found to be significantly to be raised in the nasal epithelium,
trachea, caecum/colon and rectum (Dorin, 1992a). Similar results have been found in
the other mouse models though the degree of difference in p.d. measurements is less
in the cftr "nulls" than in the cftr>mIHGU mouse (Dorin, 1996b).These channels were
found to be largely inhibited by bumetemide and therefore likely to represent
chloride secretions (Smith, 1992).
Despite the electrophysiological profiles of the CF mice, there are no reports of
spontaneous development of lung disease in any CF mouse models (Davidson,
1998). However, However in an earlier paper, Davidson (1995) demonstrated that
the cftr^'n00 mouse shows an increased susceptibility to developing lung disease
after repeated nebulised exposure to Staphylococcus aureus and Burkholderia
cepacia, as compared to non CF littermates. These bacteria have been previously
demonstrated to be of clinical significance in CF. The spectrum of pathology was
similar to that observed in CF patients including goblet cell hyperplasia and
metaplasia, mucus retention, bronchiolitis, pneumonia and inflammatory infiltration
(Davidson, 1995). Interestingly, as with human CF patients, pneumonia was only
noted in animals treated with B. cepacia and not S. aureus.
More recently, P. aeruginosa coated beads were used to deliver a high dose of
bacteria to the lungs of CF "null" and wildtype mice. After treatment, a higher rate
of morbidity in CF mice (82%) than wildtype mice (23%) within 10 days of infection
was recorded (Kent, 1997). The increased mortality in the CF group was associated
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with a markedly elevated inflammatory response and weight loss in comparison to
the wildtype animals. No CF or wildtype mice in a control group receiving sterile
beads died within 10 days of the procedure.
Using a similar method of infection, the Cowley group examined mucociliary
clearance in CF and non CF animals after infection by Pseudomonas aeruginosa
(Cowley, 1997). Two parameters were measured using an in vitro lung explant
preparation, that of ciliary beat frequency (fcb) and particle transport (PT). No
statistical difference was found between the fcb between CFTR -/- mice (CftrfmlUNC
on C57BL/6 inbred genetic background) and their +/+ controls either in the presence
or absence of Pseudomonas aeruginosa. However, PT rates (measured by rate of
movement of finely ground charcoal across a microscope field of view) were seen to
be dependent on both CFTR genotype and infection status. Uninfected CF mice
demonstrated higher rates of PT than wildtype littermates while Pseudomonas
aeruginosa infected CF mice showed lower PT rates than infected wildtype
controls(p<0.05).
This report is in contrast with that of Zahm (1997) who studied the mucociliary
transport velocity (rate of mucus clearance from the lower part of the trachea)
(MTV) in homozygous CftrfmIHGU mice (on MF1 outbred genetic background) as
compared to wildtype littermates. MTV was significantly lower in the CF mice
(14.2±4.4 (im/mm) than in the wildtype controls (30.6±5.9gm/mm)(P<0.04). These
animals were housed in germ-free conditions in an isolator unit and were found to be
free of bacteria when screened for 15 common pathogenic strains. The CF mice were
found to have higher number of inflammatory cells in than in the wildtype controls.
These data are particularly interesting in the light of data from CF infants who have
shown increased levels of neutrophils and increased levels of interleukin-8 despite
the absence of CF related pathogens (Khan, 1995).
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CF mouse versus CF Man
The use of animal models can be perceived in two, non-exclusive, ways. Firstly, as a
substitute human. That is to say a non-human species to receive often prototype
forms of therapeutic intervention. Secondly, differences between humans and an
animal model can, often by serendipity, elucidate critical steps of a disease
pathogenesis.
In the context of CF, what could explain the differences in lung disease pathogenesis
between the CF mouse and the human CF patient? Here are some possibilities.
1: Temporal: It can be argued that as human CF patients do not exhibit full lung
disease phenotypes until late infancy. Does the much shorter life span of the mouse
not permit the development of CF lung pathogenesis?
2: Size: An observation which may appear starkly obvious but yet is important to
consider further, is the difference in size between the Mouse and Man. Does the size
and therefore surface area of the lung in the CF mouse somehow, make it less
susceptible to developing CF lung disease?
3: Environment: By philosophising on the question, "What is an actual cause of
CF?", one can argue that if CF patients were kept in an isolated environment away
from pathogenic bacteria they would not go onto develop lung disease. In this case,
it is likely that the housing environment of the mice will be crucial to the
development of, or lack of, CF related lung disease (as recognised in the CftrpnlHGU
mouse when housed in non-SPF conditions (Dorin, 1992a)).
33
4: Method of Breathing: The mouse predominantly breathes through its nose (the
human breathes more through the mouth). Does nasal breathing reduce the chances
of infection?
5: Lung Structure: Is there adequate homology between the cell types, lung structure
and the ion channels between mouse and man to expect a similar pattern of lung
pathogenesis to develop?
Chapter 2 aims to investigate further the issues raised in point 5. That is, does the
mouse possess the tissues and cell types which are thought to be associated with the
development of CF pathogenesis. In other words, should we expect the CF mouse to
develop CF lung disease and if not, why? Furthermore, can we use the mouse as a
suitable animal model for the human lung in studies of CF lung pathogenesis and
cellular kinetics?
The Role Of Submucosal Glands In The Development Of CF Lung Disease
There is considerable evidence to suggest that SMGs may play a significant role in
the development of CF lung disease.
• SMGs are the predominant site of CFTR expression in the human bronchus
(Engelhardt, 1992). Engelhardt et al. localised expression of CFTR to the serous
cells and to a subpopulation of "flask like" cells in the ciliated ducts.
• When chloride transport in SMGs is blocked in vitro, mucus production is
severely reduced (Inglis, 1997a) and the mucous obstructions resembling those
observed in CF arise (Widdicombe, 1994).
• The first observable phenotype in CF infants is the dilation, hyperplasia and
obstruction of SMGs. Interestingly, this can occur prior to and independent of other
signs of lung disease or infection (Madden, 1991, Oppenheimer, 1975).
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It is therefore important, in the development of the mouse as a model for CF, to
examine the presence and nature of SMGs in the mouse.
Mice have been previously been reported to "lack" (Widdicombe, 1994)or at best, be
"essentially void" (Engelhardt, 1992)of SMGs. The "absence" (Widdicombe, 1997)
of murine SMGs has been reported as to be a likely cause of the weak CF mouse
lung phenotype.
Submucosal Glands in Man
In Man, submucosal glands (SMGs) consist of a network of secretory tubules and
associated ducts which act in the production and delivery of mucous and
antimicrobial agents to the epithelium of the cartilaginous airways (Basbaum, 1990,
Engelhardt, 1992, Meyrick, 1969).
SMGs are found in the trachea, bronchi and proximal bronchioles of the human lung,
lying most commonly between the epithelium and plates of supporting cartilage
though occasionally they can lie external to the cartilage (Tos, 1966). Serial
reconstruction and cell type analysis of the gland structure has revealed the presence
of 4 different tubule types and a number of cell types, summarised in figure 2.0.2.
(Meyrick, 1970, Engelhardt, 1992).
The SMG ciliated duct connects the surface epithelium to the collecting duct. It is
lined mainly with ciliated cells but also with cells with numerous large mitochondria
and a well developed Golgi apparatus (Meyrick, 1970, Meyrick, 1969). These cells
may be the "flask like" cells observed by Engelhardt et al. (1992). A role in fluid
transport has been suggested for the mitochondrial rich cells (MRCs) (Meyrick,
1970). However, their physiological significance is unclear as in humans they
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constitute only an average of 6% of all the duct cells (maximum frequency -23%)
(Matsuba, 1972). Furthermore, a significant positive correlation between numbers of
these cells and the age of the sample, perhaps suggesting that these cells are products
of cellular degeneration. Goblet cells may also be present (Meyrick, 1970).
The transition from ciliated duct to the collecting duct is abrupt (Meyrick, 1969).The
collecting duct has a larger diameter than the ciliated duct and is associated with the
presence of tall non ciliated columnar cells densely packed with mitochondria and
Golgi (Meyrick, 1970).
The junctions between the collecting duct and the secretory tubules also show an
abrupt change in epithelial cell type to one composed entirely of mucous cells and
serous cells distinguished primarily by differences in the ultrastructure and
histochemistry of the granules (Widdicombe, 1994). The secretory tubules end in
spherical acini which are composed of one or both cell types (Meyrick, 1969).
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Figure 2.0.2
Structure And Cell Types Of The Human SMG.
A: 3d dimensional image of a human submucosal gland based on the observations of Meyrick
(1969).
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B: Submucosal gland in cross section.
Mucous cells contain a basally located nucleus and an extensive Golgi apparatus.
The Golgi generate electron lucent secretory granules which increase in diameter
towards the apical membrane (Meyrick, 1970). These granules vary in diameter from
300 to 1800 nm, the larger ones having a tendency to fuse.
By contrast, serous cells have electron dense membrane bound granules generally
measuring between 300 and 1000 nm but occasionally up to 2000 nm (Widdicombe,
1994, Bowes, 1977). The cells have a pyramidal shape and a basally located nucleus
and are extremely rich in rough endoplasmic reticula and mitochondria (Basbaum,
1990).
The great abundance of serous cells (61% by volume of the human submucosal gland
(Basbaum, 1990)) suggests their role in human lung physiology as one of great
importance. Indeed, serous cells are reported to act as one the main lines of defence
in the lung through the production of bactericidal compounds including lysozyme
and lactoferrin (Basbaum, 1990).
This chapter aims to re-examine the question of murine SMGs in relation to their
presence or absence in the mouse, their structural homology to those of the human




Characterisation and localisation of Murine SMGs
Reported below are the results from a qualitative and structural analysis of murine
SMGs.
Materials and Methods
Six 6-week-old wildtype mice on a mixed (MF1/129) genetic background from
conventional (non-specific pathogen free) housing were sacrificed through IP
injection of 0.4ml IP injection of Euthatal (Rhone Merieoux, UK). Their lungs were
inflated with 4% paraformaldehyde and the lung and trachea then dissected out
whole. The tissue was fixed in 4% paraformaldehyde at +4°C for 6 hours then stored
in 70% alcohol at +4°C until being processed into wax blocks using a VIP wax
processor (Tissue-Tek, UK). 6pm sections were cut from the trachea and lung lobes
and these were floated out on distilled water at 58°C and transferred onto glass slides
coated with Vectabond (Vector laboratories, Peterborough UK). Slides were dried
for 2 hours at 60°C. Wax was removed and tissues rehydrated by transferring the
slides through baths of xylene (2x 10 minutes) and a decreasing gradient of alcohol
(100%, 90%, 70%, 50%, 30%) to water.
Sections were counterstained with haematoxylin by incubating the slides in
haematoxylin for 5 minutes, washing in tap water for 5 minutes, incubating in eosin
solution for 3 minutes, washing in Scott's Water and acid alcohol (5 seconds each)
before washing 3x5 minutes in water.
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Slides were left to dry at room temperature overnight and viewed with bright field
microscopy (Axioplan 2, Zeiss, UK). The identity of the SMGs was examined
through comparative histological analysis to those found in the human as discussed
above.
Results
Histological examination of the lung of the MF1/129 wildtype mouse revealed the
presence of SMGs in the proximal regions of the trachea. See figure 2.1.1.
Discussion
The cartilaginous airways of the mouse lung were examined for the presence of
SMGs. Murine SMGs were found in all mice studied and their identity was
confirmed through comparative histological analysis of mouse SMGs to human
glands described in the literature. Murine SMGs in wildtype mice on an outbred
(MF1/129 mixed) genetic background were located in the proximal regions of the
trachea. The main concentration of glands occurred between cartilage rings 0 and 2.
Gland duct openings occurred at a density of ~lmm"2 as determined by gross
planimetry (data not shown).
These preliminary data do not however demonstrate that the mouse SMGs do indeed
function or have the same cell types as in the human. Furthermore, it does not answer
the question of whether the SMG elements thought to be pertinent in the
development of CF lung disease, namely the presence of serous cells, mucus
production and cftr expression, are present.
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Figure 2.1.1
Presence Of SMGs In The Mouse Trachea As Identified By Light Microscopy.
See figure 2.0.2. for comparative histology.
2.1.1A H&E counterstained longitudinal section of the trachea of the MF1/129 mouse.
Proximal (towards the mouth) is to the right of the figure whilst distal (towards the bronchi) is
to the left of the figure. Submucosal glands can be seen towards the proximal end of the
trachea.
2.1.1B SMGs at higher power (x 40) showing the presence of tracheal epithelium (labelled
"E"), SMG region and cartilage ("C").
2.1.1C SMG (x40) showing prominent ciliated duct (labelled) producing mucus material out
onto the epithelial surface.
Figure 2.1.1
Presence Of SMGs In The Mouse Trachea
2.2
Cell Type Analysis By Transmission Electron Microscopy
Introduction
Of the cell types found in the human SMGs, the serous cells are thought to be most
importantly connected with the development of CF due to their reported expression
of CFTR and multiple antimicrobial proteins (Basbaum, 1990 ,Engelhardt, 1992). It
was therefore important to examine the cell types found in the murine SMGs. To that
end, a study using transmission electron microscopy was performed to identify cell
types present in the distal portions of murine SMGs.
Materials and Methods
Two 6 week old homozygous Cftr,mIHGU mice and two 6 week old wild type littermate
mice (MF1/129 mixed genetic background) were sacrificed with a 0.4ml IP injection
of Euthatal (2mg/ml pentobarbitone)(Rhone Merieux, UK). Tracheas from these
mice were excised and 5mm2 blocks of tracheal ring removed from the proximal end
of the trachea adjacent to the thyroid gland. Tissues were fixed in freshly prepared
gluteraldehyde fix (2.5% gluteraldehyde in 0.1 M cacodylate buffer pH 7.3 (25mls
4.28% sodium cacodylate + 1.6mls 0.2M HC1 + 10 mis H2O) + 0.1M sucrose)
overnight at +4°C. Tissues were rinsed in 0.1 M sucrose in cacodylate buffer for 2 x
10 minutes and post fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 45
minutes. After 2x10 minutes of rinsing in cacodylate buffer, the tissues were
dehydrated in increasing concentrations of ethanol. Tissues were transferred to a thin
layer of araldite overnight and heated at 60°C for 35 minutes. Immediately
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afterwards, the tissues were transferred to embedding araldite and baked at 60°C for
3 days.
Sections of 1 gm nominal thickness were cut from tissues blocks and counterstained
with toluidine blue. From observation on these slides, sections of 90nm were cut for
TEM. Sections were transferred to 200 mesh copper grids and stained with 4 %
uranyl acetate and Reynold's lead citrate. The ultrathin sections were examined with








Identification Of Serous And Mucous Cell Types In Murine Submucosal Glands By TEM
Serous cells were recognised by cell shape and ultrastructural content namely, the presence
of electron dense granules, a high frequency of endoplasmic reticulum, being of pyramidal
structure and having basally located nucleus. Mucous cells were identified by having electron
lucent granules of variable shape.
The images are taken from wildtype mice. No statistical difference was noted in comparison to




2.2.1 A Serous cell acini in a wild type mouse showing characteristic 6 cell structure. Note
presence of dark, electron dense granules (see arrows) and basally located nuclei.
2.2.1 B Serous cells contained electron dense granules which were heterogeneous in size
(550nm to 1900nm) and appearance.
2.2.1 C Serous cells were found to be extremely rich in endoplasmic reticulum (arrowed and
labelled ER) and mitochondria (arrowed and labelled).
2.2.1 D Mucous acini. Note irregular shaped mucous granules (marked with arrow).
2.2.1 E Mixed serous/mucous acini.
Identification of Serous and Mucous cell type in murine SMGs.
In the most distal portions of the human SMGs are small cups of cells referred to as a
gland acini. The presence and character of serous and mucous cell types in these
regions of murine SMGs was confirmed by the use of transmission electron
microscopy (TEM). Serous cells were identified through the presence of electron
dense granules and an extremely high concentration of rough endoplasmic reticulum
and mitochondria (figure 2.2.1a, 2.2.1b, 2.2.1c). Although homogenous in shape, the
electron dense granules varied considerably in appearance and size. The larger
granules appeared to be membrane bound and varied in diameter from 500 to 730nm
in the homozygote C/ir""///GU mice and 555 to 1500 nm in the wildtype mice.
Smaller granules had an indistinct membranous boundary or diffuse edge. These
smaller granules varied from 400 to 500 nm size in the homozygote CftitmIHGU
(n=18, median = 470nm) and 450 to 800 in the wildtype (n=20, median = 700nm).
The ranges of sizes in these groupings do not present a statistically significant
difference between genotypes (P>0.05 by Student's T-Test). A 3rd group of vesicles
were classified according to their electron lucent appearance after staining with
osmium tetroxide. These varied in size from 480nm to 550nm in size in the
homozygote CftrJm,HGU (n=20, median = 540 nm) and 550nm to 830nm in the
wildtype (n=20, median = 700nm). and were judged to be lysozomes.
Mucous cells were identified by the prevalence of irregularly shaped electron lucent
vesicles (figure 2.2.Id). In both genotypes the granules ranged from approximately
550nm to 1900 nm in diameter (n=20, median = 1400nm).
The most common type of acini (-95% by area of vision) consisted of serous cells
only as seen in figure 2.2.1a. In this figure, the characteristic pyramidal shape of the
cells is clearly seen. Mucous only, or rarely, mucous and serous were also observed
(figure 2.2.Id, 2.2.le). These mixed acini may be undergoing transdifferentiation
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from being composed of serous cells to one of mucous cells.
Discussion
Murine SMGs were found to be rich in serous cells, which displayed high similarity
to that of the human cell type. Mucous cells were also present though less frequent
in number. This experiment provided confirmation that these cell types existed in the
murine SMGs providing a strengthen platform from which to argue the similarity of
the murine SMGs to that of the human and thus, the suitability of the mouse as a
model animal for use in human CF studies.
In following experiments when light microscopy was used, serous and mucous cells
were identified by their differential appearance when viewed with Nomarski optics
after Sharma (Sharma, 1997). The mucous cell acini appeared very flat whilst




Lysozyme expression in the Murine SMGs
Introduction
Human Serous cells are reported to produce, amongst other proteins, lysozyme.
Lysozyme is an important antimicrobial agent in the lung and may be involved in CF
lung pathogenesis through its synergistic relationship with the (3-defensin family
(Basbaum, 1990) (see chapter 4). An immunohistochemical study of lysozyme
production in the murine SMGs was undertaken.
Materials and methods
Ten 6|im sections of 4% neutral buffered formalin fixed trachea from five 8 weeks
old wildtype MF1 mice were cut and floated out onto Vectabond coated slides. The
slides were dried and the sections de-waxed and rehydrated to water as before. Using
Vectastain Anti-rabbit IgG kit (Vector laboratories, Peterborough, UK) the tissues
were blocked for 20 minutes with goat serum. Serum was blotted off and lOOpl of
1:200 anti-lysozyme (DAKO, High Wycombe, UK) antibody was added and the
slides incubated for 30 minutes at room temperature. The slides were washed 3 times
in PBS before addition of the anti-rabbit secondary antibody for 30 minutes. A
further 3 washes in PBS followed before the addition of ABC solution (avidin-
biotinylated enzyme complex) and incubation for 30 minutes at room temperature.
Slides were washed 3 times in PBS and the antibody complex recognised with the
addition of a solution of diaminobenzidine (DAB) reagent (one lOmg DAB tablet
(Sigma-Aldrich, Poole, UK) in 10ml 0.05M Tris-HCl buffer pH7.4 activated with
hydrogen peroxide) for 15 seconds. The slides were washed with PBS counterstained
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with haematoxylin for 10 seconds before dehydration through alcohols and xylene to
final mounting in DPX. Slides were viewed with bright field microscopy (Zeiss




A sub-population of serous cells of the SMG were seen to express lysozyme
protein through the positive signal with anti-lysozyme antibody. Within this
population there was considerable heterogeneity of signal between cells. The identity
of the cells was recognised through the use of Nomarski optics. Mucous cells and
negative control slides with no primary antibody showed no signal.
Conclusion
Serous cells lying within murine SMGs were observed to produce lysozyme protein.
The pattern of production was observed to be highly heterogeneous between
individual cells and glands.
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Figure 2.3.1
Heterogeneous Pattern Of Lysozyme In The Serous Cells Of Murine SMGs
Murine SMGs were observed to produce lysozyme from the distal serous cells. Production
was observed to be highly heterogeneous both between tubules (figure 2.3.1b) and cells
(figure 2.3.1c). Negative control slides of no primary antibody and staining of non lysozyme
expressing tissue, resulted in no brown cellular staining (data not shown).
2.3.1a Presence of Lysozyme protein in murine SMGs using anti-Lysozyme immuno
peroxidase histology (DAKO) (positive signal appearing as brown stain). Tissue was further
counterstained with haematoxlin.
2.3.1b Lysozyme protein identified to be present in a subset of serous cells by viewing with
Nomarski optics.
2.3.1c Non-homogenous staining pattern of Lysozyme suggests that not all serous cells






Mucus Production from the Murine SMGs
Introduction
H&E histology of murine SMG revealed the presence of a mucus like material in the
ducts of the murine SMGs. The presence and pH of mucin secretions from the SMGs
was characterised through the use of Periodic Acid/Schiff (PAS) and /or Alcian Blue
(AB) staining on paraffin sections. PAS reacts with neutral mucin and AB with
acidic mucins.
Materials and methods
6pm paraffin sections of mouse trachea were de-waxed and rehydrated to PBS as
before. Periodic acid stain, Schiff s Reagent (Sigma-Aldrich, Poole, UK) and Alcian
Blue stain (1% in dH20 (Sigma-Aldrich, Poole, UK)) were warmed to room
temperature before use. For staining with PAS, slides were washed in a coplin jar for
3 minutes with Periodic acid, washed 3 times with PBS and then washed in a coplin
jar for 3 minutes with Schiff s Reagent. For AB staining, slides were washed in AB
stain for 3 minutes. When both staining methods were used, methods were run
sequentially on the same slides. After staining, slides were dehydrated and mounted













2.4. la and 2.4. lb Serial sections of murine submucosal tissue stained with Alcian Blue and Periodic
Acid /Setoffs respectively. Note weak Alcian Blue and PAS staining in the mucus situated in the ducts
of the glands and the intense PAS signal in the distal regions of the gland in the serous and mucous
tubules and cells.
2.4. lc and 2.4. Id: Serous cell acini viewed with Nomarski optics staining positive for PAS in the




cftr expression in the murine SMGs
Introduction
CFTR, in the human lung, is predominantly expressed in the serous cells and the
mitochondrial rich "flask like" cells of the SMGs (Engelhardt, 1992). In the
characterisation of the mouse as a suitable animal model for use in CF research, a
study was conducted into the distribution of CFTR in the mouse trachea using an
anti-human CFTR antibody.
Materials and Methods
Six C57BL/6 and six BALB/c wildtype mice were sacrificed as before and their
tracheas dissected. The tissues were immediately wrapped in aluminium foil and
immersed in liquid nitrogen. Tissues were later transferred to a -70°C freezer for
storage. The tissues were cryo-supported in polyvinyl alcohol and polyethylene
glycol in sucrose solution( O.C.T. compound, Tissue Tek, UK) and 10pm
cryosections cut onto Vectabond coated slides (Vector laboratories, Peterborough,
UK). Sections were thawed and dried for 2 hours at room temperature before fixation
for 15 minutes in 4% paraformaldehyde. Sections were permeabilised with 0.2%
Triton-X in PBS and after further rinsing in PBS blocked with 2% Bovine Serum
albumin, 2% goat serum (DAKO, High Wycombe, UK), 7% glycerol and 0.2%
Tween-20 (Sigma, Poole, UK) in distilled water. A polyclonal antibody, PC-termB
(Genzyme Corp., Kent, UK) raised against the C-terminal portion of the human
CFTR protein, was used to localise cftr in the mouse trachea. The primary antibody
was diluted 1:100 in PBS/1% goat serum and incubated for 1 hour. Slides were
washed three times in PBS and incubated with a 1:400 dilution of goat anti-rabbit-
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FITC (Jackson ImmunoResearch Laboratories, Luton, UK) for 30 minutes. Sections
were further washed with PBS and mounted in 1% DAPI in Vectashield (Vector
laboratories, Peterborough UK). Negative controls were conducted using tissue from





cftr Localisation Using Pcterm-B Polyclonal (Anti Human CFTR C-Terminal)
Antibody.
All the images in this figure were obtained using identical exposure parameters.
Images are composite RGB fluorescent images (IP-Lab Software) observing reactivity
of PCterm-B antibody to the murine SMGs. Blue image represents DAPI nuclear
counterstain, red image observes inherent autofluorescence and green image
represents cftr. Overlap between red and green images would suggest that the green
signal may not represent antibody signal rather, a consequence of autofluorescence.
2.5.1 A-B PC-termB reactivity to BALB/c SMGs. Cftr appears localised in the distal
portions of the murine SMGs. A high level of autofluroscence was observed
(especially in 2.5.1 B) although this was not observed to over lap the cftr image (noted
by the absence of yellow signalling).
2.5.1 C-D PC-termB reactivity to C57BL/6 SMGs. A similar pattern of reactivity was
observed as with the BALB/c although the level of autofluorescence was considerably
lower. In addition, green signal was observed in the lamina propria filaments.
2.5.1 E PC-termB reactivity to a SMG of the homozygous cftr'm1UNC (CF null) mouse
on C57BL/6 background. No green image was observed in the SMGs. Green image
was still observed in the lamina propria filaments (as with 2.5.1 C-D) suggesting that
this signal may be artefact.
2.5.1 F High power (x100) image of serous acini of wildtype BALB/C mouse. The
pattern of serous cells lying around the acini is readily observable, cftr appears to be
spread throughout the cytoplasm of the serous cells.
2.5.1 G x40 magnification of wildtype C57BU6 mouse showing high levels of cftr





















cftr was observed to be present in the serous cells of the murine SMGs through the
use of an anti-human CFTR antibody. The antibody's specificity to cftr was
confirmed through its negative reaction with tissue from the CftrfmWNC "null" mouse.
2.6
Chapter Discussion
In humans, SMGs are found in the cartilaginous airways of the lung extending from
the trachea down into the bronchi and into the larger bronchioles (Widdicombe,
1994). However, mice have been described in previous reports as not having or being
essentially devoid of SMGs (Widdicombe, 1994, Engelhardt, 1991, Sehgal, 1996,
Widdicombe, 1985). At most, SMGs in the mouse have been reported in the larynx
region, and only in the most proximal regions of the trachea (Pack, 1980). By
histological examination of wholemount tracheas and paraffin sections we show that
SMGs are clearly present in the mouse. Murine SMGs are most common in the
proximal regions of the mouse trachea with their frequency rapidly decreasing more
distally. Interestingly, the density of murine SMGs in cartilage gaps 0 and 1 was
found to be ~lmm"2 , this being the same approximate density as glands in the
human trachea (see chapter 3 for details of cartilage gap localisation). The existence
of murine SMGs may have been overlooked in the past because of their restricted
location in the trachea.
On a cellular level, murine SMGs were found to have mucous cells and be rich in
serous cells in accordance with findings in the human. The electron dense granules
in human serous cells are well characterised (Bowes, 1977) and were found to show
great similarity to those in the mouse. The electron dense granules in murine serous
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cells were seen to range in sizes (400-1500nm) similar to those observed in humans
(Bowes, 1977) and were variable in their membrane integrity. In the larger granules,
membranous structures surrounded the granules whilst in smaller granules, the
membrane was less distinct and appeared diffuse.
Through the use of Periodic Acid Schiffs and Alcian Blue reagents it was
demonstrated that murine SMGs produce mucus which shows a heterogeneous
staining pattern reflecting a variation in mucus pH within the gland. Mucous and
serous cells both appear to be highly active in the secretion of materials in the gland
lumen. The apical membrane of the serous cell also stains positive for Alcian Blue
reflecting an discrete alteration in the pH of its secretions (neutral to acidic).
Lysozyme is an antibacterial protein found in secretions protecting most of the body
surfaces and was one of the first proteins found to be expressed in human SMGs
(Basbaum, 1990). In accordance with this finding, we observe the presence of
lysozyme protein in a subset of serous cells in the murine SMGs. This heterogeneity
of lysozyme signal may be connected to the heterogeneous nature of MUC7
expression in human serous cells (Sharma, 1997) and variation in serous cell granule
composition.
Previously, studies in the human lung have revealed that SMGs are a major site of
CFTR expression (Engelhardt, 1992). The expression pattern was found to be
localised to the serous cells and a subpopulation (1-3%) of cells in the collecting
ducts of the glands (Engelhardt, 1992). It is thought that SMG CFTR may play a role
in the maintenance of ionic composition of fluid secretions, similar in role to that
found in the sweat glands (Quinton, 1996,Widdicombe, 1994).
In the study of cftr expression in the murine trachea, data is presented demonstrating
the presence of CFTR protein in the serous cells of the submucosal glands. No
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epithelial localised or collecting duct signal was noted. The serous cell staining
pattern shows considerable heterogeneity between serous cells and the presence of
non-apically localised signal. This pattern may be partially due to the thickness of
the sections and the use of permeabilised cells in the protocol or may be the
detection of non-apical CFTR in this cell type. In a previous study using anti CFTR
antibodies to study AF508 mutant CFTR localisation in sweat ducts (Kartner, 1992)
such problems were not encountered and indeed, highly apically localised staining
patterns were observed. Distinction exist between the Kartner study and those
reported in this thesis. Firstly, the Kartner group was studying human tissue (on
which the anti-human antibody may be more sensitive) and secondly, the Kartner
study used specifically generated monoclonal antibodies on non-permeabilised
frozen sections. The possibility that CFTR protein is present in epithelial cells below
the level of detection with the polyclonal PC-termB antibody cannot be excluded
from the interpretation of these data.
In conclusion, murine SMGs were found to be highly similar to human SMGs as
reported in the literature. Mucus is produced in the SMGs and the serous and mucous
cells present express CFTR and lysozyme. There is strong evidence to suggest that
SMGs play a major role in the development of CF in humans (Inglis, 1997a,
Widdicombe, 1994). The characterisation of murine SMGs in this study is thought to
further support the argument for the mouse being a useful and suitable animal model
for studying CF. One significant difference noted was that murine SMGs were only
noted in the proximal regions of the trachea. This difference in distribution is further








This chapter aims to investigate SMG distribution in mice of different genetic strain
and phenotypes.
The genotypic-phenotypic relationship of modifier genes
The route from genetic mutation to disease phenotype in CF is not straightforward
with a consider degree of phenotypic heterogeneity. This variation can only be partly
explained by the diverse spectrum of CFTR mutations (of which there are now over
800 known)(Corey, 1989, Kristidis, 1992) since family members with the same
genotype have been observed to show clinical variation (Davis, 1996). It is therefore
likely that environmental and other genetic factors modulate the CF phenotype.
Through the use of inbred mice it is quite possible to restrict the nature and control
the nurture of any genetic study with a phenotypic endpoint. Alternatively, it is
possible to make comparisons of a specific mutation on different genetic
backgrounds and thereupon examine the effects of other genes upon the final
phenotype. Such secondary acting genes are known as "modifiers". Examples of
phenotypic variation in transgenic mice on different genetic backgrounds is
presented in figure 3.0.1.
The assumption of such studies is that the genetic differences in the mouse strain are
somehow suppressing or enhancing the expression of genes involved in the patho¬
physiological disease pathway (Erickson, 1996). These studies can provide the
framework and the data to conduct genetic screens for modifier genes.
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Figure 3.0.1
Phenotypic variation in transgenic "knock out" mice on different strains
(genetic backgrounds).
Targeted gene Phenotype Variation by Mouse strain Reference
Keratin 8 Embryonic C57BL/6 FVB/N (Baribault,
lethality 1.6% viable 55% 1994)
1 viable
Epidermal Time of CF1 129/SV CD1 (Threadgill,
growth factor embryonic preimplantation mid Survival to 3 1995)
receptor lethality gestation weeks
The hunt for modifier genes is strongly dependent on there being a definitive and
measurable phenotype. Although, the lung disease phenotype in CF mice is
considered to be weak, in the complete absence of cftr, mice, on a normal solid diet,
suffer from severe intestinal obstruction and rupture leading to death before 5 weeks
of age (Snouwaert, 1992, O'Neal, 1993, Ratcliff, 1993). This phenotype is similar to
the development of meconium ileus in -20% of CF patients (Oppenheimer, 1975).
The Rozmahel group (1996) used this death by gut blockage as an endpoint in a
study of modifier genes for CF in CFTR deficient mice. A CF "null" mouse (named
Cftr>mlHSC) was established through the disruption of exon 1 of the mouse cftr gene
by homologous recombination. Severe intestinal blockage was found to occur in the
majority (>95%) of homozygous Cftr""'HSC/ CfttpnlHSC mice.
The founder mouse was on a 129/Sv genetic background. It was observed that the
mice died in one of three quite distinct time periods (termed "early", "middle" or
"late" with the "late" animals living the longest).
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The founder mouse was crossed with females from the outbred CD1 strain and 4
different inbred strains 129/Sv, DBA/2J, BALB/CJ and D57BL/6J and then
backcrossed to generate homozygous mice (Cftr/mIHSC/Cftr>m'HSC) on 4 different
genetic backgrounds.
The inbred strains were found to show quite distinct mortality profiles. F1 crosses
were made between the Cftr"nIHSC/CftrlmIHSC strains and the results shown in figure
3.0.2.
Effect Of Genetic Background On The Survival Of Cftrtmmsc/Cftrtmllisc Mice.
On the basis of these studies, a modifier locus for mouse survival conferred by
homozygosity of the CD1, C57BL/6J or BALB/cJ alleles but not the DBA/2J alleles
was found to prolong the survival of the Cftr"n,HSC/CftrtmIHSC mice.
A genome scan for the modifier locus was conducted by seeking candidate linkage
loci which also demonstrated significant deviation from the expected random
segregation of CD1 and 129/Sv alleles.
These data identified a candidate region near the centromere of chromosome 7
(Rozmahel, 1996) in which at least 2 independent loci possessing major modifiers
exist (Rozmahel, 1997). Characterisation of these loci suggested that their
contribution to the CF gut phenotype was both dependent on mouse strain and
gender. Furthermore, one of these loci has conserved synteny to a known diabetes
modifier in humans lying on 19ql3. It has been suggested that the modifier gene may
encode for a calcium dependent chloride channel that may be act to compensate for
the lack of CFTR activity.
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The previous studies focused on using mouse survival (as a result of intestinal
blockage) as the basis of their genetic screen. Yet, linkage studies in humans suggest
possible correlation between incidences of intestinal disease but no link to the
severity of lung disease. With reference to the life threatening phenotypes in human
CF disease, it may be of greater significance to use base a genetic screen on some
aspect of lung disease phenotype.
One possible measurement of the CF lung phenotype in the mouse is the altered
respiratory chloride conductance. Reduction of cAMP-dependent chloride ion
conductance (as measured by in vitro Ussing chamber) has been demonstrated in all
mutant CF mice (Dickinson, 1995) as this is assumed to be a direct reflection on the
cftr chloride channel activity. This technique has now been used to examine the
different electrophysiological profiles of wildtype mice on different mouse strains
with the aim of developing a screen for modifier genes.
Provisional data generated in a collaboration between Dr. Dorin and by Prof. Alton
(Imperial College London) describes the changes in the short circuit current across
the tracheal epithelium in response to the addition of forskolin as measured by single
point measurements in a number of mouse strains (CBA, DBA, 129, BALB/c,
C57BL/6 and FVB) (for further details of these mouse strains see appendix 1). Of
these strains there was a significantly greater chloride channel activity in BALB/c
mice compared to all the others with the greatest difference being between the




Survival Profiles of the C/fr"",HSC homozygous mouse on different genetic backgrounds
(from Rozmahel, R. et a/1996).
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3.1
Interstrain variation in SMG histology
Introduction
CF mice on different mouse strains have been demonstrated to show significant
variation in survival rates (Rozmahel, 1996) and wildtype mice on different strains
have been reported to exhibit variable tracheal electrophysiological measurements
(Dorin, J. Personal communication). It was hypothesised that there may be variation
in SMG structure and distribution between the mouse strains that may have the
consequence of affecting the CF mouse lung phenotype and tracheal
electrophysiological measurements. To begin examination of this hypothesis, a
histological comparison of SMG structure in 3 different mouse strains was
conducted.
Materials and Methods
BALB/c, C57BL/6 and CD1 mice (n=6 in each strain) were sacrificed by lethal
injection of Euthatal. Their tracheas were dissected out and after fixation in 4%
paraformaldehyde for 6 hours at +4°C and processed for embedding in wax blocks. 6
gm serial sections were cut and rehydrated to water and counterstained with
haematoxylin and eosin. In an attempt to reduce variation arising from histological
processing and sectioning, all tissues were processed and were sectioned at the same
time. Furthermore, SMG analysis was restricted to longitudinal sections of the area
adjacent to the hyaline cartilage as this area is easily recognisable and has the
highest concentration of SMGs.
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SMG Histological Interstrain Variation
Examination of SMGs from mice of 3 different genetic backgrounds revealed
marked histological variation (see figure 3.1.1). Of the 3 strains studied, the SMGs
from C57BL/6 mice (3.1.1c) were observed as being larger than those of the CDl's
(3.1.1a) and BALB/c's (3.1.1b) occupying a larger area of mesechymal tissue
between the lumen and the hyaline cartilage ring. The C57BL/6 glands showed long
and narrow ciliated ducts and multiple acini branching from the collecting ducts. It is
unclear from this evidence whether the SMGs of the C57BL/6 are larger as a
consequence of filling the larger mesechymal space present or do indeed force a
larger area to exist.
Attempts to quantify these observations (by planimetry) were unsuccessful due to the
complex 3D structure of these glands, their variable distribution within the trachea
and the elastic effects of the cartilage on the sections. However, this experiment was
repeated and the slides screened blind. The mouse strains were correctly identified
100% of the time (n=8 for each strain).
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Figure 3.1.1
Histological Comparison Of SMGs In 3 Mice Strains
3.1.1a H&E histology of SMGs in the CD1 mouse. SMGs were seen to occupy a small
tangential area although ducts were observed as considerably dilated.
3.1.1 b H&E histology of SMGs in the BALB/c mouse.
3.1.1c H&E histology of SMGs in the C57BL/6 mouse. The area occupied by the


















SMG distribution in mice of varying genetic background
Introduction
Preliminary studies (reported in chapter 2) suggested that murine SMG distribution
is restricted to the proximal regions of the mouse trachea. A more comprehensive
study of SMG distribution in 4 different mouse strains was undertaken. In both
sections 3.2 and 3.3, a method of PAS stained tracheal wholemount was used to
overcome the complexities and inaccuracies of scoring for infrequent 3D structures
on a 2D plane. This method is adapted from a similar method for human foetal lung
as reported by Tos (1966) with the assistance of Duncan Davidson.
Materials and Methods
6 week old mice from 4 different genetic backgrounds (129/MF1 Mixed, C57BL/6,
BALB/c and FVB) (n=6-9) were sacrificed by lethal injection with a 0.4ml IP
injection of Euthatal (Rhone Merieux, UK). The 129/MF1 background mice were
housed in a conventional non-SPF facility and were on an outbred strain whereas the
other mice were inbred (>8 generations) and housed in a SPF facility. The tracheal
distribution of SMGs within and between the groups was studied using a method of
PAS tracheal wholemount. Excised tracheas were fixed in 4% neutral buffered
formalin for 6 hours and then transferred to 70% ethanol for storage at +4°C. The
tissues were stained in Periodic acid for 3 minutes, washed 3 times in PBS and
stained in Schiffs reagent for 3 minutes before washing and storage in glycerol at
room temperature.
The stained tracheal wholemounts were pinned out on a flat wax bed using
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sharpened tungsten needles and the viewed with a optic fibre dissecting microscope
at x80 magnification (Volpi, Switzerland). The SMGs were visible lying between the
cartilage rings (this observation was confirmed by post fixation and histological
examination of sections). The tracheas were scored for the presence and location of
SMGs. As the more distal SMGs lay between cartilage rings, a system of scoring
with reference to cartilage ring gaps was designed. The gap distal to the hyaline
Cartilage ring was numbered gap 0 running down to gap 14 or 15 at the carina. See
figure 3.2.1.
Results
A method of wholemount PAS staining of the mouse trachea was developed to aid
whole tracheal screening for SMGs. See figure 3.2.1.
Mice from 3 different mouse strains were studied for SMG distribution. Data is
presented in figure 3.2.2. X axis of the figure represents mouse number with score on
Y axis corresponding to ring gap number as defined above. The symbol "©"
represents more than 10 SMGs being present in a single gap. Above 10 SMGs per




Method Of Wholemount Analysis Of Murine Trachea For Presence Of SMGs
(Adapted From Tos, M. etal, 1966)
SMGs
3.2.1a Trachea was stained in PAS and subsequently pinned out with tungsten
needles on a bed of wax.
3.2.1b SMGs can be seen lying between the cartilage rings in the more proximal
regions of the trachea
3.2.1c For quantification of the data received through this protocol, the ring gaps were
numbed from "ring 0" (most proximal) downwards.
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Figure 3.2.2
SMG distribution in wildtype mice of 4 different genetic strains
Mouse number is displayed on the X axis and tracheal ring gap position on

























































































1 2 3 4 5 6 1 2 3 4 5 6
© © © © © © 0 © © © © © ©
© © © © © 1 5 3 © © © ©
1 6 2 2 1 3 2 2





The SMG distribution in relation to the location in the trachea showed considerable
variation both within and between groups of varying genetic background. The
location of SMGs in the C57BL/6 mice was restricted to cartilage ring gaps 0 and 1
in 4/6 mice. One mouse had one gland present in gap 2 whilst one mouse had SMGs
located as far as gap 5. The results from the C57BL/6 are in marked contrast to
those observed in the BALB/c mice. All BALB/c mice had SMGs located in
cartilage gap 3 (n=9). 5/9 mice had SMGs at gap 6 and 2 mice had glands present at
gap 8. Mice have on average, 15 cartilage rings.
Two other mice strains were studied, namely, those of a 129/MF1 mixed genetic
background and also FVB mice. The SMG distribution phenotype in these mice lay
between the observations as seen in the C57BL/6 and BALB/c strains.
A statistical comparison was made of these data using the unpaired student's t-test.
Each mouse was scored for most distal SMG and the groups compared for statistical
significance: MF1/129 distribution versus BALB/c p=0.0001, C57BL/6 versus
BALB/c p=0.0002, FVB versus BALB/c p=0.0071. No statistical difference was
noted in the comparison of the 129/MF1, C57BL/6 and FVB strains.
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3.3
SMG distribution in wild type and CF Mutant mice
Introduction
Hyperplasia and hypertrophy (an increase in both volume and number) of SMGs in
CF infants as compared to non-CF infants has been reported (Madden,
1991,Oppenheimer, 1975, Yankaskas, Personal communication). A study into the
effect of reduced CFTR expression on SMG distribution in the mouse was
undertaken.
Materials and Methods
8 week old Mice homozygous for the CFTR insertional mutation CftrfmIHGU (Dorin,
1992a) on all three genetic backgrounds (n=4-7) and mice homozygous for the
protein mislocalisation mutation CftTpn'G55ID (Delaney, 1996) on the 129/MF1 mixed
genetic background (n=6) (all littermates of mice used in section 3.2) were
sacrificed by lethal injection with a 0.4ml IP injection of Euthatal (Rhone Merieux,
UK) and processed for PAS wholemount as before.
Results
SMGs show a significantly more Distal distribution in Cftr deficient mice
In an experiment blinded to genotype, the distribution of PAS stained SMGs was
studied by using whole mount preparation of tracheas as described above. See figure
3.3.1. Wild type mice used were littermates to the CftrfmIHGU mice. All but the
MF1/129 mice were obtained from a SPF facility. Wildtype mice showed the
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presence of more than 10 SMGs in gaps 0 and most commonly, gap 1 and extending
distally to gap number 4 in 2/7 animals. SMGs extend more distally in mice with
low level or mutant cftr expression. Homozygous CftrpnIHGU and homozygous
Cftr"""35510 mice were studied for SMG distribution. In the homozygote q^mIHGU
animals of MF1/129 mixed genetic background, gland masses (where gland
number>10 per gap) are present in gaps 0, 1 and 2 in the majority of cases. 6/7 mice
had glands present in gap number 4 and in one mouse a SMG was identified as distal
as gap number 8. In the homozygote CftrJmIG55,D mice, gland masses were present in
all mice in gaps 0 and 1. At gap number 4, 4 /6 mice scored positive for presence of
glands. The most distal glands in this group of mice were found in gap number 7 (see
figure 6c). The statistical significance of these results (generated as before with
unpaired t-test) were as follows: 129MF/1 mice wildtype versus CftrfmIHGU p=0.002
and versus CftrpnlGS5ID, p=0.02. C57BL/6 wildtype versus Cftr}m,HGU p=0.002. No





SMG distribution in CF mice and wildtype mice
Details for the design of this figure is presented in section 3.2.
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BALB/c: Inbred Genetic Background (SPF housed animals)
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3.4
Evidence for de novo SMGs generation in the adult mouse.
The question of whether the more distal distribution of SMGs in the CF mice have
arisen as a physiological response to damage was addressed by studying SMG
distribution and structure after artificial damage induction by 20gl 1% polidocanol
tracheal instillation.
Materials and Methods
Wild type mice were intraperitoneally injected with 1ml of lOmM
Bromodeoxyuridine (BrdU) solution per lOOg body weight (approximately 1 mg per
mouse) before and after instillation of 20pl 1% (v/v) polidocanol by catheter by a
method adapted from Ho and Furst (1973). After 3 to 21 days, the tracheas were
removed and processed to wax blocks. Immunohistochemistry for the presence of
incorporated was conducted on these sections using the "In situ cell proliferation kit-
AP" (Boehringer Mannheim, Lewes, UK). Tissues were de-waxed and re-hydrated
by transferring slides through 2x xylene for 10 minutes and a decreasing
concentration of ethanol (2x 100%, 90%, 70%, 50%, 1 minute each) to PBS. All
incubation steps took place in a humidified chamber at room temperature unless
otherwise directed. Slides were transferred to a large beaker containing excess PBS
and the beaker covered with cling film prior to boiling using a microwave oven at
high power for 3 x 5 minute intervals. Slides were left to cool in clean PBS.
Slides were incubated with a 1:4 dilution of anti-BrdU-AP antibody in Incubation
buffer (PBS, 1% BSA) for 30 minutes at 37°C in a humid chamber. Slides were
washed in PBS for 3x 5 minutes. Substrate solution was prepared by dissolving lmg
Fast Red (2-methyl-4-chlorobenzene-diazonium: tetrachlorizonicate (2:l)(Boehringer
Mannheim, Lewes, UK) in 2 ml of 1% BSA in PBS.
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Substrate solution was shaken for 5-10 minutes until dissolved. Slides were incubated in
substrate buffer for 15-30 minutes or until colour develops. Slides were counterstained with
haematoxylin and mounted in glycerol mountant (lOg gelatine, 60ml (IH2O, 70ml glycerol,
0.25 phenol) and dried overnight at room temperature prior to viewing with bright field
Nomarski microscopy (Zeiss Axioplan II) (see figure 3.4.1). Although SMG duct dilation was
observed, no results inferring de novo gland production was noted.
Figure 3.4.1








3.4.1a Mouse SMG counterstained with eosin showing lumenal dilation 7 days after
polidocanol instillation. Many glands demonstrated dilation in response to polidocanol damage
though no sign of new gland formation (by glandular labelling with Brdll) was noted.
Discussion
From these studies, no evidence was gained which would suggest that new SMGs
can be generated in response to tracheal damage. If this is related to a CF lung
situation, it would appear to suggest that the more distal pattern of SMG distribution
observed in the CF mouse (and in the human) is not related to an increased level and
susceptibility to tracheal damage but perhaps due to the lack of cftr expression. This
argument is further backed up by the observation of interstrain differences in SMG
distribution in mice from inbred backgrounds and SPF housing facilities. It would
be of interest to examine, if the technology permitted, whether there is stability in the
number and distribution of SMGs throughout the life span of a mouse.
3.5
Discussion
The data presented in this section demonstrates that mice with greatly reduced cftr
expression (5-10% of wildtype expression in case of CftrtmlHGU (Dorin, 1992a) or
mutant cftr in Cftrfm'G55,D (Delaney, 1996)) SMGs extend more distally than in wild
type controls (P<0.05). In addition, there was a significant variation in SMG
distribution between different mouse strains with the C57BL/6 mouse showing the
most restricted distribution and the BALB/c mouse showing the most expansive
distribution of SMGs of strains studied. Of further interest was the observation that
the distal glands were often found to lie on a very similar longitudinal plane. In such
cases, the line of distal glands was most often on the ventral side of the trachea. Data
not shown.
The SMG variation through different mouse strains is most likely to be as a
consequence of the presence of alternative genes that determine SMG distribution.
The reason for the cftr specific distribution is not yet certain, but could be explained
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either as a consequence of CF lung inflammation (though not evident histologically),
response to damage or possibly due to a developmental effect of reduced cftr
expression.
The MF1/129 mice used in this experiment were the anomaly of the experimental
animals as they are of outbred background and were housed in non-SPF facilities.
The data obtained from these animals, although reflecting similar patterns observed
in the other strains, show greater variability in results suggesting perhaps that other
modifier genes or indeed, environmental factors influence SMG distribution. It
would be of interest to see if these animals when housed in SPF facilities show a
reduced range of variability.
From the data presented, it is considered unlikely that new SMGs are developing in
response to epithelial damage. Mice received artificial epithelial damage by
polidocanol instillation and although, SMG dilation occurred, no indication of de
novo gland development was observed.
Do electrophysiology results reflect CF phenotype or SMG distribution?
The correlation between the SMG distribution in different mouse strains and Prof.
Alton's single point electrophysiology results was noted. BALB/c mice which
showed the most distal pattern of SMG distribution also showed the highest levels of
chloride conductance in the trachea by measurement in the Ussing chamber.
C57BL/6 mice showed the opposite, with a very restricted pattern of SMG
distribution and very low chloride conductance.
A model is presented below which outlines the argument that single point
electrophysiology measurements in the trachea of the mouse are not a direct
reflection of a CF phenotype but are instead a reflection on SMG distribution. The
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relationship between the two is, at this time, unclear. The first model (figure 3.5.1) is
based on the assumption that the electrophysiology measurements are taken
approximately in the middle of the trachea. Model number two (figure 3.5.2)
discusses that if the electrophysiology results were taken from different sites on the
trachea, or indeed the trachea orientation was varied, variable electrophysiological
measurements would be obtained.
Recent data from Prof. Alton's laboratory would appear to disagree with model 2
(personal communication). In this study, tracheal tissue from the laryngeal end or
carinal end of was mounted in a mini-Ussing chamber. Drugs were applied to the
tissue to measure the chloride conductance in these areas. In addition, chloride
conductance was measured after the artificial stimulation of any SMG lying in that
region. A decrease in sodium absorption was noted in laryngeal portion of the tissue
as compared to the carinal end but no similar trend in chloride conductance was
detected. These data do not wholly contradict the models presented above since
neither the mouse strain used in this experiment is revealed nor a more detailed
description of what and where the "carinal" or "laryngeal" areas of the trachea
actually are.
These models may have strong implications for the use of single point
electrophysiological measurements as a method of screening for modifier genes for
CF. To test these models experimentally, it would be interesting to correlate the
SMG distribution of tracheal tissue used in the actual Ussing chamber
measurements. Provisional approaches to conduct this experiment have been made
(in collaboration with Dr. B. Innes) however, the method of tissue fixation and




Electrophysiology measurements and SMG distribution Model 1:
Do single point electrophysiological measurements of wildtype tracheas on different mouse










SMGs found only in the very
proximal regions of the trachea
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SMG often distributed beyond
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higher chance of high chloride
conductance
3.5.2
Electrophysiology measurements and SMG distribution Model 2:
Is there any evidence for tracheal orientation (and therefore, SMG distribution) in the Ussing























Theories of the development of CF lung disease
CF lung disease is characterised by the development of mucous obstructions leading
to bronchiolitis and goblet cell hyperplasia leading to squamous metaplasia,
bronchiectasis and possibly pneumonia (Boat, 1989). While mucous obstruction may
be the primary pathophysiological event (as seen by early SMG dilation
(Widdicombe, 1994)), the persistent and chronic infections by a discrete number of
bacterial species including P. aeruginosa, S. aureus and B. cepacia would appear to
have the major destructive effect on the lung (Govan, 1996, Grimwood, 1993). Once
established, these bacterial infections are nearly impossible to clear.
The questions of why mucous obstruction occurs and why such a discrete group of
bacteria should show such tropism for the CF lung still remain unanswered.
Furthermore the relationship between the two processes is unclear.
The traditional model for CF lung disease is based on the disease causing processes
in the CF pancreas. The pancreas is a branched organ involved in the production of
enzymes crucial for the digestion of food. The movement of bicarbonate across the
apical membrane of the pancreatic duct is CFTR dependent. In CF patients a
reduction in bicarbonate secretion in the ducts can occur which leads directly to an
imbalance in the pH of secretions and inactivation of pancreatic enzymes (Lippe,
1977, Kopito, 1965, Quinton, 1996).
It is certainly conceivable that the electrolyte transport defects of the CF airway
could result in abnormal airway secretions. The failure of chloride secretion through
CFTR or the outwardly rectifying chloride channel (Li, 1988) could produce less salt
and therefore less water secretion and subsequently, increase amiloride-sensitive
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sodium reabsorption that would also tend to draw sodium with water out of the
airways. If this pattern occurred in the lung, it can be presumed that the volume of
airway surface fluid (ASF) secreted, under normal conditions, on to the epithelial
surface would be abnormally small. The normal processes of cilia clearance of
mucous and associated pathogens may be disrupted and lead to increased
concentration and colonisation of bacteria in the ASF (Jiang, 1993). This idea has
supported the popular belief that CF ASF is dehydrated and "sticky" (Quinton,
1996).
It is technically very difficult to sample and measure electrolyte concentrations in
ASF due to both the extremely low volume (the "teaspoon of ASF spread over a
tennis court" is a popular analogy; the actual volume of ASF is about 5pi per cm2
and the lung's hypersecretion reaction to many of the sampling protocols (Joris,
1993).
Models of CF airway epithelium in culture have in part supported the model of ASF
being dehydrated in the CF lung (Smith, 1994, Jiang, 1993). However, there is
considerable evidence against this model. Firstly, bronchoscopy observation of CF
airways suggests that CF ASF is not recognisably dry (Joris, 1993). Secondly,
diseases in which cilia action and mucus clearance is known to be impaired (such as
Kartagener's syndrome (Kollberg, 1978)) or in which mucus dehydration occurs
(asthma (Freed, 1987) or hypohidrtic ectodermal dysplasia (Clarke, 1987)) do not
produce the same airway pathology as in CF.
The Role Of SMGs In The Development Of CF Lung Disease
The highest density of CFTR in the human lung is in the serous and ciliated duct
cells of the submucosal glands (Engelhardt, 1992). SMGs have a dual defensive role
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in the lung; supplying the airway epithelium with both fluid and additionally a
mixture of antimicrobial proteins and mucoproteins (Basbaum, 1990, Widdicombe,
1994, Gabay, 1993). SMGs have been reported to show a high degree of plasticity in
response to inflammatory challenge altering both in shape and in the degree of
acidity and sulphation of secretions (Sturgess, 1972). The Yamaya group (1996)
reported that CF SMGs fail to respond to the normal stimulatory p-adrenergic or
cholinergic stimulation suggesting that the defensive role of SMGs may be impaired
in CF. As interesting as these data are, it is puzzling that disease known to have
defective SMG secretions do not show a CF phenotype (Clarke, 1987, Kollberg,
1978). In addition, this theory does not describe the apparent selectivity in bacterial
species that colonise the CF lung nor why CF lung disease appears to develop firstly
in an area devoid of SMGs.
Bacterial Tropism To The CF Lung
CF patients are particularly susceptible to infection by a small number of bacteria
including S. aureus (often the first bacteria to colonise), P. aeruginosa and B.
cepacia (Govan, 1996, Grimwood, 1993). This would suggest an enhanced tropism,
or reduced resistance in the CF lung for these bacteria. The development of CF lung
disease is most likely to be a multi-step process. In this structure, recent experiments
have pointed towards the interaction between bacteria and CFTR deficient epithelial
cells to be very near the head of this process.
P. aeruginosa has been found to be able to upregulate the expression of mucin genes
(Li, 1997). Indeed, there is evidence that the adherence pattern and intemalisation of
P. aeruginosa to CF pulmonary epithelial cells differs from that of wildtype. Details
of these arguments are comprehensively covered by Porteous and Davidson
(Porteous, 1997a) and Davidson and Porteous (Davidson, 1998).
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Theory Of Defensin Inactivation In CF
A currently highly fashionable and exciting theory to explain the occurrence of
bacterial infection in the CF lung has developed around the discovery of salt
sensitive antibacterial agents in the lung in particular the p-defensin family, p-
defensin are members of a family of small antimicrobial peptides which contribute
to the innate immunity mechanism of a wide range of invertebrate and vertebrate
organisms (Ganz, 1995).
In 1996, Smith et al. (1996) reported that ASF from primary CF bronchial epithelial
cultures had reduced antimicrobial activity (against P. aeruginosa and S. aureus) as
compared to wild types, indeed, bacteria were found to multiply in CF ASF. When
the chloride concentration in nasal ASF was measured in CF and non CF patients, it
was found that CF patients had a higher chloride concentration. Interestingly, it was
found that by reducing the salt concentration in the CF ASF normal anti microbial
activity resumed.
These data suggested the presence of an antimicrobial agent in the ASF that was
inactivated at high salt concentrations. Goldman et al. (1997) reported a year later
that P-defensin-1 was a likely candidate for the antimicrobial agent. Human P-
defensin-1 (hBD-1) was found to be expressed throughout the respiratory epithelia
and show a salt dependent anti-microbial profile against P. aeruginosa. In xenografts
(see chapter 7 for details of this system), correction of the CF defect with adenovirus
mediated CFTR gene therapy was found to lead to the normalisation of ASF salt
concentration and the restoration of its bactericidal activity. Furthermore, down-
regulation of hBD-1 RNA by antisense oligonucleotide led to the loss of
antimicrobial activity in ASF from non-CF xenografts.
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The publication of this paper generated a renewed interest in the anti microbial
agents of the lung. A second human (3-defensin has been cloned (hBD-2) in addition
to a murine homologue of hBD-1 (mBD-l)(Morrison, 1998, Huttner, 1997). The
theory is very attractive and accessible in explaining CF lung disease. CFTR
dysfunction leads directly to a change in the ASF environment by raising chloride
levels and although the components of the lungs defence system it is inactivated. The
lung is thereby vulnerable to infection that may precipitate a more pronounced
inflammatory response.
Recently, this picture has become more complicated through the reporting that
defensins and other respiratory anti microbial agents may operate in a synergistic
relationship (Singh, 1997).
Alterations in the ability of cilia to clear sputum and other materials from the airway
epithelium in CF patients may be related to the hypothesised change in airway
surface fluid sodium chloride concentration. Wills et al. (1997) studied the rate at
which cilia could transport sputum in CF patients. Using mucus depleted bovine
trachea, the transportability of CF and non sputum was found to be slow. Adding
sodium chloride to sputum was found to enhance its transportability by possibly
altering the sputum's rheology and the ciliary transportability.
Critics of this theory attack the assumption the CFTR defect in the lung results in
increased chloride levels as seen in the sweat ducts of CF patients (Quinton, 1983).
Attempts to measure the Chloride concentration of ASF in the lung is virtually
impossible without the use of some invasive technique (Quinton, 1996) giving rise to
arguments over whether they do in fact reflect in vivo results. One common
technique is to apply a piece of "blotting paper" to the lung epithelium in order to
soak up ASF. Bronchoscopy examination of this protocol has often observed
localised hypersecretion of mucus (Quinton, 1996). At this time, the answer to this
criticism is still unclear. Joris et al. (1993) reported an increase in chloride
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concentrations in CF patients (chloride concentration 84+9mM and 129±5pM).
Knowles et al. (1997) found no difference in the ion composition of bronchial ASF
from in vitro culture. Since the airway epithelium is characterised as being "leaky" to
the paracellular flow of water and salt, it is not clear to what extent abnormalities in
electrolyte concentration can actually exist (Davis, 1996).
Although functional studies on the human (3-defensin-l peptide had been previously
reported by Goldman et al. (1997) their data failed to present the effect of varying
salt concentration on control samples or analysis of error variation. This chapter
examines the relation between the antimicrobial activity of synthetically produced
hBD-1 and mBD-1 and salt concentration.
This work was done in collaboration with Dr. Donald Davidson. The laboratory
work was shared equally between Dr. Davidson and myself. Dr. Davidson arranged
the statistical analysis for the data with Mr. Peter Teague.
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4.1
Effect Of Salt Concentration On (1-Defensin-l Antibacterial Activity
Introduction
The effect of varying buffer salt concentration on the functional activity of human (3
defensin-1 (hBD-1) and mouse (3-defensin-l (mBD-1) against 2 bacterial strains of
clinical significance was conducted.
Materials and Methods
Mature Human (3 defensin 1 and mouse (3 defensin 1 peptide were synthesised by
Prof. Ramage (Albachem Ltd., Edinburgh, UK) and correct secondary structure
cysteine bond formation and purity was confirmed using High Performance Liquid
Chromatography and MALDI TOF MS (mass spectroscopy) analysis.
Functional analysis of synthetic mBD-1 and hBD-1
The functional activity of the synthetic defensins was tested against P. aeruginosa
(CF clinical isolate K1385) (kindly supplied by Prof. J. Govan). This bacteria was
chosen because of its recognised pathogenic involvement in CF lung disease (Govan,
1996). Overnight cultures of bacteria were grown in nutrient broth and then
suspended in PBS at a concentration of ~l x 109 colony forming units per ml. These
samples were then split, resuspended and diluted in lOmM Phosphate buffer (0.01M
KH2P04, 0.01M K2HPO4 and 0.1% D-glucose) varying in concentration on NaCl
(final concentrations and pH can be seen in table 4.1.1). Two duplicate 500pl
reactions were prepared containing either buffer alone or with synthetic peptide
rehydrated in buffer in the range of NaCl as seen in figure 4.1.1. Approximately
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5xl04 bacteria were added to these solutions. Reaction mixtures were incubated for
20 minutes at 37°C after which duplicate sets of serial dilutions were prepared from
each sample, again in appropriate saline buffer, plated out on P. isolation agar
(DIFCO , Detroit, USA) and incubated overnight at 37°C for 48 hours. Colony
counts were performed. Controls of peptide and buffer and buffer alone were run to
test for possible contamination.
Figure 4.1.1
















Data are presented in table form in graph form in figure 4.1.2
Statistical Analysis and Data representation was conducted by Peter Teague and
Donald Davidson and is reported fully in Morrison paper (1998). Briefly, data were
shown either as % killed (percentage of difference between test and control group as
compared to control) or % survival (percentage of bacteria in test group as compared
to control). The experiment was designed to give duplicate and dilutions of each
measurement thus providing four values for each point. The variance between these
groups was conducted by calculating the square root transformation of data on a
Poisson distribution. Significance was calculated at a 1% level. Analysis of test
versus controls as performed by plotting NaCl concentrations against means under
square root transformations, with grouped standard errors.
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Figure 4.1.2
Functional activity of mouse and human p-defensin-1 synthetic peptides against
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Survival rate (as expressed as the mean of colony forming units under square root transformation)
of Pseudomonas aeruginosa after 20 minute incubation with 0.05mg/ml human B-defensin-1
(figure 4.1.2a) or 0.5mg/ml mouse human B-defensin-1 (figure 4.1.2c) solutions of varying salt
concentrations. Results from control samples (no B-defensin added) are also shown. Two asterisks
denote statistical significance to 1% and one asterisk denotes significance to the 5% level. Data is
also presented as percentage bacteria killed (as compared to control samples) (figure 4.1.2b and
4.1.2c).
Discussion
Defensin inactivation as a consequence of ionic abnormalities in the CF lung is an
attractive model to explain the impaired ability to clear bacterial infection. The data
presented in this chapter described a study into the activity of human and mouse |3-
defensin-1 peptides against two CF clinically relevant bacterial strains in varying
sodium chloride concentrations (a possible scenario in the CF lung). Defensins from
both species were seen to result in significantly increased killing of P. aeruginosa as
compared to controls at saline concentrations <125 mM. It was interesting to note
that the percentage of bacteria killed was seen to be dependent on saline
concentration both in test and control groups though more affecting the test defensin
group more significantly.
pH variation due to salt concentration was negligible and thought unlikely to
contribute to the varied antimicrobial activity observed.
The clinical significance of these data cannot at this time be determined as the ionic
composition of the human and mouse ASF in CF and non-CFs is still unclear.
However, it would appear likely that altered ionic composition in the CF lung would
have the effect of impairing p-defensin activity against P. aeruginosa. Furthermore,
the biochemical mechanisms by which (Tdefensins operates are at this time, poorly
understood and therefore can not be used to elucidate this observed difference.
Dr. Donald Davidson has expanded on this line of research by investigating the salt
dependent antimicrobial profile of the mouse and human (3-defensin against other CF
related bacteria. Interestingly, when B. cepacia was tested, human [Tdefensin would
appear to have to proliferative effect (D. Davidson, Personal Communication). This
observation suggests that the predisposition of CF patients to infections by B.
cepacia may arise from the impairment of some alternative defence mechanism or
alternative defensin molecules.
It would be of great interest to expand this research into studying the salt
concentration profile of (3-defensin-l activity against a wider range of bacteria and
furthermore compare these findings with those generated by the use of an alternative
defensin or other antimicrobial agent. The generation of a (i-defensin-1 "knock-out"
mouse is currently underway (G. Morrison, personal communication). It will be very
interesting to examine whether this mouse exhibits a reduced ability to kill bacteria.
Chapter 5
Approaches towards Genotypic
Correction of Submucosal Glands
 
Introduction
This chapter aims to study the development of murine SMG with a view to
developing strategies for delivery of gene therapy vectors to submucosal glands.
Theodore Freidmann wrote in 1996, "Gene therapy is not a failure- it is simply still
too immature to deliver yet on its promises"(Friedmann, 1996). This may indeed be
so but this should not prevent discussion on what would be an ideal system for CF
gene therapy, if the technology existed. Included would be the "where" question and
the "when" question. Where would be the most advantageous site for gene therapy
correction of CF phenotype in the lung and when would be the most optimal time
(or times) for delivery.
The lack of pulmonary disease in foetal CF patients (Szeifert, 1985) is perhaps
surprising since there is robust expression of CFTR in the foetal lung, which
diminishes around the time of birth (McCray, 1992, McGrath, 1994). In the postnatal
lung, CFTR expression in the human lung becomes restricted to the serous cells and
the ciliated ducts of the SMGs (Engelhardt, 1992).
The critical steps leading to classic CF lung pathology are poorly understood. The
first signs of CF pathogenesis are noted in infants and include SMG dilation
(Oppenheimer, 1975) and increased levels of IL-8 and neutrophils (Khan, 1995).
This pathology can occur without indication of bacterial infection suggesting that
reduced CFTR may produce pulmonary abnormalities independent of the bacterial
stimuli. By 6 months postnatal, CF patients have often developed the first signs of
bronchiectasis (Oppenheimer, 1975). As lung disease progresses signs of cell
hypertrophy and hyperplasia within the SMGs occurs and the Raid index of the gland
increases (Oppenheimer, 1975). The Reid index is a measure of glandular area (on
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cross section) versus submucosa area. Later, the secretions from CF SMGs may
become dehydrated and in extreme cases, the whole gland may become completely
blocked by mucus becoming a nidus for bacterial infection (Oppenheimer, 1975).
It has been suggested that the early alterations to the lung pathology can breach a
"point of no return" after which a self perpetuating process of lung disease will
develop independent of CFTR activity (Drittanti, 1997). On this evidence the
"when" question can perhaps be answered by encouraging a programme of CF gene
therapy (or whatever form or therapy) as soon after birth as possible.
Targeting SMGs For Gene Therapy Intervention
The targeting of SMGs is likely to be an important strategy for somatic gene
therapy. However, due to the relative inaccessibility of SMGs to aerosolised vectors
(partially due to the constant efflux of mucous), the question of just where the most
optimal site of delivery becomes more complicated. One possibility would be to
target the progenitor cells of SMG (which may be more accessible). As long as gene
expression continues in the successive generation of daughter cells, total gene
correction of SMGs may occur. Before such strategies can become a realistic
possibility however, the biology of SMG development and the identity of any
progenitor cells must be understood.
The prenatal development of human SMGs has been studied extensively. Human
SMGs begin to develop at 10-15 weeks gestation at a time when the trachea and
bronchi have already developed and the bronchioles are developing (Tos, 1966).
Secreting acini begin to be observed by week 25 (Thurlbeck, 1961). D<? novo SMG
generation occurs until the 25th gestational week after which the glands expand and
mature. New-born children have between 3500 and 6000 tracheal glands at a density
of ~1 mm*' (Tos, 1966). It is widely considered that no new glands form after birth
(Sturgess, 1982, Tos, 1966).
The first indication of gland formation is the appearance of the epithelial gland buds.
This structure is spherical and consists of closely packed cells often being seen to
dome slightly (Tos, 1966, Smolich, 1978). Using animal models, this bud was found
to be associated with a high level of CFTR expression (Sehgal, 1996). The bud
rapidly divides to produce irregularly shaped tubules which extend into the
submucosa through the lamina propria and the dense basal connective tissue
(Smolich, 1978). Prolific formation of the branched network follows (Smolich, 1978)
generating the tubule structure and cell type observed in the mature SMG.
It is important to comment that the pattern of SMG development in the human
differs, in some respects, from that in other mammals. Ferrets begin to develop
submucosal glands postnatally within the first week of life. Gland buds are present at
around 3 days leading to simple tubule formation and elongation in the first week.
During the second and third week of tracheal development, dichotomous branching
of glands occurs within the onset of serous tubule formation. By 5 weeks after birth,
serous and mucous tubule is complete although gland mass and volume continues to
increase until the animal is in early adulthood (Sehgal, 1996, Leigh, 1986).
In the adult rat, SMGs have been observed at the level of the larynx and in the
proximal part of the trachea (Korhonen, 1969) but not at or beyond the origin of the
main bronchi as is the case in humans (Sturgess, 1982). As with the ferret, rat SMGs
develop in early postnatal life. During the first 3 weeks, the epithelial gland bud
forms (between 3 and 6 days postnatal (Smolich, 1978) and divides to produce the
network of ducts and tubules that make up the SMG. All cell types are normally
present 3 weeks postnatal. Over the following 3 weeks, glands increase in volume
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and there is an associated increase in number of ciliated cells in the ciliated duct and
an increase number of mucous cells in the acini (Smolich, 1978).
SMGs develop foetally in both the sheep and the dog in a pattern more akin to that
of the human than that of the rat or ferret. Further to these similarities, SMGs in the
both these species extend to the level of the small bronchi (de Haller, 1969).
Mechanisms of SMG development
In a study based on the xenograft system (see chapter 7 for details), Engelhardt et al.
(1995) investigated whether SMG are clonally derived i.e. does one single cell in the
epithelium or gland bud go to produce a whole gland? As has been highlighted
above, if such a progenitor cell existed it would be a very attractive target for gene
therapy. In this experiment, cultures of human bronchial cells were partially
transfected by recombinant retrovirus prior to seeding in xenografts. These studies
demonstrated that there was a high prevalence of non-clonality in the SMGs. This
may either be due to more than one airway progenitor cell being involved in the
initial stages of gland development or alternatively due to the frequent formation of
glands in the xenografts with more than one duct to the surface airway epithelium.
These data suggested that the classical model of one duct: one SMG may not operate
exclusively in the development of SMGs. Instead, a proportion of glands may
interact with each through the joining of glandular lumens. See figure 5.0.1.
Figure 5.0.1.
Polyductal Development Of SMGs As Displayed In The Xenograft Model (After
Engelhardt EtAI. (Engelhardt, J. F.etal, 1995))
A
5.0.1a Model obtained through transgene expression studies of bronchial xenografts
describing the development of SMGs through interaction between multiple glands to produce
a polyductal gland network. SMGs of this nature were not observed in the studies presented in
this thesis.







Advances towards understanding the molecular control of SMG progenitor cells was
made with the discovery of the Ferret HMG transcription factor Lymphoid Enhancer
Factor-1 (LEF-I). LEF-1 was found to be expressed specifically in a subset of
epithelial cells associated with the development of the gland bud in the ferret,
suggesting that LEF-1 may act as a developmental switch for SMG development
(Duan, 1998). Using recombinant retroviral vectors, SMG progenitor cells were
successfully targeted leading to stable expression of transgene throughout
subsequent gland development.
Just how critical and necessary LEF-1 is in SMG development was explored using
antisense technology directed against LEF-1 expression in the xenograft model
(Duan, 1997).When anti-sense oligonucleotides were applied to newborn tracheal
xenografts, a 4-fold decrease in the number and size of SMGs was noted. To the
other extreme, an experiment was conducted to over express LEF-1 in the xenograft
using AAV. Although that a significant proportion of the epithelium was transfected,
there was no significant difference in SMG size or number. This suggests that LEF-1
is necessary but not sufficient to promote SMG development. At this time, a "knock¬
out" LEF-1 mouse is currently being developed (D. Duan, personal communication).
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5.1
Development Of SMGs In The Mouse
Introduction
There would appear to exist a correlation in mammals between the size and the time
of SMG development. SMGs in larger mammals (humans, sheep, dogs) (Goco, 1964,
Tos, !966,de Haller, 1969) develop prenatally whilst in smaller mammals including
the ferret and rat (Leigh, 1986, Engelhardt, 1995) SMG development is postnatal.
An experiment was conducted to study SMG development in the mouse.
Materials and Methods
Matings between SPF MF1 mice were set up to provide embryonic and perinatal
mice at E17.5, E18.5 and post natal days 0.5, 3.5, 6.5 and 10.5 (n=4). Day E0.5 was
defined as the day when cervical plugs were found in the mating females. The
gestation period of the MF1 mice was around 19.5 days. Tracheas were dissected
and processed to produce wax blocks from which semi-serial (approximately one
section every lOOpI) longitudinal sections and also cross sections (n=4 at each time
point). Sections were prepared and counterstained with haematoxylin and eosin







Early Development Of Murine Smgs.
SMGs were observed in the tracheas of mice aged 3.5, 6.5 and 10.5 postnatal. Mice
of ages 0.5 postnatal and embryonic days E17.5 and E18.5 showed no signs of
SMGs
5.1.1 A: Longitudinal section of proximal trachea from 3.5 day old mouse. SMGs were
observed to be already present and are highlighted by arrows.
5.1.1B: Proximal trachea of 6.5 day old mice displaying presence of SMGs.
5.1.1C: Proximal trachea of 10.5 day old mice displaying presence of SMGs.
5.1.1 D-E Higher power images of SMGs at 3.5 days postnatal. The ciliated and




These data suggest that SMGs develop in the mouse between days 1 and 3 postnatal
after which time, SMGs develop rapidly increasing in volume and complexity. This
pattern is in common with that observe in the ferret and the rat, other potential
mammalian models (Leigh, 1986, Engelhardt, 1995).
It is interesting to consider whether the time of SMG development is related to the
diameter or physiological environment of the animal. In the context of studying lung
physiology and disease, it is as yet unclear whether the prenatal establishment of and
the physiological activity of SMGs in an essentially aqueous environment may be
important in pathogenesis of CF lung in humans.
As was the argument for using the wholemount method reported in section 3.1, it can
not be said conclusively that there are no SMGs in mice in the mice younger than 3.5
days from evidence provided by thin sections. Wholemount preparation proved to be
technically unfeasible due to the size of the tracheas at these stages of development
so thin sectioning was the only practical alternative. To make this method as
effective as possible, semi serial sectioning was made of tracheas in both
longitudinal and cross-section orientation was made.
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5.2
A Study Of SMG Development Through The Generation And Study Of
Aggregation Chimaeric Mice
Introduction
Human SMGs act in the production an efflux of mucous and antimicrobial materials
out onto the luminal epithelium of the trachea and the bronchi. Due to the complex
structure and the presence of mucous, the SMGs are considered inaccessible to
conventional aerosolised delivery systems of gene therapy vectors.
One possible strategy to overcome this problem would be to target and correct the
genetic defect in the cell or cells which go to produce SMGs. Correction of the SMG
progenitor cell population will, theoretically, give rise to a SMG in which every cell
would be corrected.
Although xenograft based studies have been conducted into the mechanisms of SMG
development (Engelhardt, 1995), there has been little in the way of in vivo studies.




Two series of adult aggregation chimaeric mice were produced each carrying a
contribution of transgenically marked cells. The CA series chimaeric animals carried
a contribution of cells carrying a 1000-copy tandem array murine 8-globin insert
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detectable by DNA:DNA in situ hybridisation as described by Keighren and West
(1993). The CJ series carried a contribution of cells which express a Lac-Z
transgene. The Series CA was analysed by DNA in situ hybridisation against the (3
globin transgene and series CJ was analysed by [3 galactosidase histochemistry to
detect expression of a Lac Z transgene. The strain designation are shown in table
5.2.1.
This work was done in collaboration with the lab of Dr. John West. Margaret
Keighren and Jean Flockhart generated the large majority of chimaeric animals. The
author conducted most of the transgene detection protocol and GPI analysis.
Figure 5.2.1
Details the stocks of mice used in the production of CA and CJ chimaeras.
Stock name Details Genotype
Albino GPI-1 T
EXP (BF! female x TGB male)Fi C/C b/b
- — A.
AAF, (BALB/c female x A/J male)F, hybrid C/C a/a •t : . '
CMA Derived from transgenic strain 83 C/C a/a Tci/rq
BF, (C57BL/Ola female x CBA/Ca male)F1 hybrid C/C b/b -/. -
ROSA Derived from transgenic strain ROSA26 C/C b/b Lac /TLacZWSMmWM.
TGB Derived from transgenic strain 83 and BF! C/C b/b Tcm
Transgenic abbreviations; Tg = TgN(Hbb-b1)83Clo; lac Z=TgR(ROSA26)26Sor
Females were induced to ovulate by interperitoneal injections of 5IU of pregnant
mares' serum gonadotrophin at -12 noon, followed 48 hours later by interperitoneal
injection of 5 IU of human chorionic gonadotrophin. Females were caged overnight
with males of appropriate stock, and mating was confirmed the following morning by
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the presence of a vaginal copulation plug; the day following the vaginal plug was
designated 0.5 day postcoitum (d.p.c) On the same day as vaginal plugs were
identified, CF| females in oestrus were paired overnight with vasectomized CF|
males and matings were verified the following morning by the presence of a vaginal
plug. These provided homozygous, pseudopregnant females differing in GPI status
for embryo recipients. . • .
Embryos were flushed from the superovulated females at 2.5 d.p.c. with HEPES-
buffered M2 handling medium. After overnight culture, the aggregated embryos
were surgically transferred to the uteri of pseudopregnant CF| females. Chimaeric
mice were born some 18 days later. The chimaeric nature of the mice was confirmed
by coat colour and glucose-phosphate isomerase analysis of blood taken from the
mouse at 6 months of age and the left kidney, cerebrum, lung and the median lobe of
the liver taken at time of sacrifice. Briefly, 50pl blood was dissolved 1:5 in distilled
H20. An acetate gel plate was pre-washed in TBE buffer and then dried. 0.2pl of
diluted bloods were applied to the gel plate and the gel run at 200V for 1 hour
(blood applications ran from the anode towards the cathode) to separate the different
enzymes according to electric charge and size. Controls of group B, group A and
group AB bloods were also run. The gel was removed and dried on a glass heater.
Staining solution was freshly prepared (0.75mls glycerol, 0.75ml 0.2% MgCl2, 170pJ
tris-citrate (pH 8), 170|il 20mg/ml Fluoride-6-phosphate, 170|il NBT, 170|il 2.7
mg/ml NADP, 4 unitsG6PD, 20pl 2.7mg/ml PMS) and poured over the plate and
incubated for 3 minutes in the dark before washing in distilled H20 + 5% ethanoic
acid. The GPI bands was visible on the gel plates. Quantitative measurements of
band intensities were made by use of the Helena Process 24 plate reader.
The tissues chosen for GPI analysis include derivatives of all three germ layers:
endoderm (liver and lung) mesoderm (kidney and blood) and ectoderm (brain).
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At 6 months of age, the mice were sacrificed and tracheas dissected as outlined
above. Tracheas from the CJ mice were rinsed in PBS and fixed for 6 hours at +4 °C
in a solution of 1% formaldehyde, 0.2% giuteraldehyde, 0.02% NP-40 in PBS.
Samples were washed in PBS and incubated over night at 37°C in X-gal stain (0.43
mg/ml 5-bromo-4-Chloro-3-indolyl-l-D-Galactosidase in N'-N'-dimethyl-formamide
(Melford Laboratories, Chelsworth, UK), 3.1mM K3Fe'"(CN6 ), 3.1mM K4Fem(CN6),
I mM MgCL in PBS). The next morning the tissues were washed twice in PBS and
then fixed into wax blocks as outlined above. Serial 6pm sections were cut and
dewaxed and hydrated by passing the slides through 2x xylene (40 seconds each)
and a gradient of alcohols (70%, 50%, 30%; 15 seconds each). Sections were
counterstained with neutral red then dehydrated to xylene and mounted with DPX.
Generation Of Digoxygenin (DIG) Labelled Probe
Digoxygenin-labelled pMfS82 ((3-globin) probe was prepared by Midi prep of an E.
coli based vector and plasmid DNA purified using the Quiagen Plasmid Midi Kit
(Quiagen, Crawley, UK) and identity confirmed by digestion with Hindlll and
EcoRl (see figure 5.2.2). DIG label was incorporated into the plasmid using
Boehringer Mannheim DIG labelling kit (Boehringer Mannheim, Lewes, UK). Probe
was further purified using the High Pure PCR Product Purification Kit (Boehringer
Mannheim, Lewes, UK). To test the identity of the probe, DNA was extracted from
the lung of a mouse homozygous for the (I-globin insert and one wildtype mouse by
phenol chloroform extraction. The DNA was randomly digested and run on a 0.8%
midi gel.
Bacterial Cell Culture
Glycerol stocks of the pM(382 (3-gal expression vector transformed in E. coli was
gifted by John West. Glycerol stock were streaked out on L-broth agar plates (2.46g
magnesium sulphate, lOg tryptone, 5g yeast extract, lOg sodium chloride, 15 g agar
(Oxoid ltd., Sussex, UK), in 11 dH20) and incubated overnight at 37°C to give
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identifiable single colonies.
5ml of Terrific Broth (12g Bacto-tryptone (D1FCO, Detroit, USA), 24g Yeast
extract (DIFCO, Detroit, USA) and 4g glycerol added to 900ml distilled water prior
to autoclaving and the addition of 100ml sterile phosphate solution (0.1M potassium
dihydrogen phosphate and 0.72M dipotassium hydrogen phosphate)) and was
inoculated with a single colony of E.coli. Bacteria were grown up for 3 hours in a
37°C shaker prior to transferring the solution to 500ml Terrific broth and overnight
incubation at 37°C.
DNA was extracted from the bacteria by the method of alkaline lysis. Bacteria in
broth were centrifuged at 5k rpm for 15 minutes. Supernatant was discarded and the
pellet resuspended in 20mls solution 1 (50mM glucose, 25mM Tris-HCl, 50mM
EDTA, lOmg/ml lysozyme (Sigma)). The solution was incubated for 5 minutes at
room 10 minutes. 27.6mls of 1% (w/v) SDS in 0.2M sodium hydroxide was added
and the solution gently mixed and left on ice for 15 minutes. 14mls pre-cooled
potassium acetate was added and the lysis mixed gently. The mixture was incubated
for 15 minutes on ice. Cell debris was removed by centrifugation at 12 krpm (4°C for
30 minutes) retaining the supernatant which was filtered through muslin and mixed
with 0.6 volumes isopropanol. The mixture was spun at 5000 rpm for 10 minutes and
the supernatant discarded. The pellet was rinsed in ethanol and dissolved in 2.5mls
Tris-EDTA buffer and store at -20°C.
DNA was purified using the Quiagen Plasmid Midi Kit according to manufacturers
directions. Digestion of pMp82 with the restriction endonucleases Hindlll and
BamFU will (according to plasmid sequencing data) produce fragments of specific
size which will be readily identifiable by mini gel electrophoresis. In this case, Hind
III digestion of pMp52 produces fragments of 2.43 and 5.38 and the BamHl digest
produces fragments of 5.64 and 3.23 kb. See figure 5.2.1.
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Digestion of DNA by restriction enzymes was carried out on lpg plasmid DNA
using one unit of restriction enzyme in a total volume of 20pl. Incubation was
conducted overnight at 37°C. 0.8% v/v agar was mixed with 30ml dH20 and boiled
in a microwave for approximately 2 minutes. 2pl ethidium bromide was added and
the mixture poured into a gel mould which included a toothed comb. When set, the
comb was removed . Agarose gel electrophoresis was used to separate the DNA
fragments of different sizes. lOpl of the digested DNA samples was mixed with lpl
xlO stop buffer (20% w/v Ficoll (Pharmacia), lOOmM EDTA, Orange C (Sigma))
and pipetted into the comb marks. The gel was submerged in lxTAE buffer (0.04M
Tris-HCl, ImM EDTA pH8.0, 0.02M Acetic acid) and a voltage of 100V passed
across the gel (the DNA being attracted to the anode) for one hour. The ethidium
incorporated DNA was visualised using UV light.
The plasmid was linearised with incubation with EcoRl (1 unit/pg) at 37°C for 90
minutes. DIG labelling of the probe was performed according to and using the
Boehringer Mannheim DIG labelling kit.
Isolation of mouse DNA by Quick Lysis method
DNA was isolated from mouse lungs by the quick lysis technique. Lungs were
dissected out and the tissue incubated at 37°C overnight in a proteinase K solution
(lOOmM Tris-HCI pH 8.5, 5mM EDTA, 0.2% w/v SDS, 200mM Sodium chloride
and lOOpg proteinase K (Boehringer Mannheim). DNA was precipitated through the
addition of an equal volume of isopropanol . Precipitated DNA was spooled out
using a glass rod and washed briefly in 70% ethanol. The DNA was left to air dry
before incubating at 4°C in 500pl Tris EDTA buffer overnight.
DNA:DNA In-situ hybridisation technique for B-globin transgene detection
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The CA series chimaeric animals carried a contribution of cells carrying a p-globin
insert detectable by DNA:DNA in situ hybridisation as described by Keighren and
West (Keighren, 1993). Hybridised Digoxygenin-labelled DNA probe was detected
by diaminobenzidine staining for peroxidase-labelled antibody (non-radioactive
DNA labelling and detection kit; Boehringer Mannheim, Lewes, UK). Slides were
counterstained with eosin and examined by bright-field light microscopy. See below
for further details of protocol. Individual SMGs were selected at random and the
cells scored for presence of absence of hybridisation signal. The absolute number of
cells scored was dependent on the size of the SMG tissue on the section but varied
from -100 to -300 cells. Cells of the tracheal epithelium were also scored for
presence of marker.
Chimaeric and control animals were sacrificed by cervical dislocation and tissues
fixed in 3 parts ethanol :1 parts ethanoic acid and processed to wax blocks. 6pm
sections were prepared on Vectabond coated slides. Sections were dewaxed in
Histoclear (B.S. and S., Edinburgh, UK) for 2 x 10 minutes at room temperature.
Slides were washed in 100% ethanol for 2x5 minutes, in freshly prepared 3% H2O2
in methanol for 30 minutes (to reduce endogenous peroxidase activity) then washed
in 70% ethanol for 2x5 minutes prior to final washing in PBS for 2 x 5 minutes.
To partially denature the cells, slides were incubated in ImM NaOH at 70°C for 3
minutes then washed in PBS at +4°C for 2 x 5minutes.
Pre hybridisation (to reduce background signal) was carried out by incubating slides
with 2 parts 50 x Denhardt's regent (9 parts deioinised formamide, 6 parts 20 x SSC,
3 parts sonicated salmon sperm and 6 parts distilled dH20 for 15 minutes at 60°C).
Slides were hybridised overnight in a humidified chamber at 60°C with 40pl of
hybridisation mixture which contained lOpl labelled DIG probe (freshly boiled for
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10 and sat on ice for 3 minutes), 20pl sonicated salmon sperm, 200pl 20% dextran
sulphate, lOOpl 20 x SSC and 70pl H20.
The next day, slides were washed in 2xSSC, 0.1 triton X for lx 10 minutes and lx 5
minutes, washed in 0.lx SSC, 0.1 triton-X for 1 x 5 minutes, washed in O.lx SSC,
0.1 triton-X for 1 x 5 minutes (at 50°C), then finally 0.1 x SSC, 0.1 triton-X , 5 %
BSA (by mass). Washes were carried out at RT unless otherwise noted.
Signal was visualised by washing slides in buffer 1 (0.1M Tris 0.15M NaCl pH 7.5)
for 5 minutes at room temperature. Slides were then place in a humidified chamber
and tissues flooded with a 1:100 dilution of anti-Digoxygenin HRP antibody
(Boehringer Mannheim, Lewes, UK) in buffer 1 for 30 minutes. Slides were washed
in buffer 1 (2x 5 minutes at room temperature) then washed in DAB buffer (buffer I
+ 5% BSA) for 5 minutes. Tissues were flooded with developmental reagent for 40
minutes (45pl NBT solution (75mg/ml dimethylformamide 70% v/v), 35 p.1 X-
phosphate (Boehringer Mannheim, Lewes, UK), lOmls 0.1M tris, 0. IM NaCl (pH
9.5), 0.05M MgCL) in a dark humidified chamber and then placed directly in H20 to
stop the reaction.
To counterstain the tissue, slides were incubated in 1% Eosin for about 20 seconds
(the timing varied depending on the freshness of the eosin) and then dehydrated
through a increasing concentration gradient of alcohols. Slides were incubated in
Histoclear for 2 minutes then rinsed in xylene prior to coverslip mounting with liquid
pertex solution (Cellpath pic, Herts, UK).
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Hemizygous transgenic (Tg/-) and homozygous non-transgenic (-/-) tissues were
used as positive and negative controls for comparison with hemizygous chimaeras
(Tg/- «• In cells carrying the transgenic marker (especially hemizygous
transgenic cells) it is possible for the hybridisation signal not to be detectable
(Quinn, 1996). This will commonly be due to the process of tissue sectioning;
cutting a nucleus in two and removing the transgene from tissue otherwise
histologically intact. The uncorrected percentage of cells with a hybridisation signal
was categorised on a non-linear scale (see figure 5.2.5).
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Results
Generation of Probe pMp82
Confirmation of probe pMp82 production was provided through digestion of the probe with
Hindlll and BamHl and running out products and controls on a 0.8% agarose gel (see figure
5.2.2).
Figure 5.2.2
0.8% Agarose gel demonstrating correct generation of the is-globin probe plasmid.
Lane 1: Marker Ladder
Lane 2 : Undigested probe plasmid
Lane 3 : Plasmid digested with Hindlll showing 2.43kb and 5.38kb bands.
Lane 4 : Undigested probe





Evidence for generation of chimaeric offspring by GPI assay.
A simple and quantitative technique to measure the contribution of each donor mating to the
final chimaera was to select the mice strains so that the different donor pairs have different
blood groups. This difference is measurable by the GPI assay which detects different isomers
of the enzyme glucose phosphate isomerase 1. The isomers are detectable by a method of
acetate gel electrophoresis and staining. Examples of GPI assay results are given in figure
5.2.3.
Figure 5.2.3
Evidence For Chimaerism By GPI Allozyme Assay.
Each band is blood from different mice with the bands demonstrating the varying composition
in GPI status of the aggregation chimaeras. The allozyme bands are referred to as GPI-1aand
GPI-1b due to their occurrence in bloods of particular groupings.
Lane 1 2 3 4 5 (Marker)
Lanes 1-4: Mice demonstrating evidence for chimaerism by possessing both blood containing
the GPI-1a and GPI-1b band. The cellular contribution by the donors to the chimaeras can be
estimated by quantifying the comparitive level of band intensity.
Lane 5: Marker from known AB blood. Intermediate band shows the presence of a GPI-1a
and GPI-1b dimer.
Evidence for Clonal development of murine SMGs
The development of murine SMGs was examined through the generation of
aggregation chimaeric mice. Two different series of chimaeras were produced
(referred to as CJ and CA) and the percentage contribution of transgenically marked
cells was confirmed and quantified by analysis of glucose phosphate isomerase
allozymes in tail tip blood and other tissues (5-95% transgenic contribution). 120
SMGs from 30 of these mice were studied for transgenic cell contribution.
CJ chimaeras were composed of two different transgenic genotypes. The
composition of these chimaeras was determined by the contribution of cells
expressing the Lac Z transgene. Non chimaeric positive control (either standard lac
Z/- hemizygotes or mice in the CJ series that proved to be non chimaeric) were
stained with X-gal solution resulting in a blue staining pattern in all SMG and
epithelial cells type. Negative controls of X-gal stained wildtype mice showed
occasional weak background staining. This staining pattern was readily
distinguishable from positive control staining on account of signal intensity and
variation on serial sections.
By studying the SMGs of the CJ chimaeric animals, the glands were found to be of
single ductal structure and composed of either cells all staining positive with X-gal
or all negative (figure 5.2.4).
CA series chimaeras (Tg/- « -/-) carry a contribution of cells which are genomically
marked with a large 1000 copy (J-globin insert. This marker is detectable not by
identification of an expressed gene product as in the case of the CJ chimaeras, but by
DNA in situ hybridisation. For technical reasons, as discussed in section 5.2, a
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proportion of transgenically marked cells may not be identifiable by DNA in situ
hybridisation.
To analyse the development of SMGs using a non-expressed transgenic marker,
chimaeras carrying a contribution of cells heterozygously marked with a (f-globin
insert were studied. The percentage of cells carrying the transgene in the chimaeric
animals was estimated through analysis of coat colour pigmentation in the animal
and by analysis of body tissues by the glucose phosphate isomerase assay (transgene
carrying cells were homozygous GPI-lb/GPI-lb whilst non transgene cells were
homozygous GPI-1 '7GPI-1a). Cell contribution to SMGs and the tracheal epithelium
was then estimated by DNA in situ hybridisation in CA chimaeric tissue and both
positive and negative control tissues containing respectively 100% or 0% of Tg/-




Examples of Chimaeric tissues after staining for transgene visualisation
Tracheal tissues from either the series of Lac-Z aggregation chimaeric mice or those
carrying the [3-globin transgene. Lac-Z gene product is visualised using X-gal stain
(staining blue) and histology visualised with Neutral red nuclear counterstain (red).
5.2.4A The cartilage ring also stains for neutral red and was found to buckle when cut
in cross sections. The tissue showed both stained and non-stained SMGs. Area
circled is at higher power in figure 5.2.4b.
5.2.4B-C, E-F A positively stained SMG was determined as that whose cells
consistently and concurrently stained blue, the staining intensity of which was readily
observed to be above that of background. SMGs were found to either completely be
composed of cells expressing the transgene or completely devoid of transgene
expressing cells. Furthermore, SMGs were found to be only of single ductal type.
5.2.4D The epithelium surrounding the ductal opening was observed to carry the
same genotype (with relation to marked gene) as the SMG. This observation is
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5.2.4G, J Examples of images from CA series chimaeras after transgene visualisation
with DNA:DNA insitu hybridisation. Cell were counted in each SMG for presence or
absence of transgene marker (seen as a brown dot).
5.2.4H SMG acini at higher power showing presence of (3-globin transgene. In some
cells both (3-globin inserts in the homozygous transgene carrying cells can be
observed (see arrow on figure H). In some cells, one or both (approximately 20%) the
signals are lost due to sectioning.
5.2.41 Other tissues showed evidence for chimaeric development including the
oesophagus. This tissue showed blocks of epithelial tissue staining positive for Lac-Z.
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Figure 5.2.5
Analysis Of CA Chimaeras; % Contribution of Tg/- cells in Tg/-<=>-/- chimaeras
(CA) and controls
Tissue compositions of adult (Tg/-o-/-) chimaeras (Series CA; EXPxEXP<=>AAF! x
AAFi) and both positive (Tg/-) and negative (-/-) control animals (n=6). The proportion
of transgenic (EXP x EXP) cells was estimated by coat colour and GPI assay on a
variety of body tissues. The contribution of transgenic (Tg/-) cells in the tracheal
epithelium and three randomly chosen SMGs is shown as the uncorrected
percentage of cells with a hybridisation signal after DNA in situ hybridisation.
Coat colour hybridisation score was measured by the extent of coat colour
pigmentation in the mouse. Brain, kidney, cerebrum, lung, liver and trachea scores
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The uncorrected percentage hybridisation score was categorised as follows:
0%-4% O ;5-29% O ;30-49% ® ; 50-74% ®; 75-100%*
Co=Coat, B=Blood, K=Kidney, Ce-Cerebrum, Lu=Lung, Li=Liver, T=Trachea,
1=SMG#1, 2=SMG#2, 3,SMG#3, Positive = positive controls, Negative =Negative
controls.
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Submucosal glands from the CA chimaeras were analysed to the percentage of
transgene carrying cells in each gland by way of in situ hybridisation. Analysis of the
data from CA chimaeras shows distinct groupings of scoring for detection of
transgene in the SMGs. The first group contains SMGs in which at least 75% of cells
had a hybridisation signal, indicating the presence of P-globin transgene (mean 84.8,
SD 4.7) and the second group which contains SMGs in which fewer than 5% of cells
had a hybridisation signal (mean 0.58, SD 1.06).
These groupings and levels of detection are similar to those observed in controls
(positive control mean 81%, SD 0.42, negative control mean 0.4%, SD 0.12). The
failure of this assay system to detect 100% of marked cells in the positive controls
will be due in part to the loss of transgene from a part of a nucleus which is cut
during histological sectioning. This problem is highlighted by the infrequent
observation of the double hybridisation signal in individual cells. The infrequent
hybridisation signal seen in negative control tissue may be due to staining artefacts.
The level of transgene detection in chimaeric tracheal epithelial tissue was highly
variable with a mean of 40.0% (SD 15.3) inferring a low level of clonal
development.
The composition of the SMGs by transgenically marked cells in both CA and CJ
chimaeras was similar to either the positive or negative controls. This suggests that
the each SMG is clonally derived from a single cell.
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Discussion
Chimaerism is closely associated with naturally occurring cellular mosaicism in
which the inactivation of X-chromosomes occurs in females. In this example, the
cellular patterning can be shown histochemistically (Griffiths, 1988). Griffiths et al.
(1988) observed that the patterning of glucose-6-phosphate dehydrogenase (G6PD)
expression in the cells of female mice can either be normal or low. This observation
was used as the basis of system of somatic clonal marking for the study of large
intestinal development and showed, most eloquently, clonal development of the
individual crypts.
Chimaeric mice provide means by which developmental pathways can be studied in
a completely in vivo and developmentally sensitive manner. 2 series of chimaeric
mice were generated; one series (CJ) contained a contribution of cells carrying lac Z
and another series (CA) contained a contribution of cells carrying a non expressed (3
-globin transgene. Chimaeric CJ SMGs were found to be either composed of cells all
expressing Lac Z (noted by blue staining with X-gal) or composed entirely non
expressing Lac Z cells. In SMGs from the CA chimaeras, the contribution of |3-
globin carrying cells in the SMGs was estimated using DNA:DNA in situ
hybridisation. The composition of transgenically marked cells in the chimaeric SMG
was similar to that observed in the control animals. These data suggests that the
SMGs are clonally derived from a single progenitor cell type.
These observations differ from the findings of Engelhardt et al. (1995) who studied
the development of SMGs in a partially ex vivo xenograft model of the human
bronchi and reported the presence of submucosal glands which appeared to be non
clonally derived. Two possible explanations are cited: either the glands are derived
from more than one progenitor cell or alternatively, some glands contain more than
one duct opening and are formed by glands interacting through the formation of joint
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lumen. This situation can be seen as somewhat akin to the small intestine where
crypts are clonal whilst the villi are polyclonal (Ponder, 1985).
Over 120 chimaeric mouse SMGs were examined by semi-serial sectioning in this
experiment and recorded no evidence for glands either being derived from more than
one progenitor cell or through poly-gland interaction. Furthermore, no previous
studies of SMGs have reported on finding glands with more than one ductal opening.
From our findings we conclude that the novel gland morphogenesis (as compared to
the "classical" single duct glands) seen in the xenograft model does not operate in
mice and perhaps its occurrence is restricted to the xenograft model.
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Chapter 6
Liposome Mediated Gene Transfer
To The Mouse Tracheal Epithelium
 
Introduction
Through the rapid advances in molecular genetics and gene transfer technology, gene
therapy has become one of the landmarks of 90's technology. In gene therapy,
molecular biology has met clinical science head on. However, possibly due to media
and scientific hype (Friedmann, 1996), some of the original lustre of the science has
been lost. After a decade of gene therapy research no single patient out of over 2000
patients involved in gene therapy trials has definitely improved in health (Friedmann,
1997b). That is not to say however, that the results from such trials and other
research have been entirely negative. Examples of successful gene transfer to cell
culture, ex vivo models and to laboratory animals are now common place
(represented in part by in the number of citations to "gene therapy" (Friedmann,
1996)) and gene transfer and expression in clinical trials have been reported for
treatment for a variety of diseases. In this introduction, gene therapy as a method of
therapeutic intervention to CF will be discussed outlining the theory, the difficulties,
the actualities and the plans for the future.
Gene therapy has been defined as any treatment of any disorder or pathophysiologic
state which is based upon the transfer of genetic information (Curiel, 1996). This
broad statement can be rationalised into two areas of research; that of somatic gene
therapy and germ line gene therapy. Germ line gene therapy is based on the
manipulation of the embryo or germ cells to change or add to the existing genome
resulting in a permanent correction which moreover will be then heritable to future
generations. At this time, germ line gene therapy is not permitted on ethical and
moral grounds. Somatic gene therapy results in a non heritable form of intervention.
That is to say correction or alteration of an individuals genome is likely to be
localised and temporary (often dependent on the life time of the target cell). There is
of course a scenario where the two areas can overlap when a treatment designed for
somatic gene therapy reaches and affects the germ line cells of a patient. This
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situation is a part of the design of any gene therapy trial programme (Porteous,
1997b).
CF somatic gene therapy is based on the concept that by replacing the single
abnormal gene defect (mutant CFTR) with a functional copy, normal gene
expression and protein function could be returned to the epithelium. The assumption
being that by correcting CFTR function, the CF lung phenotype will be reverted to
that of the non CF patient.
The lung represents an attractive target organ for gene therapy for a number of
reasons. This is reflected in the disproportionately large fraction of number of lung
orientated gene therapy trials which have been conducted (Sobol, 1996). Firstly,
there are a number of relatively common pulmonary diseases whose genetic basis has
been determined. CF and arantitrypsin deficiency represent the two most common
single gene disorders of Caucasian North Americans (Curiel, 1996). Secondly,
current treatments for pulmonary disease although often improving survival rate and
symptoms, rarely represent a cure. Thirdly, on a more practical basis, the lung is a
highly accessible organ with an extremely large surface area making it likely to be
able to receive high doses of the vector.
When CF is considered as a candidate for gene therapy, the concept becomes even
more attractive for it is believed that a towards wildtype correction of just 5-10%%
may be sufficient to correct the CF lung phenotype (Dorin, 1996a). Other clinical
data suggests that some CF individuals which have as little as 8% normally spliced
CFTR mRNA are phenotypically normal (Chu, 1992). This notion is backed up by
studies using the CF mouse models. By crossing mice of different genotype to
produce compound heterozygotes, it was found that as little as 5-10% of wildtype
cftr expression was sufficient to restore gut electrophysiological measurements and
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mouse survival to near normal (Dorin, 1996a). As a consequence, CF was held up,
by many, as a model disease for correction by gene therapy.
Research into CF lung gene therapy can be seen as belonging to three intertwining
sets. The first set (the "How?" set) aims to design an efficient system by which a
piece of foreign DNA can be delivered by means of a carrying vector from the air,
into a cell and there remain stable and be expressed to produce functional protein.
The second set (the "where?" set) asks where would be the most efficient area of the
lung (often in reference to cell types and specific tissues) to deliver the gene therapy
to. This area can only be fully explored once the first set of questions have been
answered. The final third set (the "when" set) considers the timing and frequency of
gene therapy dose delivery. Such research is based on the pathogenesis of the disease
in the infant and also the life span of target cell types.
Vector Systems for Gene Therapy
One of the requirements of gene therapy for any disease is the development of a
vector system by which the DNA is delivered to the target cell. There are a number
of different approaches that are available which can be grouped into two general
categories- viral and non viral. Each vector system however has its own drawbacks.
Viral based vectors
In the search for a vector which would carry DNA into a cell and there express it,
many groups chose to study and use viral systems. It would appear on the outset the
obvious choice; for evolution has been fine tuning viruses for this very purpose.
Viruses could be adapted to remove genes involved in viral replication and replacing
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them with the gene of choice. In principal the altered, tamed gene should transfer the
gene into the cell with great efficiency yet not multiply or cause disease (Friedmann,
1997a).
The design of a gene therapy virus vector involves first producing a shuttle DNA
construct which may include the transgene, a promoter (often a viral promoter such
as CMV or SV-40), genes which allow the packaging of the retroviral genome into
viral capsids and sequences to permit the integration of the construct into the viral
genome. The site of incorporation is such that the wildtype viral genes necessary for
the production of new replication-competent viruses are lost.
Adenoviral Based Vectors
Out of the 3 main types of viruses, recombinant Adenovirus vectors have been
traditionally favoured for CF gene therapy (Porteous, 1997b). Their original
attraction stemming from the natural tropism of Serotypes 2 and 5 to the human
airways (Curiel, 1996). Adenoviruses have a double stranded DNA genome and a
naked protein capsid coat. Cell entry can occur in either dividing or non dividing
cells and is thought to be through endosomes (Inglis, 1997b). Once in the cell, the
viral genome does not become integrated into the cell's genome rather remaining in
the cytoplasm. This feature is possibly favourable in gene therapy as it would avoid
the possibility that genomic incorporation of the gene therapy cassette may disturb
vital cellular genes or indeed cancer inducing genes (Friedmann, 1997a). However,
adenoviruses often behave transiently in the cytoplasm which may results in low
expression of the transgene (Porteous, 1997b).
In vitro studies using adenoviral vectors mediated gene transduction have been very
encouraging: transduction efficiencies to both murine and human cultured airway
epithelial cells of 90-100% (Zabner, 1994) and full correction of CF phenotype in
160
culture by electrophysiological measurement (Johnson, 1992). Although prolonged
in vivo exposure of Adenovirus vectors to rodents and primates did show evidence of
correction (Zabner, 1994, Wilson, 1995, Engelhardt, 1993), the level of transduction
was disappointing. Hopes that adenovirus may be a suitable vector for CF gene
therapy were further dimmed when transduction to CF mice and in human trials
(Grubb, 1994, Crystal, 1995) were found to be poor and were associated with a dose
dependent inflammatory response (Wagner, 1997). With CF gene therapy likely to
be administered on a frequent time course, the problem of adenovirus induced
inflammatory response has become a major issue for its continued use as a vector.
Modifications of early generation vectors have produced new viruses lacking in or
having a reduction in expression of late viral genes, and subsequently, the host
immune response (Wilson, 1997).
Progress towards understanding the levels of poor in vivo transduction have been
made. Pickles et al. (1996) with the reporting that adenovirus is poorly trophic to
airway columnar cells though highly trophic to basal cells and poorly differentiated
epithelium. In one experiment, the tracheas of the mice were mechanically damaged
prior to infection with non-replicating adenovirus carrying the type CMV driven
LucZ. High levels of LacZ expression were found in basal cells exposed by
mechanical damage. The pattern of transduction efficiency was seen to remain high
during the process of epithelial repair. Adenovirus entry into cells involves both high
affinity fiber attachment and integrin-mediated internalisation (Wickham, 1993). The
authors argue that the difference in transduction efficiencies may be due to
differences in integrin receptor populations in the basal and poorly differentiated cell
types and mature columnar cells (Pickles, 1996). Cultured airway epithelial cells
often exhibit a poorly differentiated basal cell-like phenotype (Grubb, 1994) and this
may explain the high transduction efficiency of Adenovirus in vitro. It hoped that by
incorporating regions antigenic against columnar cell integrins onto the adenovirus
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fibres the adenovirus may become more trophic to columnar cells (RJ Pickles,
personal communication).
Retrovirus Based Vectors
Retroviruses are single strand RNA viruses which can only transduce dividing cells
(Inglis, 1997b) with a lifecycle which involves integration into the host chromosome
(Curiel, 1996). This may be thought to exclude retroviruses from gene therapy to the
lung, a largely quiescent organ, from the outset. However, the extremely high rate of
gene transfer in dividing cell in culture and long term expression has made the
retrovirus the most commonly used viral vector in gene therapy trials (Inglis, 1997b,
Curiel, 1996). Possible problems arising from integration into the host genome must
also be treated with caution for the reasons outlined above.
Adeno-Associated Virus (AAV)
One final viral vector type, which may theoretically bypass the problems of both the
retrovirus and the Adenovirus, is the adeno-associated virus (AAV). They can infect
a wide range of host cells in a wide range of mammalian species (including man) but
have never been shown to be pathogenic or lead to an inflammatory response,
suggesting a significant safety margin for use in gene therapy (Curiel, 1996). Unlike
adenoviruses and retroviruses which have comparatively large genomes, the AAV's
genome is very small and consequently is limited in its capacity to carry a transgenic
insert (Flotte, 1993). This is partially overcome by using the nascent AAV promoter
regions. AAV is a naturally replication deficient single stranded DNA virus which
relies on co-infection by a helper virus (such as adenovirus) for replication.
Normally, without the presence of a helper virus transgenic AAV will integrate into
the host genome, perhaps site specifically and remain quiescent in the cell until
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permissive condition arise. However, when AAV carrying a transgene is used, the
virus most commonly exists extra-chromosomaily (Kotin, 1990).
Non Viral Vector Systems.
Viral vectors continue to show promise for use in CF gene therapy however the
possible problems of associated inflammatory responses, restricted transgenic loads,
possible hazards of transgene integration and restricted cell type transduction has
remained. It is still unclear whether theses disabled viruses could mutate in vivo to
return to a pathogenic form (Friedmann, 1997a). Consideration of these factors have
led some groups to develop other non viral methods of gene delivery. Non viral
vectors come in two main areas: liposome-DNA complexes and molecular
conjugates. Like the viral vectors, these systems aim to condense the DNA and
encourage safe delivery of a transgene package into the cell.
Liposome-DNA complexes
The negative charge of DNA in solution tends to cause it to be repelled from the
negatively charged membranes of cells. Cationic liposomes are self assembling
positively charged lipids resembling small portions of eukaryotic cell membranes.
When mixed with DNA, liposomes encapsulate the DNA thus hiding its electrical
identity. The liposome-DNA complex is thought to either fuse with the target cell
membrane or enter the cell by endocytosis where it releases its DNA load into the
cell (Stamatatos, 1988).
Liposome based vectors do not face the same size constraints as seen with viral
vectors. However, there do face their own selection of draw backs. Although,
reports for successful systemic delivery of liposome-DNA it is widely considered
that such complexes have are prone to rapid degradation in plasma (Crook, 1996).
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Liposome complexes may face the same fate when passing from the airway lumen
through the layer of airway surface fluid and mucus into the cells of the airway
epithelium (Crook, 1996). This problem can be only magnified in CF patients whose
mucus may exhibit abnormal rheological properties (Crook, 1997). A number of
different cationic liposomes are now available in the market place. By varying the
type and mixture ratio of liposome and plasmid, a wide range of results have been
reported (Puchelle. 1985). The addition of cholesterol to the DNA liposome mix was
found to both increase the efficiency of transfection and stability of complexes in
serum (Crook, 1996).
Liposomes lack tropism for airway epithelium. One way envisaged to counteract this
problem is to attach a receptor, cell surface protein, ligand or antibody into the lipid
layer of the liposome and deliver the liposome construct either through
aerosolisation or perhaps systemically. Such approaches have been successful in
increasing transfection efficiencies for other cell types. Transferrin molecules
coupled to liposomes were shown to significantly increase transfection efficiencies
to bone marrow erythroblasts (Stavridis, 1986) as did glioma cell specific antibodies
coupled to liposomes (Mizuno, 1990).
With reference to CF gene therapy, liposome-mediated gene transfer has been
reported to be effective in a variety of both in vitro and in vivo systems. MacVinish
et al. (1997) reported the normalisation of calcium dependent chloride ion secretion
in homozygous Cft""'ICAM mice after liposome mediated gene transfer of CFTR.
McLachlan et al. (1995) reported delivery and expression of reporter genes to the
lungs of mice which furthermore showed no signs of toxicity. Progress towards
conducting human trials on cationic liposome-DNA complexes for CF was made
when a number of groups reported complete or partial correction to the
electrophysiological defect in CF mice (Hyde, 1993, McLachlan, 1996, Alton, 1993).
Recently, Goddard et al. (1997) reported that a second delivery of cDNA-liposome
complex resulted in a similar level of functional CFTR expression to a single
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delivery. These data represents a fundamental stepping stone towards the concept of
repeated liposome gene therapy delivery in the treatment of human CF patients.
Three cationic gene therapy human trials have been conducted in the UK (Caplen,
1994, Porteous, 1997b, Gill, 1997. These studies were all preliminary phase I trials
delivering a single dose of DNA: cationic liposome complex to the nasal epithelium
of CF patients. Phase I trials are primarily designed to both investigate the efficiency
of transduction as well as the safety of the protocol before phase II trials delivering a
single gene therapy dose to the full lung are planned. The Caplan trial (1994)
delivered a CFTR construct under SV40 promoter control complexed with DC-
cholesterol:DOPE. Variable and transient expression (until 4 days after treatment) as
well as a modest functional restoration, as measured by electrophysiological
correction was observed. However, a false positive result in the placebo group
limited the complete interpretation of this study. The Porteous phase I trial
(Porteous, 1997b) chose a different DNA-liposome complex. Human CFTR was
driven by a CMV promoter which had been previously been showed to show
sustained in vivo expression to at least 17 days after transfection to mice by
aerosolisation (McLachlan, 1996). The cationic liposome DOTAP had been
previously shown to be non toxic after repeated doses to mice (McLachlan, 1995)
and when complexed to CMV driven CFTR, correct up to 80% of the
electrophysiological deficit in CF mutant mice at up to 9 days after administration
(McLachlan, 1996). The trial was successful in mediating gene transfer and for a
longer period as compared to the Caplan trial (Porteous, 1997b). No false positives
were noted instead, presence of the transgene was noted in 7/8 patients 3 days after
administration and in 2 patients at day 28 after administration. Expression of the
transgene as measure by RT-PCR showed a positive result in one patient at day +3
and one at day +7. The results of the trial are comparable to adenovirus trial results




Molecular conjugates are a non viral system of gene delivery which may overcome
the problem of the lack of airway tropism as found in liposome based vectors. One
successful example of this approach was by the development of a complex including
adenovirus virions, polylysine and a DNA plasmid. The polylysine condenses the
DNA whereas the adenovirus particles augment tropism by binding to transferrin
receptors. (Curiel, 1991, Cotton, 1987). Encouraging as these in vitro results were,
there is as yet, no evidence for in vivo transfection in laboratory animals.
In this chapter, liposome mediated gene therapy approaches to the delivery of a
marker transgene to the steady state and injured mouse lung are investigated.
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6.1
Liposome Mediated Gene Transfer To The Steady State Mouse Trachea
Introduction
A study was made into the efficiency of gene delivery to the tracheal epithelium by
liposome gene therapy
Materials And Methods
14 female CD1 mice (approximately 6 weeks old) were separated into a test group of
9 and a control group of 5 animals. Animals received a 0.75ml IP injection of
hypnovakhypnorm anaesthetic and placed in a frame as described by Ho and Furst
(Ho, 1973). 20pl of (3-gal reporter gene:DOTAP construct (lOpl 12mg/ml. DOTAP,
lOgl CMV-p-gal) delivered to the trachea of test animal just distal to the vocal folds.
Control animals received a 20pl dose of sterile PBS by the same method.
Animals were left for 5 days before sacrifice by cervical dislocation. Lungs of the
animals were removed and further dissected to provide separate samples of the
trachea, upper lobes and lower lobes. Tissues were processed for DNA extraction by
proteinase K digestion and purification by phenol-alcohol extraction. Polymerase
chain reaction (PCR) analysis was conducted to test for the presence of the transgene
in the tissue. PCR primers were designed against the (3-gal transgene. These were for
the 5' end TTG GCG TAA GTG AAG C and for the 3' end AGC GGC TGA TGT
TGA ACT G. PCR reactions using the enzyme Thermus aquinus (Taq) were run on
test and control samples using a 30 cycle protocol: 1 cycle at denaturing at 94°C for
3 minutes, annealing at 50 °C for 1 minute and elongation of strands at 75 °C for 1
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minute and 29 cycles at denaturing at 94°C for 30 seconds, annealing at 50 °C for 1
minute and elongation of strands at 75 °C for 1 minute. If the transgene was present,
a band of 350 base pairs would be produced. Agarose gels bathed in buffer and
placed between a cathode and an anode were used to separate the DNA samples.
DNA is negatively charged and will be attracted to the anode through the gel.
Sections of DNA can, through this method, be separated according to size or state of
condensation. Results from the PCR reaction were run on a 0.8% agarose gel with
ethidium bromide in TBE buffer for 1 hour at 100V. The gel was illuminated in
ultraviolet light and a photograph taken (see figure 6.1.1). Internal controls of two
negative control lanes (no Taq) and known concentrations of p-Gal plasmid DNA
(lOOfg, 10 fg, lfg, lOOpg) were also run to validate this assay. It should be noted that
no experimental confirmation of presence of DNA in the samples was made prior to
PCR amplification.
Tissue samples were also removed for analysis by reverse transcriptase PCR (RT-
PCR). This method is used to measure the presence of transgenically expressed
RNA. The RT-PCR protocol was conducted by Hazel Davidson-Smith. No positive
results for test or negative control samples were observed.
Results
Gel data is presented in figure 6.1.1 and summarised in figure 6.1.2.
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Figure 6.1.1
Detection Of Transgenic DNA by PCR In The Pulmonary Tissue Of Mice After Liposome
Mediated Gene Transfer
3 tissues (trachea, proximal left lob, distal left lobe) were removed from each test
(DNA:DOTAP (1 Opil, 1mgml"1 CMV-p-gal, 10pl x12mgml1 DOTAP) and control (just DOTAP)
mouse. Tissues were assayed for presence of transgene by DNA PCR. Amplified PCR
products were separated using a agarose gel plate lying within a voltage gradient. The keys
for each lane is as follows (lanes not referred to are of <j>x molecular marker ladder):
350bp ^
Mouse Trachea Proximal Distal Mouse Trachea Proximal Distal
1 - LaneB Lane C 8 Lane X LaileY Lane Z
2 Lane D Lane E Lane F 9 Lane 1 Lane 3 Lane 4
3 Lane G LaneH Lane I 10 Lane 5 La ne6 Lane 7
4 Lane K Lane L LaneM 11 Lane 8 Lane 9 Lane 10
5 Lane N LaneO Lane P 12 Lane 12 Lane 13 Lane 14
6 Lane Q Lane R Lane T 13 Lane 15 Lane 16 Lane 17
7 Lane U LaneV LaneW 14 Lane 18 Lane 19 Lane 20
Figure 6.1.2
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Positive controls of known concentrations of the (3-gal plasmid (1 OOfg, 10fg, 1 fg,
100pg) were used to confirm protocol efficiency. All positive control samples resulted
in a positive result. Negative control of water only was used to test for contamination.
Discussion
Presence of transgenic DNA was detectable in 8/9 test animals by PCR. RT-PCR
studies revealed that there was however, no detectable level of transgene expression.
The design of the experiment permitted a profile of the areas transfected to be
generated which provided some interesting data. A higher level of transgenic DNA
was detected in the upper lobes of the lung as opposed to the lower lobes. This was
largely to be expected, due to the relative distance from the sight of dose delivery.
One exception was animal 7 which showed presence of transgenic DNA in the lower
lobes but not the upper lobes. No transgenic DNA was detected in the mouse trachea.
These data were surprising as the delivery catheter was positioned in the proximal
regions of the trachea.
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6.2
Liposome Mediated Gene Transfer To The Polidocanol Damaged Mouse
Trachea
Introduction
It was of interest whether the mouse trachea demonstrates a reduced tropism to the
liposome vectors. A hypothesis was tested along the lines of the adenoviral studies
conducted by Grubb et al. (1994) (as discussed above) namely whether the liposome
vector would demonstrate increased tropism and transfection efficiency to areas of
damaged trachea.
Damage to the trachea was produced through the tracheal instillation of polidocanol
solution. Polidocanol is a detergent that acts to remove the columnar cells of the
pseudostratified epithelium of the trachea (see section 7.3 for further details).
Materials and Methods
24 female CD1 mice (approximately 25g in weight) were separated into 4 groups.
Group 1 contained negative controls and received a 20pl dose of sterile PBS by the
tracheal instillation after anaesthetic as described above. Group 2 animals received
tracheal instillations of 25pl 1% polidocanol solution to just beneath the vocal cords
to partially denude the tracheal epithelium. Group 3 animals received instillations
of 20pl 1:12 CMV-p-gal:DOTAP. Group 4 animals received both tracheal damage
by polidocanol instillation and 20pl 1:12 CMV-(3-gal:DOTAP.
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The animals were left for 5 days (two group 4 animals died during this period of
unknown causes) prior to sacrifice by cervical dislocation. Tracheas were dissected
out. Transfection by the (3-gal construct was assayed for by PCR using two tracheas
from each group. The tracheas from the remaining animals were assayed for (3-gal
presence by PCR or for expression by staining for Lac-Z activity with X-gal stain.
These protocols are described either in section 6.1 (PCR) or in chapter 5 {Lac-Z
staining). In the PCR analysis, a series of positive and negative control samples were
also used as described in figure 6.2.1. Thyroid tissue endogenously expresses Lac-Z
and was retained during the tracheal dissection protocol to act as an internal control.
Results
Presence of (3-gal transgene construct was detectable by PCR as described in section
6.1 generating a PCR product of 350bp. Expression of (3-gal was assayed for by
examining for X-gal blue staining in tissue by bright field microscopy of 6jxm tissue
sections.
Polidocanol was seen to denude the tracheal epithelium of columnar cells exposing
basal cells to the air. For a fuller description of this damage and recovery process
please see section 7.3.
PCR results are shown in figure 6.2.1. Examples of X-gal stained tissues are shown
in figure 6.2.2 and the data from section 6.2 is summarised in table 6.2.3.
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Figure 6.2.1
PCR Data From Gene Therapy Experiment To Steady State And Damaged Tracheal
Tissue
The tracheas from test and control mice were assayed for presence of transgenic DNA (B-
Gal) by PCR. Tracheas were excised from test and control animals and DNA extracted and
purified. PCR was used to amplify and transgenic DNA which may be present. The amplified
products were examined using a 0.8% agarose gel (see text for details.)
Lane A: Standard Marker Ladder
Lanes B-E: Mouse controls #1-4
Lanes F-l: Mouse tests #5-8
Lane J: Standard Marker Ladder
Lane K: 10Ofg control
Lane L: 10fg control
Lane M: 1 fg control
Lane N: 100A
Lanes O-R Negative control lanes
6.2.2
Detection of transgene expression by X-Gal staining
Test and control tissues were stained with X-Gal stain to assay for the presence of (5-
galactosidase, the protein product of Lac-Z expression.
6.2.2a Stained mouse trachea (mouse number 7) embedded in wax. Note heavily stained
thyroid glands adjacent to the proximal end of the trachea. No staining observed in the
tracheal lumen.
6.2.2b Mouse trachea 13 after staining and prior to sectioning. When positive Lac-Z staining
was noted in the trachea, it was most commonly concentrated to the proximal end of the
trachea. This coincided with the site of liposome construct delivery. This image shows a
heavily stained thyroid gland and bands of blue staining in the tracheal lumen.
6.2.2c On thin section, intermittent weak staining was observed in the tracheal epithelium
(mouse number 19).





Data Summary From Liposome Gene Therapy Delivery And Construct Expression
To Injured And Uninjured Lung Experiment
# Positive control in this sample did not work.
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Discussion
In section 6.1 an experiment was conducted to investigate liposome mediated gene
transfer to pulmonary tissues in steady state. One of the conclusions from this
experiment was that although lung lobes showed evidence of transfection, there was
no detectable level of transgene DNA in the trachea. Section 6.2 aimed to study
whether the levels of transfection to damaged tracheal epithelium would be
increased in comparison to "steady state" or undamaged epithelial tissue.
It is therefore surprising to note in experiment 6.2, data is presented showing a
positive results for transgene detection in the undamaged trachea after a single
liposome gene therapy dose. In this test group 3/6 animals show positive evidence
for transfection. There were no observable difference in protocols in sections 6.1 and
6.2. Indeed, every effort was made to make the tracheal instillation protocol
reproducible. No negative control samples produced positive results.
5 days after tracheal damage by polidocanol, the tracheal tissue demonstrates full
recovery to normal histology (see chapter 7 for more details). There is no evidence
for an increased efficiency rate of transgene expression or transfection to the
damaged tracheal tissue as compared to the undamaged tissue. On analysis of the X-
gal stained tissue sections (figure 6.2.2), X-gal staining was observed in the
epithelial lining of the trachea and also in the ciliated SMG duct. Staining was most
localised to the proximal region of the trachea, where delivery of the construct was
made, which may infer that distant aerosol delivery, as is envisaged in the treatment
of the human lung, may be problematic. There is no evidence from these images to
suggest that transfection levels to the basal cells are increased in comparison to
columnar cells.
180
One possibility to explain why an increased transfection efficiency is observed is
that the residual polidocanol in the trachea is acting as an emulsifier and interfering
with the liposome:DNA interaction. One possible way to alter the protocol to avoid
this issue would be to put in a time delay between damaging and dose delivery.
However, the hours after polidocanol injury are characterised by rapid tissue renewal
(as demonstrated in chapter 7). It is perceived that mucus and inflammatory cells
already affect liposome transfection efficiencies. Therefore, establishing a time delay
in the protocol may infact result in an even greater barrier to transfection.
Such issues were not faced in the Grubb paper (1994) as a surgical method of
tracheal damage was utilised. It would be of interest to repeat this study using this
surgical procedure.
From the evidence presented in this section, evidence is presented showing
successful gene transfer using liposome vectors to the pulmonary tissues of mice.
There was no observable difference in transfection efficiency to damaged tracheal
versus steady state tissue. Disappointing as this is, it was interesting to observe gene
delivery to the top region of the SMG ciliated ducts and to the tracheal epithelium:








Many epithelial tissues act as physical (though dynamic) barriers between two opposing
environments and as such, are prone to damage therein requiring the means for self renewal
and repair. Stem cell theory describes the role of the different epithelial cell types in terms of
occupying different locations on a hierarchy of cellular differentiation and proliferative
capacity. The primary assumption of this model is that the processes of proliferation and
differentiation can be perceived as individual entities (Potten, 1990). At one end of this
system lies the stem cell which is characterised by poor morphological differentiation but
seemingly infinite proliferative capacity while at the other end of the model exists mature and
functional end point cells. See figure 7.0.1.
Figure 7.0.1.
Different Epithelial Cells Types Can Be Perceived As Existing At Different Positions On





The stem cells are not the only the only cells in an epithelial model which have
proliferative capacity. Transit amplifying cells (TACs) are a transition population of
proliferating cells which occupy the area between stem cells and the mature
functional cells. According to the stem cell model, they will retain some stem cell
properties including proliferative capacity yet also have some properties of the
mature cells. A primary feature of TACs is that they are predestined to move towards
functional status (Potten, 1990). TACs at different positions of the model can
therefore be termed either as Early TACs or Late TACs.
The identification of stem cells can be fraught with difficulties as they can only be
truly identified by merit of their future potential. The situation is not indifferent to
the Uncertainty Principle which describes the difficulties in measuring the position
of a particle. Light (or some other form of radiation) is used to illuminate the
particle. This radiation has momentum and therefore distorts the position of the
particle we are trying to see. Examples of such a predicament can be seen in
everyday life; i.e. a thermometer used to measure the temperature of a bath will
absorb some heat energy in that process thus changing the original temperature of the'
bath water. So with the stem cell; experiments to test their functional capabilities
may, by merit of the assay procedure, may alter the cell's characteristics.
There is at this time no universal molecular or any other kind of marker for the virtue
of sternness. So how can stem cells be identified? Most research has been conducted
by considering some definitions of what characteristics a stem cell should exhibit
and then comparing and contrasting these against what is observed in vivo. Potten
and Loeffler (1990) set out such a frame work which would hopefully help in the
identification of stem cells. They reported that stem cells should have 4 main
features(Potten and Loeffler, 1990, Mason, 1997):
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©: Stem cells are poorly differentiated (i.e. morphologically simple)
©: The Stem cells' capacity for proliferation extends throughout the life span of an
individual dividing asymmetrically as to maintain its own population.
©: Progeny of stem cells will give rise to functional progeny
©: Stem cells should be able to regenerate an entire tissue which has been damaged
and is therefore likely to be spatially restricted to a specific compartment.
From these definitions, a perceived image of stem kinetics can be sought. Stem cells
are likely to be slow cycling morphologically simple cells being compartmentalised
away from the most common sites of epithelial damage (Potten, 1988). It is thought
that the slow turnover of stem cells may be advantageous as to avoid potential
mutations arising through DNA replication.
There is a number of possible systems of cellular division by which the stem cells
can maintain their own population whilst also giving rise to TACs. These are





Possible patterns of Cell Division in a Stem Cell driven lineage
"S" refers to Stem Cell, "T" refers to a transit amplifying cell (a cell with restricted proliferative
capacity and committed to deriving mature cell types), "P" refers to physiologically functional
end point cell.
In model A, the stem cells is dividing in an asymmetric pattern thus maintaining its own
population but incapable of expanding it.
B
Model B describes the action of four different stem cells. Their division is symmetrical but half
the time they are self-renewing.
In this model, the cell lineage is asymmetric yet is not intrinsically so. The behaviour of the
daughter Stem cells can differ owing to local environmental or cell adhesion factors (depicted
by the shaded boxes)(Morrison, S. J.etal, 1997).
It must also be appreciated that the nature of stem cells, the virtue of ,can at times
be invisible to the features outlined above. If a stem cell was to stop replicating, i.e. become
quiescent, it is fair to appreciate that the cell has not lost any of it potential qualities of
sternness since it could re-enter the cycle at any time. Therefore, the concept of "potential
stem cells" (Potten, 1990) must be introduced. Stem cells which are active in division as thus
termed "actual stem cells".
The most readily identifiable trait of stem cells is their long life time and slow cellular
turnover. The life time of a particular cell type can be quantified through the use of
nucleotide analogue labels such as bromodeoxyuridine (BrdU) and tritiated thymidine. These
chemicals are incorporated into a cell's DNA at the time of mitosis and will remain
incorporated in the cell until cell death occurs or the cell divides in which case in which case,
both daughter cells will also retain label. After repeated cell division, the faster cycling cells
will dilute their label dose. Eventually, this reduction in dose will result in the cell marker
content becoming so low that labelled cells will become invisible to the sensitivity of
antibody (immunohistochemistry) or autoradiographic techniques. Dilution of label is
depicted in figure 7.0.3.
Figure 7.0.3
Decrease in BrdU dose after repeated cellular divisions.
This model describes the dilution of BrdU labelling after repeated cellular division. The rate of
BrdU dilution being directly proportional to the number of cell divisions that have occurred.
Cell




By a cell's BrdU labelling profile it is therefore possible to deduce the approximate
life span and kinetics of a cell. Here are two examples. Firstly, a cell labelled at
mitosis with a long life time will retain the nucleotide analogue for an extended time
period in comparison to a cell with a short life span. Secondly, a marked cell with a
high proliferative capacity will give rise to a high number of marked daughter cells
whereas a marked cell with low proliferative capacity may not give rise to any
further marked cells. Cells will eventually loose their detectable signal depending on
the number of cell division that have occurred and the sensitivity of the label
detection method.
Label retaining profile of stem cell
A BrdU labelled stem cell, which is, as proposed by the model, inherently slow
cycling and has a huge proliferative capacity, will retain its label for a longer time
than its progeny. Cell's displaying such characteristics are termed Label Retaining
Cells (LRCs). This theoretical label retaining property has been used widely in the
search for stem cells (Bickenbach, 1984, Bickenbach 1981, Bickenbach, 1984,
Cotsarelis, 1989, Cotsarelis, 1990, Graeter, 1996, Mackenzie, 1985).
One example is in the skin and oral mucosa of both hamsters and mice where cells
retaining tritiated thymidine labelling characteristics have been recognised. These
two tissues are similar in histology both possessing a thick layer of stratified
epithelium. Cells retaining tritiated thymidine label (LRCs) some 69 days after
dosing were recognised in the deepest part of the epithelial papillae in both tissues
and in both hamsters and mice. This observation suggests that retention of a nuclear
label is a reproducible phenomenon across different tissues and species (Bickenbach,
1981, Bickenbach, 1984).
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Seeking LRCs in tissues which are, usually, largely quiescent by nature can lead to
an important practical problem namely, a single pulse of label, such as of BrdU or
tritiated thymidine, is not likely to results in the labelling of stem cells. The
epithelium of the bronchus is such an example. Using immunohistochemistry
techniques on human bronchial tissue, it was found that less than 0.2% of epithelial
cells were marked as undergoing cell division in the steady state(Leigh. 1995).
The epithelium of the trachea is another example of a largely quiescent tissue. With a
low cell proliferation index in trachea of rodents (Breuer, 1990, Donnelly, 1982,
Randell, 1992) it is unlikely that if a stem cell was present that a single pulse would
result in its marking. It is much more likely that the TAC population would be
labelled. One way around this problem would be to design an experiment in which
the cell proliferation is first raised prior to BrdU injection. A common way to do this
is by artificially damaging the epithelium with the hope that this will increase the
recruitment of stem cells into dividing and therefore increase the possibility of
actually labelling them.
This approach was used in a study into the progenitor-progeny relationship in the
cornea of rabbits (Cotsarelis, 1989). After physically damaging the cornea, tritiated
thymidine was delivered to the rabbits for a 14 day period. By sampling groups of
animals at different time points after damaging and dosing, cells in the limbal basal
epithelium were observed to have been stimulated into division leading to the
migration of new cells to the wound site in the cornea epithelium. These limbal basal
cells show 2 functional traits which suggests stem cell behaviour. Firstly, the limbal
basal epithelium contains the least differentiated cells of the corneal epithelium.
Second, the limbal basal epithelium contains cells which exhibit the proliferative
characteristics of tritiated thymidine retention(Cotsarelis, 1989). At 4 weeks a
subpopulation of the limbal basal cells still retained labelling.
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To establish further that these LRCs possessed stem cell properties, topical
application of the tumour promoter TPA (12-O-tetradecanoylphorbol-13-acetate) was
used to induce terminal differentiation of corneal and limbal cells in vitro. Treatment
of corneal cells with TPA resulted in rapid maturation of all cells whilst a fraction of
cells from the limbal epithelium retained their undifferentiated phenotype and
continued to proliferate despite the presence of TPA. These TPA-resistance cells are
the least differentiated cells in the epithelium and thus, the authors argue, are stem
cells (Kruse, 1994).
Compartmentalisation of LRCs
The variability in the label retaining property of cells that are otherwise
morphologically similar, can be used to the further categorise cells types. In the case
of rat caecal enterochromaffin cells, two kinetically distinct populations of cells were
identified by their BrdU retaining properties (de Bruine, 1992). One population,
comprising of 60-65% of cells, has a high turnover time of approximately 16 days,
whilst 35-40% of cells have a turnover time of approximately 150 days. These data
suggest the presence of two distinct cell populations occupying different position of
the scale of proliferative potential.
The LRCs of the cornea also show the property in common with LRCs from other
tissue, that of being spatially restricted to specific tissue compartments. Similar
compartmentalisation of stem cells is seen in a variety of tissues including palm skin
(Lavker, 1982), the dorsal tongue (Bickenbach, 1981) and in the small intestine
(Potten, 1990).
Some epithelial tissues, such as the dorsal skin of the mouse, exist as a stratified
structure composed of flat basal layers and columns of keratinocytes arranged like
stacks of coins (Hall, 1989). Can such compartmentalisation still exist in such a
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tissue? Potten proposed the concept of Epidermal Proliferative Units (EPU) (Potten,
1974). The theory describes that each column of cells corresponds to a single EPU
which is in turn composed of a single stem cell surrounded by 5-6 transit amplifying
cells. This work suggests that even in an epithelial layer, compartmentalisation can
still occur.
The small intestine has become one of the model tissues for stem cell research
possibly due to its rapid turnover of tissue and well established histology. The lining
of the small intestine is an epithelial monolayer divided histologically into crypts and
finger like projections called villi. Small intestine stem cells are found lying either
proximal to the paneth cells in the base of the crypts (Potten, 1982, Potten, 1990).
The stem cells proliferate to produce TACs migrating downwards to produce paneth
cells and upwards to produce the cells of the crypt and the villi. Migration of the
cells towards the tip of the villi (where they are eventually shed off) takes between 2
to 3 days and involves the differentiation of stem cells into four mature cell types
which have no further proliferative capacity. The proliferative capacity of the gut
stem cells is remarkable. It is estimated that each crypt produces approximately 300
new villi cells a day and over 2 x 108 villi cells are shed off every day (Potten and
Loeffler, 1990). It is now thought that small intestinal crypts contain between 4-16
actual stem cells producing clonally derived crypts yet polyclonal villi (i.e. only one
stem cell is active in each crypt at any one time)(Potten and Loeffler, 1990). In the
hair follicles, LRCs are located in close proximity with the follicular papillae and
associated vasculature (Cotsarelis, l989).This spatial localisation greatly adds to the
conceptual understanding of stem cells.
Regulation of stem cell behaviour
Stem cell research for many tissues has now progressed beyond the stage of stem cell
identification to investigating the methods of stem cell control. This has become a
194
large and complex field in itself pulling fate map technology from C. elegans and
Drosophila melanogster (Morrison, 1997) as well as in vitro studies designed to
identify the signals that regulate stem cell differentiation (Johe, 1996). The brain has
provided much scope for study due to its cellular diversity and the presence of easily
identifiable cell types. The Johe group (1996) studied the differentiation mechanism
of embryonic cells of the central nervous system into 3 main cell types: neurons,
astrocytes and oligodendrocytes. He showed that both proliferation and
differentiation of the neural stem cells could be controlled in vivo through the
addition of different extracellular signals. Platelet derived growth factor supported
neuronal differentiation, ciliary neurotrophic factor acts on stem cells to generate
astrocytes and addition thyroid hormone T3 results in the production of
oligodendrocytes.
Growth factors have also been found to be able to regulate the proliferation of cells
in the small intestinal crypts in v/vo(Potten, 1995). Three different assays were
developed to measure the effect of in vivo delivery of growth factors on the position
of tritiated thymidine labelled cells and mitotic activity in the gut. The effect of 8
different growth factors was assayed using this method. Epidermal growth factor was
found to be the most effective in stimulation proliferation on the complete gut
whereas Insulin-like-growth-factor showed a proliferative effect on only the upper
crypt and transforming growth factor (3-1 was shown to have a proliferative effect in
the lower (stem cell) regions of the crypt.
Recent evidence from transgenic mice suggests that cell to cell interactions may have
a profound effect on stem cell behaviour. When cell-cell adhesion molecule E
cadherin was over expressed in both the crypts and villi of mouse small intestine
under the control of a fatty acid promoter, cell proliferation was seen to decrease and
the rate of cellular migration was reduced (Hermiston. 1995). In the opposite
situation, when an N cadherin mutant that functions as a dominant negative for E
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cadherin is over expressed in the small intestine, the rate of proliferation and
migration increases (Hermiston. 1996, Hermiston, 1995). It is believed that then
phenotype of these transgenics may be as a consequence of a disruption of cell to
cell adhesion or a disruption to in the intracellular distribution of (J-catenin (Jones,
1997, Peifer, 1992).
This situation is thought to be akin to the Drosophilci mutation Wingless. (J-catenin
has a Drosophila homologue called Armadillo which is a member of the Wingless
signal transduction pathway proteins (Peifer, 1992). The Wingless proteins are short
range secreted molecules which act over a range of several cell diameters. In
Drosophila the Wingless proteins specify the local fate of epithelial cells whose
cellular distribution has been shown to be disrupted by misexpression of cadherins
(Jones, 1997).
This research suggests that cell to cell adhesion is crucial for stem cell activity is
likely to have implications on in vitro or ex vivo study into stem cells. It can be
envisaged that disturbing cell to cell adhesion through experimental manipulation
(i.e. protease methods of digestion) may have a considerable effect on the activity of
stem cells.
The kinetics of the epithelium of the upper respiratory airways
The mammalian respiratory system is a structurally complex arrangement of organs
whose primary function is in the intake of oxygen into the blood and the elimination
of carbon dioxide. The respiratory system is lined with epithelial tissue which in
addition to the processes of gas exchange, forms a physical barrier to prevent
penetration of noxious substances, and also serves an essential role in bacterial and
pathogenic defence through the production of mucous and anti microbial agents
(Pack,, 1981 .Basbaum, 1990,Widdicombe. 1994).
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Efficient gas exchange in mammals is based upon the respiratory system having a
huge surface area of thin simple epithelium. To this evolutionary end, the structure
of a respiratory system is structured in a huge branching system of tubes of every
decreasing lumen. The trachea is the largest of the branches and connects the lung
towards the mouth. The trachea splits into two bronchi at the carina thereby forming
the two sides of the lung (the left lung is slightly smaller than the right to make space
for the heart). The trachea and the bronchi are structurally supported against collapse
by cartilage rings connected to a layer of muscle. The bronchi split to form the basic
structure of the lung lobes giving rise to the non-cartilaginous bronchioles.
Bronchioles further split to eventually form the alveoli.
There are three quite discrete epithelial types in the human adult lung: those of the
trachea and the bronchi (the cartilaginous airways), the bronchioles and those of the
alveoli. The role of these tissues vary widely as does complexity in respect to the
number of different cell type and kinetic models. At least eight principal types of
epithelial cells have been identified in the linings of the conducting airways of
mammals (Breeze, 1977, Pack, 1980, Boren, 1978) and a further 3 cell types in the
alveolar regions (these cell types are introduced in figure 7.0.4). The primary cell
types are the ciliated cells, the mucous goblet cells, the Clara cells, the basal cells,
neuroendocrine cells, the serous cells, brush cells and K cells. There is yet unclear
whether a cell type referred to as the "Intermediate" or "indeterminate" is a discrete
cell type or a histological artefact (Mercer, 1994, Houck, 1985, Breuer, 1990), The
possible implications of this argument are more fully discussed later in this chapter.
In the alveoli there are type 1 cells , type 2 and type 3 cells. The cell types found in





The Primary Cell Types Of The Human Trachea And Bronchus
Approximate percentage contribution of the cell types are provided after Mercer et al. (1994).
These figures are derived from analysis of non smoking adults who had normal lung function.
It should be noted that the percentages would be seen to alter considerably in diseased or
inflamed tissues.
Ciliated Cell Muco-goblet cell Serous Cell Neuroendocrine Cell
32% 12% 3% <1%
30% 17% 4% <1%
(see discussion)
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The difficulties of studying the kinetics of the upper airway epithelium.
The kinetics of the human terminal bronchioles and the alveoli are largely
understood (and appear to be well conserved through a number of different species)
(Breeze, 1977, Randell, 1992, Evans, 1976b, Evans, 1976a, Evans, 1975) and will
therefore not be investigated directly in this thesis. Briefly, in the alveoli, type 1 cells
are large squamous cells that cover 93-97% of the alveolar surface. Type 2 cells are
smaller and more cuboidal in shape and cover most of the remaining alveolar
surface. A type 3 cell, albeit very rare, does exist though its physiological and
proliferative role is poorly understood. The kinetics of this system is simple. Type 1
cells are terminally differentiated and type 2 cells are capable of cell division, acting
as the progenitor cells for the alveolar epithelium.
The kinetics of the human terminal bronchioles are also straightforward. Only two
cell types are present; the Clara cell and the ciliated cell. The Clara cells are non
ciliated columnar cells and are believed to be the progenitor cells in this tissue, being
capable of cell division to produce terminally differentiated ciliated cells (Evans,
1976b).
The mechanism by which the tracheo-bronchial epithelium undergoes self-repair has
still to be resolved despite considerable research into this area being conducted over
the last 40 years. There are a number of technical reasons why this may be so.
Cell identification
Unlike many of the well characterised epithelial cells types, identification of the
cells of the tracheo-bronchial epithelium is often difficult due to the lack of strong
and easily applicable cell-type-specific biochemical markers. Additionally,
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ambiguous histology has often lead to the use of phrases such as, "poorly
differentiated" (Randell, 1992) or "intermediate" (Breuer, 1990, Engelhardt, 1995) to
describe cell types. To aid identification, Shimizu et al. (1992) reported the
development of "cell type specific" monoclonal antibodies. The expression of
specific keratins and lectins has been previously shown to be useful in the
identification of cell types in a number of different epithelial tissues (Purkis, 1990).
By raising antibodies against a range of keratins and lectins, identification of 5 main
mature cell types in regenerating in vitro rat trachea was possible (Shimizu, 1992).
Poorly differentiated cells were not seen to react with any mABS used. Such
approaches, though restricted to mature epithelium and restricted at this time by
immunological reactivity to rat tissue (Randell, personal communication), may pave
the way for better experimental approaches to the study of tracheal epithelium.
The identity of the "intermediate" cell type has instilled a degree of uncertainty into
many quantitative attempts to understand the tracheobronchial epithelial kinetics.
"Intermediate" cells are classified as cells either lacking sufficient cytoplasmic
characteristics for proper categorisation or cells which had the morphological
characteristics of basal cells but lacked basement membranes (Mercer, 1994). It is
yet unclear whether further classification of the intermediate cells is a problem
associated directly with histology (for it is easily possible to generate a cell lacking
basement or apical membrane by making a tangential cut through a columnar cell) or
whether cells are transforming from one cell type to another or indeed, they exist as a
discrete cell type. Whichever way the argument is considered the problems arising
from this cell type are considerable.
The Breuer study (1990) of hamster bronchial epithelial kinetics is victim of the lack
of sound epithelial cell identification. Breuer et al. reported that 15% of epithelial
cells are of "intermediate" phenotype. Further more, in their classification of basal
cells they "assume contamination by non basal cells of as much as 50% of the B2
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(taller basal cell) category." The "corrected" B2 population increased from 7.6% to
11.4% and this figure is used throughout their calculations. Mercer et al. (1994)
identified 17% of cells to be of "indeterminate" identity in their EM study of the
human trachea and 9.5% in the rat. Such studies would appear to be inherently
hazardous due to the weak statistics they generate. However, it is a weakness that
must be faced as any study into the kinetics of the lung epithelium will ultimately
rely on histological examination and cell identification until such time as reliable cell
markers can be found.
It is therefore interesting to examine the workings on the Engelhardt study on
epithelial kinetics using the xenograft system (Engelhardt, 1995). See chapter 7 for
details. The model generated describes among other things, the requirement of goblet
cells to pass through an intermediate cell type to become ciliated cells. The main
basis for this claim is that there were no clones found with just ciliated and goblet
cell types but always had intermediate cells present, //however, a single intermediate
cell was misidentified in the process and a clone of just the ciliated and goblet cells
types existed, the whole model would collapse.
Factors Affecting Cell Type Distribution
There are a number of factors which affect the cell types found, their frequency and
their location in the tracheobronchial tree. In response to lung disease (such as CF)
and pollutant damage, there can be considerable cellular plasticity ranging from
hyperplasia and hypertrophy of goblet cells and a proportional reduction in ciliated
cells to squamous metaplasia and neoplasia (Davidson, 1995, Pack, 1981, Thurlbeck,
1963,Kruse, 1994, Breeze, 1977, Randell, 1992). Subtle changes such as conditions
for housing of laboratory animals can result in considerable change in epithelial
composition, especially in transgenic mice prone to lung disease such as a the CF
mouse (Dorin, 1992a, Davidson, personal communication).
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Many different animal species have been used experimentally to study lung kinetics.
These animals usually being used on the basis that they will model the dynamics of
the human lung. Many of the cell types in the mouse resemble those of other species
including humans (Pack, 1981). Goblet cells are rare (<0.5%) in mice from SPF
conditions though more common in the CF mice and mice kept in non SPF
conditions (Dorin, 1992a, Davidson, , 1995). Ciliated cells only appear in scattered
patches (Pack, 1981) at a frequency of -38%. Basal cells are present in both humans
and the mouse. In humans, they contribute to 30% of the cells of the bronchi
(Mercer, 1994) and in the mouse, about 10% (Pack, 1981). Clara cells are non-
ciliated columnar cells that show considerable variation in ultrastructural
characteristics between species. In many non human species (e.g. horse, sheep,
rabbit, mouse, rat) more than 40% of the cytoplasm is occupied by endoplasmic
reticulum whereas in the human and other primates, this is restricted to the apical
side of the nucleus (Plopper, 1983, 1989). There are also species differences in the
distribution of the Clara cells. The Clara cell is the most common cell type in the
mouse trachea and shows a slight variation in frequency through the length of the
trachea (Pack, 1981). At the top of the trachea, 53.2% of cells are Clara cells,
reducing to 49.4% in the lower trachea but again rising to be 57.5% of cells at the
carina (Pack, 1981). These data are starkly different from observations in the human
bronchi where only 3.2% of cells are Clara cells but more similar to the human
bronchiole where 35% of cells are Clara cells (Mercer, 1994, Pack, 1981). The
human bronchiole however lacks basal cells (Mercer, 1994).
A Review Of Kinetic Studies Of The Epithelium Of The Upper Airways
Understanding the kinetics of the lung is fundamentally important to understanding
pulmonary diseases in which epithelial remodelling occurs and to the development of
gene therapy targeted to progenitor cell populations in the lung. Probably due to the
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difficulties of studying the kinetics of the lung epithelium as outlined above there
have been numerous reports published which propose nearly as many different
mechanisms for the kinetics of the lung. They can be separated into two groups:
those studying the steady-state lung and those on diseased, damaged or disturbed
lung.
Kinetic Role Of The Ciliated Cell
It is widely considered that ciliated cells are terminally differentiated and have a very
low proliferative capacity (Johnson, 1990a). Under steady state conditions, the
ciliated cells are thought to be incapable of division and only under exceptional
conditions (hamster tracheal epithelium in vitamin A deprived culture medium
(McDowell, 1985a)) have ciliated cells been seen to divide and synthesise new
DNA.
Kinetic Role Of The Basal Cell
Traditionally, basal cells have been perceived as the progenitor cell type in the lung.
This is possibly due to their positioning in the epithelium being in accordance with
progenitor cells in other tissue types (for instance, the in the skin (Potten, 1988).
Indeed, there is some evidence that this may be the case for basal cells in both
injured and steady state tissues in vivo have been shown to be capable of DNA
synthesis (Boren, 1978, Donnelly, 1982, Lane, 1974).
Inayama et al. (1989) tested the proliferative capacity of basal cells by purifying
basal cells from rabbit trachea by centrifugal elutriation and inoculating tracheal
xenografts. The purified cell solutions were found to rapidly give rise to epithelial
tissue composed of basal, ciliated, goblet and secretory cells. The conclusion being
that since basal cells could give rise to all the major tracheal cell types, they were the
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"main stem cell". However, it must be noted that firstly, the basal cell suspensions
were only between 83% and 94% pure (as determined by EM) or alternatively,
between 6% and 17% contaminated with other cell types. These other cell types were
of ciliated, mucous, Clara and "undetermined" morphology. It is therefore, possible
to consider an alternative conclusion to this experiment that of the "main stem cell"
being one of the other cell types and of being of sufficient proliferative capacity to
produce the mature epithelium.
Both Zepeda et al. (1995) and Engelhardt et al. (1995) used a system of clonal
analysis in xenografts to explore the kinetics of the human bronchial epithelium.
Primary isolates of human bronchial epithelial cells (HBECs) were partially infected
with retroviruses carrying marker constructs (LacZ and alkaline phosphatase in both
the studies). This infection resulted in the partial retroviral transfection of dividing
cells. These cells integrated the transgene into their own genome from where they
were expressed. Cultures were seeded into denuded rat tracheas and implanted
subcutaneously in mice where they repopulate the tracheas and produce epithelial
tissue indistinguishable in terms of morphology from human bronchus at the light
and electron microscopic level (Engelhardt, 1991, Zepeda, 1995, Engelhardt, 1995).
Engelhardt et al. studied the epithelial regions marked by the transgene expression.
The study was based on the premise that clusters of transgene - expressing epithelial
cells, which express a single histochcmical marker, reflect the expansion of a single
progenitor cell which was genetically tagged in vitro (Engelhardt, 1995). The authors
predicted a possible error in clonal assignment of less than 2.0% though concede that
they cannot rule out the seeded clones are derived from smaller clumps of cells
which expanded clonally in vitro. 4 cell types were considered (basal, intermediate,
goblet and ciliated) however, analysis of the clones revealed that not all possible
clone compositions were present. No clones of just ciliated and goblet cells were
found. Furthermore, there was correlation between the number of different cell types
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and the clone size. By far the largest clones were those containing the four cell types
and the smallest, those of just basal cells. From these data a model was produced to
describe the lineage of the airway epithelium differentiation. See figure 7.0.5.
Figure 7.0.5.
Engelhardt Lineage model of airway epithelial differentiation (after Engelhardt (
1995))
This model describes the presence of two types of basal cells and two types of
intermediate cells. Basal cell type I possible acts as a stem cell. Both ciliated and
goblet cells are mature and have no proliferative capacity.
Zepeda et al. described a similar experiment though declared that the overlapping
cells in the 5pm sections in addition to the diffusion of the histochemical reagent
products made the identification of cell type by light microscopy "difficult" (Zepeda,
1995). The possible problems arising from false identification of the "intermediate"
cell type in the Engelhardt paper are discussed above. Therefore, anti keratin 14 and
anti keratin 18 antibodies were used to differentiate between basal and columnar
cells respectively (Lane, 1974). The data from these experiments describe the
Intermediate type 1 > Ciliated
A
Basal cell type 1 * Basal cell type 2
V
Intermediate type 2 * Goblet
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presence of a significant number of cytokeratin 14 and cytokeratin 18 restricted
clones (termed "simple" clones) (ranging from 6.1% to 40.0% of total clones in
individual xenografts) as well as mixed ("complex") expression clones. These data
support a model of epithelial reconstruction through a restricted number of highly
proliferative stem cells from which all the cell types in the human lung can develop
although the nature of the proliferative cells cannot be determined.
There are now several lines of evidence to challenge the concept of the progenitor
role of basal cells. During development, ciliated and secretory cells appear in the
hamster bronchial epithelium prior to basal cells (McDowell, 1985b). Furthermore,
intense proliferation of secretory cells appear prior to extensive mitotic activity in
basal cells in Rhesus monkeys (Plopper, 1989) where pre-ciliated cells were seen to
contain both secretory granules and basal bodies suggesting a secretory to ciliated
cell pathway.
One of the traditional attractions of considering the basal cells as the main
progenitor type in the epithelium relies on the notion of stem cells being poorly
differentiated. Indeed, out of the main cell types, the basal cell does appear,
morphologically, the simplest. This observation may be misleading as a complex
system of junction adhesion structures (including keratin filaments,
hemisdesmosomes and desmosomes) have been identified in the basal cells of a
variety of mammalian species (Evans, 1989, 1990). The structure and composition of
the junction adhesion molecules were found to vary according to animal age and cell
height. These data therefore suggest that the basal cells are indeed differentiated and
have functionality in the attachment of columnar cells to the basal lamina.
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Kinetic Role Of Clara Cells
The ability of a cell to synthesise its own DNA is not necessarily an indication of
proliferative capacity. Instead, it may just be that basal cells are maintaining their
basal cell population. Evans et cil. (1976b) studied the dividing cells of the rat
bronchi using tritiated thymidine and identified about 28% of the labelled cells as
basal cells and 45% were Clara cells and the rest unidentifiable. After a mild N02
exposure, the proportion of labelled cells that were Clara cells rapidly increased
suggesting that the Clara cells played a more major role in the repair of epithelial
tissue.
Kinetic Role of Secretory Cells
In vitro culturing of purified rat tracheal basal and secretory cells gave data
suggesting that the secretory cell and not the basal cell was primarily involved in the
maintenance of the normal tracheal epithelium (Johnson, 1990b). Rat tracheal cells
were isolated by DNase treatment (over 95% of cells were found to be viable). The
proliferative nature and capacity of the basal versus secretory cell types was analysed
by measuring the proportion of each cell type undergoing cell proliferation and the
colony forming capacity of the different cell types. 10% of the original cell
suspension was found to be in S, G2 or M phase (according to their increased per cell
DNA content). Cells were separated by Flow cytometry using flow cytometric
analysis of the cell suspensions involving 90° light scatter versus 2° (forward) light
scatter. Two major ceil populations were revealed showing distinct morphological
and ultrastructural characteristics of basal cell type and secretory cell type. The
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purity of the basal cell and the secretory cell type was 94±1% and 91 ±3%
respectively. The remaining cells could not be identified as they showed no
definitive characteristics (Johnson, 1990b). Of the cycling cells, >85% were found to
be secretory cells. When the separate cell type groups were grown in serum free
culture conditions, the secretory cell group were found to have a higher colony-
forming efficiency (3.4%) than basal cells (0.6%). The authors suggest that as the
secretory cells show a higher proliferative activity than the basal cells, secretory cells
are the main cell type involved in epithelial maintenance.
A similar method and outcome was published by Johnson and Hubbs (Johnson,
1990a). Rat Basal cells purified to in excess of 94% and secretory (muco-goblet and
Clara) cells purified to in excess of 92% (separated by forward angle and side scatter
cytometry) were seeded into rat tracheal xenografts. 4 weeks after subcutaneous
implantation, the xenografts were removed and the epithelium studied for cell type
(by TEM) and epithelial height. Tracheal grafts inoculated with sorted basal cells
resulted in the re-establishment of epithelial linings in 5 out of 10 experiments. The
epithelium was composed of low cuboidal cells (76%) and prominent basal cells
(24%). Less than 1% were secretory cells. This was in comparison to grafts re-
seeded with purified secretory cells which re-established epithelium showing basal,
secretory and ciliated cells (17.1%, 44.3%, 38.5% respectively). These results are
slightly different to those in control xenografts which had been seeded with unsorted
tracheal cells (21.0%, 28.8%, 50.2% respectively). Although the same problems of
non-100% purity are encountered in this experiment, these data provide convincing
evidence that in the rat trachea, the secretory cell is the main progenitor cell type and




A Study Into The Cell Proliferation Index In Mouse Trachea
Introduction
A number of transgenic mice deficient in or completely without cftr expression have
now been generated. Although these animals display the electrophysiological defect
in the gastrointestinal and respiratory tract as seen in humans, the mice do not
spontaneously develop lung disease (Porteous, 1993, Davidson, 1995, Davidson,
1998). In humans, Leigh et al. (1995) observed that the percentage of bronchial
epithelial cell undergoing cell division (as determined by proliferating cell nuclear
antigen (PCNA) nuclei immunostaining) was significantly higher in CF patients
(17.0±4.6%) as compared to non CF patients (<0.2%). Infrequently, in both test
groups, PCNA positive cells were recognised in the ciliated ducts of the submucosal
glands. This increased cell proliferation index in CF patients is most likely to be a
response to increased damage in of CF epithelial tissue.
An experiment was designed to determine whether a similar increased cell
proliferation index (CPI) would be found in the CF mice as compared to wildtype
animals. The Leigh study used tissues from patients who had either died as a
consequence of lung disease or from patients receiving lung transplantation (Leigh,
1995). As CF mice do not die of lung disease, a direct comparison of tissue
pathology was not possible. CF mice do however, show varying degrees of lung
pathology according to their housing conditions and after receiving repeated doses of
bacteria (Davidson, 1995, Dorin, 1996b, Dorin, 1992a). Therefore, 3 different groups
mice were used; those housed in a non Specific Pathogen Free facility (Biomedical
Research Facility (BRF)), those from a Specific Pathogen Free facility (Evan's
Building) and those who had received either one month or two months repeated
nebulisation with S. aureus.
An immunohistochemistry procedure for identifying proliferating cells was utilised.
Proliferating cell nuclear antigen (PCNA) is a 36-kD nuclear protein that peaks in
nuclear concentration during S phase of the cell cycle (Morris, 1989, Jonsson, 1997).
Several commercially available monoclonal antibodies are now available against this
antigen. Detection of PCNA does not depend on the incorporation of labelled
nucleotides such as BrdU or tritiated thymidine.
Materials and Methods
Animals
Mice of 4 different genotypes, two different methods of housing and groups of mice
which had received 2 different repeated nebulisation treatments with S. aureus (30 or
60 days: kind gift from Dr. Donald Davidson) were used in this experiment. Of the
different genotypes, mice homozygous for the cftr insertional mutant Cftr"nlHGU,
heterozygous Cftr"nlHGU mice and wildtype littermates on a outbred mixed MF1/129
genetic background were used. In addition, compound heterozygote mice between
the Edinburgh insertional mutant mouse and University of North Carolina CF "null"
(Cftrm 1 HGV/Cftrm 1UNC) also on the mixed MF1/129 genetic background were used.
This experiment aimed to directly compare the cell proliferation index of mice of
different genotypes and environments. The mice were all between 5 and 6 weeks
old. The mouse is a fully developed adult by week 4 of life. Due to a limitation in the
availability of the transgenic animals direct comparisons between all these variable
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cannot be made. Furthermore, the experiment used animals of both sexes. Full details
of the animals and results are given in figures 7.1.1., 7.1.2 and 7.1.3.
PCNA immunohistochemistry
Mice were sacrificed by cervical dislocation and tracheas dissected out. Tissues were
fixed in 4% paraformaldehyde and dehydrated and processed to wax blocks using
the VIP tissue-tek processor. 6mm sections were cut and floated out on a 56°C water
bath before transferring to a Vectabond coated slide.
Slides were dried out at room temperature overnight. Tissues were de-waxed and re-
hydrated by transferring slides through 2x xylene for 10 minutes and a decreasing
concentration of ethanol (2x 100%, 90%, 70%, 50%, 1 minute each) to PBS. All
further incubation steps took place in a humidified chamber at room temperature.
Tissues were immunologically blocked against non specific binding of the secondary
antibody by incubating with donkey blocking solution (5% donkey serum (DAKO,
Bucks, UK) , 1% fish gelatin (DAKO, Bucks, UK) 1% BSA (Sigma-Aldrich, Poole,
UK) in PBST). Mouse monoclonal PC 10 anti PCNA (Santa Crux biotechnology,
CA, USA) was incubated at a concentration of 1:50 in blocking solution (1% fish
gelatin (DAKO, Bucks, UK) 1% BSA (Sigma-Aldrich, Poole, UK) in PBST) for an
hour. Tissues received 3x5 minute washes in PBST and further blocked for 20
minutes in donkey serum blocking solution. Tissues were incubated with 1:50
dilution donkey serum, 1:500 dilution biotin-SP-conjugated affinity purified donkey
anti-mouse IgG (Jackson Immunological Research, ME, USA) in PBS for 1 hour
prior to washing 3 times in PBST. Peroxidase conjugated streptavidin (Jackson
Immunological Research, ME, USA) was incubated at a 1:500 concentration in PBS
for one hour which binds with great affinity to the conjugated biotin of the secondary
antibody. After 3 further 5 minute PBST washes, DAB solution (lOmg DAB (Sigma,
St. Louis, NJ) in 50 ml 0.0.5M, pH 7.6 TRIS-HC1 activated with 30ml 30% FECF for
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15 minutes) provided a substrate with a visual product. The DAB peroxidase
reaction was stopped by washing slides in H20
Tissues were de-hydrated by transferring slides through a increasing ethanol gradient
to 100%. Tissues were dehydrated in xylene (2x10 minutes) and mounted with a
coverslip using DPX. Slides were examined by brightfield microscopy in
conjunction with the High Optimised Microscopy Environment (HOME) for
presence of marked cells (Brugal, 1992). Basal cells were identified by having
adherence to the basal lamina propria only, intermediate cells having cytoplasm
which did not reach either the luminal surface of the epithelium or the basal layer
and columnar cells whose cytoplasm reached the luminal surface only. Cell counting
was conducted on the pseudostratified epithelium of the trachea. Cells were counted
on one side of the trachea only (chosen at random). Cells were not counted where
poor histology was encountered.
Results
See figures 7.1.1 for examples of immunohistochemistry and HOME counting system.
See figures 7.1.2 and 7.1.3 for numerical data and data analysis.
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Figure 7.1.1
Examples of HOME Cell Counting System
A
'' **** HI i ii ijii hl
f - ' Vis'[Basal Cell /; '
~* *' *6Pu,tn *-
7.1.1a Example of PCNA immunohistochemistry showing the presence of one
labelled basal cell (labelled brown) in a section of tracheal epithelium.
7.1.1b Cells labelled positive for PCNA were counted using the HOME microscope
system. This system interfaced a standard brightfield microscope through a computer
interface permitting accumulation of data on computer files. The green filter was





Description of mice used and PCNA immunological count data.


































1 +/+ BRF f 18 0 0 18 699 2.5 1.1
2 +/+ BRF f 13 0 0 13 846 1.5 0.1
3 +/+ BRF f 7 0 0 7 706 1.0 0.8
4 +/+ BRF f 8 0 0 8 947 0.8 1.4 0.6 0.7
5 H/H BRF f 24 0 1 23 586 4.0 0.2
6 H/H BRF m 33 0 0 33 574 5.4 1.2
7 H/H BRF f 29 0 0 29 830 3.1 4.2 0 0.5
8 U/H BRF f 13 0 0 13 677 1.7 0.7
9 U/H BRF f 3 0 0 3 469 0.6 IWiill^MBU 0.4
10 U/H BRF f 4 0 0 4 478 0.7 1.0 0.3 0.5
ll H/+ 30 d 21 0 0 2! 394 5.2 0.0
12 H/+ 30 d 45 0 0 45 515 3.1 2.1
13 H/+ 30 d 18 0 0 18 441 4.1 l.l
14 H/+ 30 d f 72 0 0 72 795 8.3 5.2 3.1 1.6
15 H/H 30 d f 41 0 0 41 484 7.8 4.3
16 H/H 30 d r 9 0 0 9 635 1.3 2.2
17 H/H 30 d f 10 0 0 10 683 1.4 2.1
18 H/H 30 d f 17 0 0 17 584 2.8 0.7
19 H/H 30 d f 32 0 0 32 687 4.4 3.5 0.9 2.0
20 +/+ 60 d t" 10 0 0 10 194 4.9 1.4








































































Housing notation: SPF = Specific pathogen free facility (Evan's Building)
BRF = Biomedical research facility (non Specific Pathogen free facility)
30 d= 30 day repeated nebulisation with S. aureus. 60 d= 60 day repeated
nebulisation with S. aureus .
Genotype nomenclature: H/H = mouse homozygous for the insertional CFTR
mutation 0/rf/Jm1HGU on a mixed MF1/129 background. H/+ = mouse heterozygous for
the insertional CFTR mutation cfti>vnWGU on a mixed MF1/129 background. +/+ =
mixed MF1/120 genetic background littermate of the above transgenic animals
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Figure 7.1.3
CPI data and error analysis summary
Percentage of PCNA nuclei marked cells presented in each test group with mean
error (in brackets). Number of animals in each group (N) is also shown.
+/+ / % H/+/% H/H / % U/H/%
non SPF 1.4 (0.7) N=4
_
4.2 (0.5) N=3 1.0(0.5) N=3
SPF 2.2 (1.2) N=4 1.8 (0.3) N=3 3.7 (-)N=1 3.1 (1.1)N=2
30 day / 5.2(IT6)N=4 3.5 (2.0) N=5 7
60 day 3.5 (1.4) N=3 10.9 (7.7)N=2 3.5 (1.2) N=4
Statistical analysis between test groups
Data from each test group was compared to each other group using the unpaired t-
test method.
The only differences of statistical significance (p<0.05) were:
Non SPF H/H versus Non SPF wildtype: p=0.0128
Non SPF H/H versus Non SPF U/H : p=0.0138
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Discussion
The results from this experiment can be discussed from two different viewpoints:
that of the relationship between genotype and environmental conditions on tracheal
CPI of mice and secondly, what cell types were observed to be undergoing division.
Great variation in the CPI was found within each test group. This, in addition to the
non comprehensive N number cover of some groups makes direct comparison
between the groups difficult.
It was noted that the CPI of the Cftr"nlHGU / Cftr""IHGU non SPF group is significantly
higher (p=0.0128) than the wildtype animals in the same group. As exciting as this
results is, the possible relationship between cftr expression and CPI is not
maintained. The Cftr""IUNCl Cftr""'HGU animals should have approximately half the
cftr expression of the Q^r'm,HGU animals (Cftr"nlUNC animals are CF nulls and
Cftr""'HGU animals express between 5-10% of wildtype signal (Dorin, 1992a,
Snouwaert, 1992)). However, there is no significant difference between wildtype
animals and Cftr""IUNC / Cftr""IHGU compound heterozygotes. Indeed, the Cftr""IUNC /
Cftr""IHGU non-SPF animals were shown to have a significantly higher CPI than their
Cftr""IUNC / Cftr""IHGU counterparts. Furthermore, in the groups that had received
bacterial instillations, the heterozygote animals showed higher CPIs than either CF
homozygotes or wildtypes. Therefore, it is difficult to argue a credible case for a
genotypic effect on mouse CPI.
The CPI of the mice were found generally to be low with only 4 mice out of 38
showing a CPI of >5%. These mice were all found in the S. aureus groups suggesting
greater cellular turnover hence, a greater degree of epithelial damage in these
animals. It is interesting to note that these animals are deficient in cftr (2 are
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Cftr""'HG" /+ and 2 are cftr""IHGU / Cftr""IHGU) perhaps suggesting an increased
susceptibility to progression of lung damage as observed in Davidson et al. (1995).
However, it can be equally argued that mice in the same group showed lower CPIs
than wildtype mice in the SPF group. It would be of obvious interest to repeat this
study at a time when sufficient mice stocks existed, to remove the areas of possible
error as outlined above.
Although that this experiment does not show a relationship between CFTR
deficiency and raised CPI in the mouse as was seen in the Leigh paper (1995) it is
worthwhile repeating that the CF tissue used in that study was obtainable only
because the patients had either died as a consequence of lung disease or had received
a lung transplant. The high CPI in these subjects was therefore to be expected and
probably represent CPI towards the extremity of possible results.
Beyond the original aims of this experiment, it is very interesting to note that of the
cells marked as positive for reaction with PCNA over 99% of them are basal cells.
These data do not directly relate to the question of epithelial kinetics as it portrays a
single steady state measurement. The role of PCNA in DNA synthesis is still largely
not known (Jonsson, 1997) but is known to show a 2-3 time increase in
concentration during DNA synthesis (Morris, 1989). The decrease of which, in the
G2 phase, has been reported to take up to 18 hours (Prelich,1987). It would seem
likely then that both daughter cells should show a positive reaction with PCNA for
some time. No data backing up this hypothesis was produced in this study.
It is interesting (and perhaps surprising) to note that the positively marked basal cells
do not occur adjacent to positively marked columnar cells. This may infer that basal
cells do not divide to produce any other cell type but more basal cells as suggested
by McDowell (1985b).
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To further study the kinetic relationship between cell types in the mouse trachea, a
more long term BrdU labelling experiment was designed.
7.2
Steady State Kinetics Of The Murine Tracheal Epithelium
Introduction
There is, at this time, no in vivo method for following the fate of individual cells
through time. Instead, it is possible to make a projection of the fate of individual cell
types by following the spread of an incorporated nuclear label. Breuer et al. (1990)
used such a method to study the cell kinetics of the adult hamster bronchial
epithelium. 7 groups of hamsters were sacrificed at 1 hour and 1,2,3,4,7 and 14 days
after an intraperitoneal injection of [3H ] thymidine. Autoradiograms of bronchial
tissue was prepared. Cells were classified into 7 categories and the number of
labelled and unlabelled cells counted. The cell categorisation was as follows: basal
type 1 (B i) and basal type 2 (B2), depending on nuclear height; secretory cells which
were described as S type 1 (with zero to four secretory granules: possibly Clara
cells), S type 2 (5 or more granules with intervening cytoplasm) or S type 3 (where
the cytoplasm was completely filled with granules); ciliated cells and indeterminate
cells. At 1 hour after injection, labelling (as a percentage of unmarked cells of the
same type) was highest for the Bt and B2 type cells while the most commonly stained
cell (as a percentage of all unmarked cell types) was the S type I cell. With time, the
fraction of labelled Bi and B2 cells decreased whereas the percentage of S type 2,
ciliated and intermediate cells increased. The fraction of S types 1 and 3 did not
change. These results suggests that the basal cells and the secretory type 1 cell
contribute the most to the processes of self renewal in the steady state hamster
bronchus.
The potential errors and statistical instability arising from cell identification in this
paper must be born in mind when regarding the paper's conclusions. The potential
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errors and statistical instability are described above (e.g. the authors are "assuming
contamination" of the identification of the basal cell type by 50%). The paper does
not show any figures of the autoradiographs. Furthermore, regression projections are
made through the 14 day period for all their results which does not take into
consideration non linearity. This is particular hazardous considering the very low
levels of labelled cells which are being considered.
An experiment was designed to repeat the study done by Breuer et al. (1990) but
trying to avoid the areas of potential uncertainty as outlined above. At the upper
level of safe cell type identification, only 4 cell type groupings were identified;
basal, ciliated, non-ciliated columnar, intermediate. Linear regression of data was not
conducted.
Materials And Methods
Thirty five 6 week old male mice on an outbred MF1 genetic background weighing
approximately 25g were obtained from Charles Rivers Ltd and separated randomly
into 7 groups of 5 animals. BrdU labelling and immunohistochemistry was
conducted according to and using the contents of the Boehringer Mannheim "In situ
Cell Proliferation kit, AP". Mice in 6 of the groups received a lml IP injection of
lOmM BrdU in PBS per lOOg of mouse (approximately lmg dose per mouse) whilst
group 7 was left as a negative control. Mouse groups were left for between I hour
and 14 days (as shown in figure 7.2.1) prior to sacrifice by 0.5ml Euthatal (Rhone
Merieoux, UK) IP injection. Trachea and duodenum tissue was dissected out and
fixed in 10% buffered formalin for 6hrs at +4°C prior to processing to wax blocks. 4
pm sections were cut and floated out on a 56°C water bath onto Vectabond coated
slides. Slides were dried over night at 37 °C.
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Tissues were de-waxed and re-hydrated by transferring slides through 2 x xylene for
10 minutes and a decreasing concentration of ethanol (2x 100%, 90%, 70%, 50%, 1
minute each) to PBS. All incubation steps took place in a humidified chamber at
room temperature unless otherwise directed. Slides were transferred to a large beaker
containing excess PBS and the beaker covered with cling film prior to heating using
a microwave oven at high power for 3x5 minute intervals. Slides were left to cool
in clean PBS.
Slides were incubated with a 1:4 dilution of anti-BrdU-AP antibody in incubation
buffer (Boehringer Mannheim) for 30 minutes at 37°C in a humid chamber. Slides
were washed in PBS for 3x 5 minutes. Substrate solution was prepared by dissolving
one substrate table(bottle 4) in 2 ml of substrate buffer (bottle 5) and shaken for 5 -
10 minutes until dissolved. Slides were incubated in substrate buffer for 15-30
minutes or until colour develops. Slides were mounted in glycerol mountant (lOg
gelatine, 60ml dPBO, 70ml glycerol, 0.25 phenol) and dried overnight at room
temperature prior to viewing with bright field Nomarski microscopy with a Zeiss
Axioplan microscope.
The number of labelled and unlabelled cells of each cell type was counted. One side
of the trachea was chosen at random an counting was started at the proximal end of
the trachea where the pseudostratified epithelium begins. Cells were not counted
where poor histology was encountered. Cell types were defined as: Basal, cuboidal
cells with basal membrane attachment only; intermediate cells, cells with neither
basal or apical membranes; ciliated cells, columnar cells with cilia visible on apical

















4 1 mg IP 1 -72Hr - -
5 1mg IP _r _,
6 1mg IP 336hr
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7 -ve control n/a
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336.2 645 807 11 1.7 1NC 0.1
336.3 592 677 10 1.6 0 0
336.4 125 155 2 1.5 0 0
336.5 208 341 4 1.9 <q 0.2 0 0 0.1 0.1
7 c.1 465 866 0 0 0 0
c.2 481 621 0 0 ■■I 0 0
C.3 384 597 0 0 0 0
c.4 166 245 0 0 0 0
c.5 277 366 0 0 0.0 0.0 0 0 0.0 0.0
Table Abbreviations:
B= Basal Cell Type
Bm= Marked (labelled) Basal Cell Type
I = Intermediate Cell Type
NC= Non Ciliated Columnar Cell Type




Examples of immunohistochemistry data are displayed in figure 7.2.2. Numerical data is
presented in figures 7.2.3 and 7.2.4.
Figure 7.2.2
Incorporated BrdU detection by anti-Brdll-AP Immunohistochemistry.
An Alkaline phosphatase bound anti BrdU antibody and a neutral-red endpoint was used
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200pm
7.2.2A Presence of 2 labelled intermediate cells 336 hours after mouse BrdU dosing.
7.2.2B + C Positive control slide (small intestine 1 hours after BrdU dosing) showing
presence of labelling in the small intestine crypts but not on the villi.
7.2.2D Negative control slide showing anti-BrdU immunohistochemistry on small intestine
tissue which had not received BrdU dosing. Occasional non cellular neutral red crystals
were noted.
Figure 7.2.3
Number Of Marked Basal And Non Basal Cells As A Percentage Of Total Cells
At Different Times After IP BrdU Pulse Injection.
See base of table for abbreviations.
Gp. Mou b Non bm Bm/B Mean Mean Marked Bm/ Me Mean








1 1.1 534 619 14 2.2 0 0
1.2 369 691 8 2.2 k 0 0
1.3 321 390 17 5 0 0
1.4 419 612 5 1.1 2.6 1.1 1NC 0.2 0.1 0.1
2 3.1 259 334 4 1.5 0 0
3.2 250 329 3 1.1 0 0
3.3 562 731 15 2.6 0 0
3.4 845 972 25 2.8 2xC 0.2
3.5 145 201 10 6.4 2.9 1.4 2x C 1 0.1 0.3
3 24.1 621 795 24 3.7 7x NC 0.9
24.2 431 519 7 1.5 1 x NC 0.2
24.5 459 624 7 1.5 2.2 1.0 2x NC 0.3 0.5 0.2
4 72.1 560 817 0 0 0 0
72.2 376 451 2 0.5 1C. 0.4
72.3 290 341 3 0.1 0.2 0.2 1 C 0.8 0.4 0.3
5 168.1 449 581 4 0.8 0 0.0
168.2 450 672 27 5.9 1 C,1 I,
1 NC
0.4
168.3 311 371 7 2.2 11 0.2
168.4 684 792 12 1.7 ' i• '* I
/ y.
2C 0.3
168.5 37 120 3 7.5 3.6 2.7 0 0 0.2 0.1
6 336.1 974 1213 11 1.1 3x1 0.2
Figure 7.2.3
Data from Brdll single dose experiment
Cell Proliferation Index
(marked/total cells) / % % marked Basal Cells
% marked Columnar
Cells
Time after dosing/ hours
Graph displays data obtained from the single pulse BrdU tagging experiment. Data at different
time points was obtained from mean CPI from groups of animals (n=3-5) from cell counts of
>1000 cells per animal. Error bars show mean standard error. Asterisk denotes statistical
difference between time point and the preceding time point to <0.05 probability by unpaired
student's t-test.
Discussion
At 14 days (336 hours) after the initial labelling, a subpopulation of epithelial cells
were observed to retain their BrdU labelling characteristics. This included 1.6%
(mean error 0.2%) of basal cells and 0.1% (mean error 0.1%) of non basal cells
(these cells were identified to be of non ciliated or intermediate cell type). The label
retaining property of the non basal cells is not statistically valid however, the
presence of labelled basal cells 336 hours infers that (when viewed as a static time
point) at the very least, the basal cells have a slow rate of cellular turnover.
Basal cells show a higher frequency of BrdU labelling than non basal cells at all time
points. The data presented in graph 7.2.3 shows a two phase cycling of levels of
BrdU labelling peaking firstly at 1 hour after labelling (mean basal cell labelling =
2.9% mean error = 1.4%), dropping to a mean of 0.2% (mean error =0.2%) at 72
hours then peaking again at the next time point, 168 hours at 3.6% (mean error 2.7%)
before dropping to 1.6% labelling (mean error 0.2%) at 365 hours.
An increase in the labelled percentage of cells can only occur if previously labelled
cells divide and thereby, give rise to more labelled daughter cells. Therefore, the
second phase of increased labelling is likely to be as a consequence of basal cells
marked in the first phase undergoing cell division. Only one non basal cell was
labelled in the 1 hour time point. The infrequency of dividing non basal cells
suggests that these cells are either end point cells or have an extremely slow rate of
cellular turnover. It is more likely that the first theory is true as the non basal cells
would have to have an near infinitely long cell cycle for only 1 cell out of 2312 cells
counted to be dividing at the time of BrdU injection. Furthermore, it is interesting to
note that this bi-phasic pattern of basal cell labelling is associated with an slight
increase in the number of labelled non basal cells at 24 hours. This time point
coincides with the trough of basal cell labelling. The apparent discrepancy between
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the number of dividing basal cells and the number of non basal cells produced is
compensated for differences in the cellular frequency (basal cells only contribute
between 5 and 10% of cell types in the mouse epithelium (Pack,, 1981) and cell
death of columnar cells during the experimental duration. This increase in non basal
labelling suggests that new non basal cells are being produced from the labelled
basal cells.
A kinetic model for this pattern is presented in figure 7.2.5. Two types of basal cells
exist in this model. Type 1 basal cells act as progenitor cells to new non basal cells.




Bi-phasic Model Of Epithelial Kinetics In The Steady State













Type 2 basal cells
produce basal cells
Although data analysis on results of small quantitative size is always inherently
fragile there is external evidence that firstly, two types of basal cells exist and
secondly, bi-phasic patterning of the epithelial kinetics occurs.
The evidence for there being two types of basal cells is provided by the
morphological evidence of basal cells in cell suspension as reported by Inayama et
al. (Inayama, 1989). Cells suspensions of basal cells were produced by the pronase
digestion of rabbit tracheas and subsequent purification by centrifugal elutriation.
This method resulted in basal cell purity of between 92 and 94%. TEM analysis of
purified basal cells revealed two morphologically difference types of basal cells. The
most common type (91% of cells) was small (6.7±0.6pm) and exhibited a high
nucleus to cytoplasm ratio with electron dense cytoplasm, irregular shaped nucleus
and conspicuous perinuclear tonofilaments. The second type of basal cell (9%) was
slightly larger (8. l±0.4pm), had a round nucleus with few indentations and less
abundant heterochromatin and the cytoplasm was less electron dense.
This experiment was modelled on the study conducted by Breuer et al. (1990). Data
on percentage labelled cells against time was presented as mean value and regression
lines (see figure 7.2.6a). Re-examination of these data show that a very similar bi-
phasic pattern of basal cell labelling is present (see figure 7.2.6b). However,
discussion of this pattern was not presented in the paper.
These data presented in this section suggests that in the steady state mouse tracheal
epithelium, basal cells acts as the primary progenitor cell population. Basal cells are
of two types, the first a fast cycling population which divide to produce new non
basal cells and a second population which cycle slower and divide to maintain the
basal cell population. This second population of basal cells show BrdU labelling




Evidence for Bi-phasic model after Breuer et al. (1990)
Figure A Figure B
Labelling index analysed over time for "B-l" cells (solid line and circles) and "B-2" cells
(dotted line and open circles) after a single injection of tritiated thymidine. B-l and B-2 cells
were categorised as cells having nuclei adjacent to basement membranes with B-2 cells being
larger than B-l cells. No histological examples for these cell types were presented in the
paper. Compare figure B to the pattern observed in figure 7.2.3.
7.3
A Study Of Label Retaining Cells In The Mouse Tracheal Epithelium
Introduction
According to the Potten and Smith model of stem cell behaviour (Potten, 1988) if a
population of epithelial cells are labelled at the time of cellular division, the stem
cells will retain their label for a longer duration than other cell types. This non¬
functional assay has been used in a number of different tissues to identify stem cells
(Lavker, 1982, Potten, 1988, Bickenbach, 1981, Potten and Loeffler, 1990). An
experiment was designed to examine whether cells could be found in the mouse
trachea that exhibited BrdU label retaining characteristics. Due to the slow rate of
cellular turnover in the mouse trachea it was unlikely that a single pulse dose of
BrdU would results in any stem cells being labelled for reasons discussed above.
Therefore, to make such an experiment practically possible, mice received repeated
tracheal damage (to increase stem cell recruitment) and repeated BrdU delivery.
Materials and Methods
Animals
Male CD1 mice (22-25g at start each experiment) from Charles Rivers Laboratories
were used throughout these experiments.
Damage by poloxethylene 9 lauryl ether (polidocanol) instillation.
Polidocanol (Sigma, St. Louis, MO) was diluted in sterile PBS to 2 % w/w. Mice
were anaesthetised with 70pJ IP injection of lOOmg/ml Ketamine: lOOmg/ml
Xylazine in PBS (2:3:5 ratio v/v) and placed in a tracheal instillation frame as
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described in Ho and Furst (1973). 10 pi polidocanol solution was slowly instilled by
24Gx3/4" catheter to the proximal region of the trachea. This protocol had a 100%
survival rate.
Damage by sulphur dioxide inhalation.
Mice were received 3, 3.5, 4 or 4.5 hours doses of sulphur dioxide at a
concentration of 500ppm. This protocol was performed under guidance and
assistance by the Environmental Protection Agency facility in Research Triangle
Park, NC 27711, USA.
Assay Of Tracheal Damage By Polidocanol Or Sulphur Dioxide.
The effect of damage to the mouse trachea by polidocanol instillation or sulphur
dioxide inhalation was examined. 9 mice received polidocanol damage and 6 mice
received sulphur dioxide damage (3 hours at 500ppm). Of these animals, 3 of the
polidocanol animals were sacrificed 10 minutes after damage, 3 from each damage
group were sacrificed 2 hours after cessation of damage protocol whilst remaining
animals were sacrificed 23 hours after damage. Tracheas were dissected out, fixed in
omnifix and examined by H&E counterstained histology as outline above. Controls
of air inhalation animals and PBS instillation animals were run in tandem.
Results
Pathology Of Damage By Polidocanol And Sulphur Dioxide
Damage to the mouse trachea by polidocanol instillation and sulphur dioxide




Mouse Trachea After Damage By Polidocanol Instillation Or Sulphur Dioxide
Inhalation.
Polidocanol Damage
10 minutes after Polidocanol damage, the columnar cells are seen to have been
partially stripped from their adhesion to basal cells (figure 7.3.1 A).
2 hours after polidocanol damage the entire layer of columnar cells was observed to
have been removed from the mouse trachea from just beneath the larynx to as far as
the carina. This damage was observed from just beneath the top of the trachea
(figure 7.3.1 B complete trachea and at higher power 7.3.1 C) to the base of the
trachea. In the regions affected, basal cells and the lamina propria were still present
and had been exposed to the lumenal air (figure 7.3.1 D).
24 hours after polidocanol damage a thick layer of nucleated material existing in the
previous epithelial location (figure 7.3.1 E)
At later time points (>7 days), epithelial architecture was seen to have been
completely restored. In a low number of cases, extreme tracheolytis obliterans (gross
metplasia of the epithelial tissue produces an outgrowth of epithelial and
mesenchymal tissue) pathology was also noted (figure 7.3.1 F showing extreme
epithelial pathology 12 days after polidocanol damage).
Sulphur Dioxide Damage
2 hours after the cessation of damage by Sulphur dioxide inhalation, columnar cells of
the mouse tracheal epithelium appear diffuse and irregular in shape (figure 7.3.1G).
24 hours after sulphur dioxide damage the epithelium appears to be composed of
poorly differentiated cells containing a high nuclear:cytoplasmic ratio (figure 7.3.1H).
Figure 7.3.11 Control slide showing tracheal epithelium from undamaged mouse.
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Effect of Damage To The SMGs
7.3.1 J Control SMG from undamaged mouse
7.3.IK SMG 36 hours after Polidocanol damage. Note dilation of the collecting and
secretory ducts and the narrowing of the ciliated duct on reaching the lumen. This
constriction proved to be a difficulty in obtaining histological sections showing the
top of the ciliated duct (narrowing of the duct reduces the ductal opening area and
therefore the chance of cutting a thin section through this area is reduced).
7.3.1L SMG 36 hours after Sulphur dioxide damage. Gross dilation of the ciliated
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An Investigation into Using Osmotic Pumps to deliver BrdU
Material and Methods
BrdU has a short unincorporated half-life in an in vivo environment. This property
results in single injections producing a spiked dose rather than a steady bathing
effect. Although this fast rate of in vivo degradation is highly desirable for single
time point experiments it is less so for long term dosing experiment. To overcome
the potential problem of spike dosing the mice with BrdU, the use of osmotic pumps
were investigated.
Alzet osmotic pumps (Alzet, Palo Alto, CA). were used to provide continuous dose
delivery of BrdU to mice. Each pump was loaded with 200pl 50 mg/ml BrdU
solution (distilled H20, 1% NH4OH, pH=8.0), immersed in saline solution at 37°C
for 4 hours and implanted subcutaneously to Ketamine/Xylazine anaethnetised mice
according to the suppliers guidelines.
To assess the rate of BrdU delivery versus detection by immunohistochemistry, 4
different types of pumps were used delivering doses of 12.5gg/hr (pump model
2004), 27.0pg/hr (pump model 2002), 47.5pg/hr (pump 2001) and 372.6pg/hr (pump
200Id) BrdU over a 24 hour period. After this time, the mice were sacrificed with
lethal IP injection of "Sleepaway" (Fort Dodge Labs, Iowaalthough).
The gut was used to assay the level of BrdU incorporation due to its well-
characterised pattern of cellular division and easily recognisable histology. 20mm
duodenum adjacent the stomach sphincter was dissected out, flushed out with NBF
of omnifix (Fisher, Fair Lawn, NJ.) and fixed overnight in NBF or omnifix at +4°C
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before processing to wax blocks. 6pm sections were cut and incorporation of BrdU
assayed by immunohistochemistry.
BrdU Immunohistochemistry
6pm paraffin sections of control or test tissues were mounted on pre-coated
microscope slides.
Sections were dewaxed with xylene and rehydrated through a decreasing
concentration gradient of ethanol. Incorporated BrdU was antigenically exposed by
incubating the slides in 4M HC1 for 20 minutes and trypsin: EDTA solution (0.1%
trypsin type III (Sigma T-0646) ImM EDTA in Dulbeccos PBS). Two different sets
of antibodies were used:
Set 1:
Tissues were immuno-blocked in 5% Goat serum, 1 % fish gelatin, 1% BSA in
PBST (Sigma, St. Louis, NJ.) and incubated with 1:10 dilution of FITC anti BrdU
(Boehringer Mannheim, Lewes, UK) Antibody binding was visualised using a
1:2000 dilution of Rabbit anti FITC (Boehringer Mannheim, Lewes, UK) in PBS and
a 1:200 dilution of peroxidase goat anti rabbit (Jackson laboratories, ME, USA). See
below for visualisation protocol.
Set 2:
Tissues were immuno-blocked in 5% rabbit serum, 1 % fish gelatin, 1% BSA in
PBST (Sigma, St. Louis, NJ.) overnight at 4°C and incubated with 1:200 dilution of
sheep anti BrdU Antibody (Fitzgerald labs, FL, USA) binding was visualised using a
1:200 dilution of rabbit anti streptavidin (Jackson laboratories, ME, USA) and a
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1:1000 dilution of horse radish peroxidase- streptavidin (Jackson Laboratories, ME,
USA)
To visualise the signal, slides were incubated with DAB solution (lOmg DAB
(Sigma, St. Louis, NJ) in 50 ml 0.0.5M, pH 7.6 Tris-HCI activated with 30ml 30%
H202 for 15 minutes. Slides were washed in dH20 and counterstained in 1% methyl
green in water for 15 minutes. Slides were dehydrated back to xylene and mounted in
DPX.
Results
Quantification Of BrdU Immunohistochemistry (Pumps And Fixation
Methods)
Alzet osmotic pumps can be used in vivo to provide a continuous dose of chemicals
into laboratory animals. The potential for using these pumps to deliver a continuous
dose rate of BrdU over a 22 day period was investigated. Additionally, two methods
of tissue fixation (omnifix or NBF) were assayed. 4 different models of pumps were
investigated, as outlined in figure 7.3.2 using detection of incorporated BrdU in the
duodenum as an end point.
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Figure 7.3.2.
Dose Rate And Duration Of Activity Of Varying Models Of The Alzet Osmotic
Pumps.
Model Pump life time/
days
Mean pump






2001D 1 7.45 0.25 50.0 372.5 8940
2001 3 0.98 0.04 50.0 47.5 1140
2002 14 0.54 0.02 50.0 27.0 648
2004 28 0.25 0.02 50.0 12.5
Pumps were prepared and loaded as described above and implanted for 24 hours
prior to sacrifice. Duodenum were fixed in either 10% NBF or omnifix and prepared
for BrdU visualisation by immunohistochemistry. Set 1 of antibodies was used in
this experiment. Pumps and detection methods were assayed for staining
visualisation by light microscopy. See figures 7.3.3 and 7.3.4.
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Figure 7.3.3
Immunohistochemistry Results For BrdU Detection After Pump Dosing For 24
Hours Using Different Pump Models And Different Fixation Methods.
7.3.3A Set 1 antibody used on mouse small intestine which was sacrificed and fixed
in Neutral Buffered Formalin (NBF) 1 hr after the injection of 2mg BrdU in PBS, 1%
NH4OH. Cells in the crypts observed react with DAB (brown colour). Tissue
counterstained in methyl green (green/blue colour).
7.3.3B As with 7.3.3A but tissue fixed in Omnifix. Note higher clarity and intensity of
signal yet slightly higher cytoplasmic background.
7.3.3C Omnifixed small intestine from a mouse which had carried a 2001 d Alzet
osmotic pump filled with BrdU (200pl 50mg/ml) for 24 hours. High intensity of staining
in the crypts.
7.3.3D As with 7.3.3C but using pump model 2001. Fainter signal than with pump
model 2001 d.
7.3.3E As with 7.3.3C but using pump model 2002. The results from using this
protocol, as with pump 2004 (result not shown) resulted in no measurable sign of
BrdU.
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Summary Of Incorporated BrdU visualisation by Immunohistochemistry After
BrdU pump Dosing for 24 hours. N=4







In both fixation methods, BrdU was detectable using pumps 200Id and 2001 only.
The working duration of these pumps was however, unsuitable for use in a 22 day
experiment. Omnifixed tissue was found to give a much stronger
immunohistochemistry signal (as seen by intensity of brown cellular signal) than
with NBF fixed tissue. The omnifixed tissue also showed a higher endogenous
background (faint brown background colour) and slightly poorer histology
(especially in the villi).
Omnifix was found to be the most suitable fixation method for viewing BrdU. As
the osmotic pumps proved unsuitable for this experiment, the use of repeated single
dose injections were investigated
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Study of BrdU injection frequency versus cellular labelling in the mouse small
intestine.
The osmotic pumps were found not to be useful for the purposes of a prolonged
labelling experiment. An alternative was to deliver frequent IP injections of BrdU to
the animals. One possible draw back from such an approach would be that repeated
pulse delivery of BrdU would be likely to produce peaks and troughs of BrdU serum
levels and thereby conceivably not labelling every cell undergoing division. An
experiment was conducted to examine whether a rate of injections one every two
days would be able to provide a sufficient and useful dose for this experiment.
Localisation of BrdU labelled cells in the small intestine was examined after the
delivery of two 2mg BrdU IP injections 48 hours apart. 6 mice received a 2mg IP
injection of BrdU (50mg/ml in H20/ 1%NH40H). These mice were split into 3
groups. Group 1 animals were left for 48 hours and then sacrificed and tissue from
the small intestine fixed in omnifix and processed for BrdU immunohistochemistry
as before. Group 2 animals received another BrdU injection after 24 hours and were
sacrificed 24 hours later and tissues processed as with group 1. Group 3 animals
received addition injections at 24 hours and 47 hours after the original injection. At
48 hours after the start of the experiment, these animals were sacrificed. Negative
control animals which did not receive BrdU injections were also processed for BrdU
immunohistochemistry.
The results are shown in figure 7.3.5.
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Figure 7.3.5.
Evaluation Of BrdU Labelling In Gut After Multiple BrdU Pulses
7.3.5A Group 3. Small intestinal tissue fixed with omnifix and stained for BrdU using
set 1 antibody. This animal had received three 2mg BrdU doses at 48hours, 24hours
and 1 hour prior to sacrifice. BrdU labelled cells (as identified by nuclear DAB stain)
were distributed from the base of the crypts to the central region of the villi.
7.3.5B Group 1. Small intestinal tissue fixed with omnifix and stained for BrdU using
set 1 antibody. This animal had received one 2mg BrdU doses at 48 hours prior to
sacrifice. Labelling was considerably weaker than in the group 3 animals and




Low frequency pulse injections of BrdU are likely to results in varying levels of
BrdU in the serum. In this study of BrdU labelling in the duodenum it was shown
that by providing a high dose of BrdU at 48 hour intervals produced a high degree of
staining homogeneity. This suggests that repeating pulse injections at 48 hour
intervals would be suitable to maintain a satisfactory degree of continuity in the
labelling of dividing cells. Labelling was planned to be used in conjunction with
stem cell recruiting tracheal damage. As it was unknown when stem cells (if present)
are recruited after tracheal damage, the schedule of BrdU injections was made
asynchronous and an addition BrdU injection was made on the day of tracheal injury.
Study of LRCs in the mouse trachea
70 age matched CD1 male mice were randomly separated into 13 groups. These
groups were further randomly chosen to give 5 test polidocanol damage groups, 5
test sulphur dioxide groups and three control groups (either receiving no damage or
no damage but BrdU injection).
Test mice repeatedly received in vivo tracheal damage by polidocanol instillation or
SCL inhalation (SO2 incubations were performed by T. Krantz) as outlined below in
figure 7.3.6. In addition, the mice received 200pl 10 mg/ml IP injections of BrdU
solution every two days over the 22 day period of the experiment plus an additional
dose approximately one hour after tracheal damage.
At different time points after the 22 day period , groups of mice and control animals
were sacrificed by lethal IP injection of Euthatal (see figure 7.3.6). Tracheas and
duodenum were excised, fixed in omnifix and processed to paraffin blocks. 6pm
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sections of tissues were cut. On each slide, one sections was examined by
immunohistochemistry for cellular incorporation of BrdU with set 2 antibodies,
while a serial section was run as a negative control (no primary antibody added.)
Figure 7.3.6.
Schedule For Experiment: Tracheal Damage, BrdU Injections And Sacrifice
times. Control Groups Included Mice Receiving No Damage And No BrdU
Injections And Mice Receiving BrdU Injections Only.
Day 0 7 14 21 22 25 29 57 117
Shorthand +3 +6 +21 +95
Damage" * * * • i ' "
:
BrdUb — — -
Sacrifice
. Ill
[|| • : .i ♦ ♦ ♦ ♦
; 4 4 4 9
a
either 10pl 2% polidocanol solution or 500ppm S02 inhalation (the duration
of S02 damage increased from 3hrs to 4.5hrs at 0.5hr steps at the different
time points)
b
200p! 50mg/ml BrdU in 1% NH4OH in PBS
The degree of cellular labelling was measured at the different time points.
Approximately 100 cells of both basal and columnar type at each of 3 different
regions of the trachea were examined for cell type and presence of nuclear
immunohistochemistry signal. Signal was confirmed as being positive if the signal
was nuclear localised and the brown staining above that detected as background and
on control slide. These 3 regions were at cartilage ring number O, number 5 and
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number 9 (see chapter 3 for description of cartilage ring positioning). Cellular
staining on sections were compared to serial negative control sections or control
tissue. Stained and unstained cells were identified as either being basal cells (B)
(small cuboidal cells with basolateral membrane attachment), intermediate cell (I)
(cells with neither basolateral membrane or luminal interface), ciliated cells (C)
(columnar cells with visible cilia) or non ciliated columnar cell (NC) (cells with
luminal interface but no visible cilia). Areas of distorted histology or bronchiolitis
obliteran pathology were removed from the counting process. Small intestine tissue




The percentage of BrdU labelled cells at different time points was measured at three
different sections of the trachea. The full data is presented in appendix 2 and is
summarised below in figure 7.3.7a and sulphur dioxide damage only in 7.3.7b.
Figure 7.3.7.
Summary of Data From Label Retaining Experiment
Data are displayed in two tables; each one referring to the data gained through the
use of a specific antibody set (see above). The "positions" refer to the sections on the
trachea where the counts were made: position 1 = cartilage ring 0, position 2 =
cartilage ring 5, position 3= cartilage ring 9.
Data are presented as mean percentage marked cells and standard error of the
mean in brackets.
The abbreviations to the methods of damage are "S02" = damage by sulphur dioxide,





Position 1 / %
■
■
Position 2 / % Position 3 / %
B c B C B C
+3 days S02 47.3 (13.1) 18.9
(6.5)
32.6 3.3) 8.8 (4.6) 35.8
(9.6)
13.6 (5.3)
Poiidoc 1.6(1.1) 0.3 (0.4) 3.3 (0.9) 1 (1.3) 3.0 (1.0) 1.0(0.0)
- 4.0 0.0 2.0 2.0 3.0 4.0












Poiidoc 8.0 (5.0) 0.8 (1.2) 7.0 (4.0) 2.0 (2.5) 3.3,4.0, 0.5 (0.8)
- 2.0 0.0 0.0 0.0 0.0 0.0
+ 21 days
1 1.
so2 29.5 (7.5) 18.0
(8.5)
0.5 (0.5) 0.5 (0.5) 0.8 (0.8) 0.0 (0.0)
Poiidoc 0.8 (1.0) 0.3 (0.4) 0.0 (0.0) 0.3 (0.4) 0.5 (0.5) 0.0 (0.0)
- 3.0 2.0 0.0 0.0 0.0 0.0
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Antibody Set 2
Damage Positio5 tmlk 5? Position 2 / % Position 3 / %
method
B C B C B C









3.5 (1.5) 7.5 (1.5) 4.5 (1.5) 3.0 (2.0) 1.0 (0.0)
3.0 0.0 2.0 0.0 4.0 0.0




17.2 (8.8) 8.8 (1.4) 18.2 (3.4) 10.5 (1.0)
Polidoc 5.8 (3.1) 2.5 (2.2) 1.8(1.3) 1.3 (1.4) 2.8 (2.7) 1.3 (1.3)
- 6.0 1.0 4.0 1.0 0.0 1.0






18.0 (8.5) 16.0 98.5)
Polidoc 13.6
(5.8)
3.7 (2.6) 11.3 (6.2) 5.3 (2.4) 15.3 (5.3) 5.3 (3.3)
11.0 2.0 4.0 2.0 5.0 1.0
+95 days so2 9.3 (3.8) 3.0 (1.0) 1.8(0.8) 1.3 (1.3) 1.3(0.6) 1.3 (0.4)
Polidoc 4.0 (3.2) 1.8(1.3) 3.4 (2.6) 1.4 (0.9) 1.4(1.0) 0.6 (0.4)
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Figure 7.3.7b
Summary of BrdU Profiles- S02 Damage
Summary of BrdU positive cell counts. Position 1 is adjacent to cartilage ring 0,
position 2 is adjacent to cartilage ring 5, and position 3 is adjacent to cartilage ring 9.
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Figure 7.3.7b
Summary of Data from figure 7.3.8. Immunohistochemistry results from
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Examples of BrdU immunohistochemistry images from sulphur dioxide
damaged mice
For 4 weeks, mice received repeated tracheal damage by sulphur dioxide inhalation
and repeated BrdU injections. After this time, groups of mice were sacrificed at 3
days, 6 days, 21 days and 95 days. Tracheal and gut tissues were processed for
BrdU visualisation by immunohistochemistry using one of two possible sets of
antibodies. Examples of these images are presented below.
+3 days
7.3.8A Set 2 antibody visualising a SMG ciliated duct and neighbouring epithelium
(x40). Antibody labelling appears as brown nuclear staining.
7.3.8B Set 2 antibody negative control (no primary antibody)on serial section of
7.3.8A
7.3.8C Set 1 antibody on SMG region (mucus staining grey after omnifixation). Note
high frequency of labelled cells
7.3.8D High power view of 7.3.8C ciliated duct. Note presence of heavily stained cells
in the base of the ciliated duct.
7.3.8E Control section from mouse (no primary antibody).
7.3.8F: Set 1 antibody on small intestine sample from a +day 3 animal showing
cellular staining in the base of the crypt- an area associated with gut stem cells.
+6 days
7.3.8G Set 2 antibody visualising a SMG ciliated duct and neighbouring epithelium
(x40).
7.3.8H Negative control (no primary antibody) on serial section of 7.3.8G.
7.3.8I Set 1 antibody. High frequency of epithelial cells are still labelled.
7.3.8J Higher power of ciliated duct of 7.3.8I shows presence of heavily stained cells.
7.3.8I Set 1 antibody on small intestine sample from a +day 6 animal showing similar
staining pattern to that observed in 7.3.8F demonstrating retention of BrdU labelling
characteristics of stem cell populations
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7.3.8L Set 2 antibody visualising a SMG ciliated duct and neighbouring epithelium
(x40).
7.3.8M Control (no primary antibody) on serial section of 7.3.8L.
7.3.8N, O and P: Set 1 antibody on SMG ciliated duct region. 3 different cell types are
detectable by BrdU immunohistochemistry in this image, each existing in a discrete
spatial niche: labelled round cells in the ciliated ducts, labelled basal cells adjacent to
the ductal openings and labelled intermediate cells lying out-with this region.
7.3.8 Q: More distal epithelium shows very low levels of labelling (as detected by set 1
antibodies). This is in contrast to the previous time points and the results gained by
using set 2 antibodies.
+95 days
7.3.8 R and T: Set 2 antibodies demonstrating very similar pattern of labelling to that
observed with set 1 antibodies at day +21 namely, heavy label retention in the ciliated
duct and labelling of basal cells adjacent to the ductal opening and intermediate cells
further beyond this zone.
7.3.8 S and U: Control serial sections of slides 7.3.8 R and 7.3.8 T.
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BrdU labelling profiles in Sulphur dioxide damaged tracheas
At 3 and 6 days after the cessation of damage and injections, a very high number of
cells were marked for presence of BrdU. This was to be expected due to the
stimulation of cellular proliferation by S02 damage. At this time there was a trend
towards higher labelling indexes in position 1 of the trachea although this was not
statistically significant. By cell type, a higher percentage of basal cells were labelled
with BrdU than were columnar cells. It should be noted however, that basal cells
occur with lower frequency in the mouse trachea than do columnar cells
(approximately 5% of epithelial cells are of basal type (Wright, 1996, Pack, 1980))
so if any comparison of cell type labelling indexes was to be made, the data should
be weighed for cell type frequency.
In day +21 S02 damaged tissues, a stark change in the pattern of labelling was noted
using the antibody set 1. In these samples, the percentage of cells labelled in regions
2 and 3 was seen to drop to near control (no damage) levels. However, a high
number (29.5% (7.5% mean error)) of cells in region 1 were seen to still be labelled.
Closer examination of this area revealed this these labelled cells were only found in
the proximity of submucosal gland duct openings. Associated with this observation
was the presence of heavily labelled cells within the epithelial lining of the
submucosal gland ciliated duct. See figure 7.3.9.
This pattern is not observed when using the 2nd antibody set at day +21. At day +95
however, a similar profile (though with a lower labelling index) is seen as with set 1,
day 21 samples. It is thought that this time shift in the observation of the pattern may
be due to differences in the sensitivity of the antibody methods. Although there is no
direct evidence to prove this a marked similarity between the labelling patterns of set
I samples and set 2 at one time point later. Antibody set 2 can be envisaged to be
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able to detect BrdU levels at lower concentrations than with set 1. If this was the
case, then the labelling profile of daughter cells would be seen to change.
BrdU labelling profile in Polidocanol damaged tracheas
Although significantly higher than the labelling profile of control tissues, the
polidocanol damaged animals showed much lower levels of labelling in comparison
to that observed in the SCB damaged animals. This was at first surprising considering
that polidocanol was observed to completely remove columnar cells from the
epithelium. A theory of why this may occur is presented later.
The results from the two different sets of antibodies show considerable variation in
the results. With set 1, basal cell labelling is seen to peak at +6 days at all three
sampling positions. With set 2, labelling is seen to peak at day +21. This again is
most likely as a consequence of differences in assay sensitivity.
Despite these differences, cells retaining the label to +21 days of +95 days were
observed most commonly in tracheal position 1. In addition, the niche of strongly
labelled cells in the submucosal gland ciliated ducts were observed.
Further analysis of the region of label retention
At day +21 using antibody set 1 and day +95 using antibody set 2, cells within the
ciliated duct and on adjacent luminal epithelial tissue were observed to retain their
BrdU labelling properties. The labelled cells were observed to be of 3 types and to
exist in 3 quite discrete morphological regions or zones (see figure 7.3.10).
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Zone 1: Heavily labelled cells were observed to lie in a discrete niche in the base of
the submucosal gland ciliated duct. These cells were morphologically simple in
structure (by bright field microscopy).
Zone 2: In a region spanning from the top of the ciliated duct out onto the adjacent
epithelium, labelled basal cells only were observed.
Zone 3: External to the previous region, labelled cells of intermediate morphology
(i.e. showing no cytoplasmic adherence to either the luminal or apical surface of the
epithelium) were observed.
The three zones also displayed a hierarchy of staining intensity with cells in zone 1
showing the strongest level of staining and those in zone 3 the weakest level of
staining. This pattern was consistently observed in all slides examined. The number
of SMG ducts examined for this experiment was: set 1 day 21 polidocanol damage
n= 3, set 1 day 21 S02 damage n=8, set 2 day 95 polidocanol damage n=8, set 2 day
95 S02 damage n=13. A lower number of polidocanol damaged SMG ducts of
suitable histology were observed than those from the S02 animals. It is not clear
whether this is a purely coincidental sectioning artefact or indeed, chronic
polidocanol treatment constricts the gland duct volume or alternatively, S02 damage
increases gland volume or even gland number.




3 Zone Model for Label Retention in the Mouse Trachea.
LRCs exist in the mouse trachea in 3 distinct zones. In each spatial zone, only one
cell type is observed as being labelled. The three zones also displayed a hierarchy of
staining intensity with cells in zone 1 showing the strongest level of staining and those
in zone 3 the weakest level of staining.
Zone 1: In the SMG ciliated duct: poorly differentiated
Zone 2: epithelium adjacent to the ducts: basal cells
Zone 3: epithelium adjacent to zone 2: intermediate cells
This pattern of label retention is consistent with there being a population of cells




Zone 3 Zone 2
Discussion
This experiment was designed to examine whether BrdU LRCs, which may represent
stem cells, existed in the mouse trachea. In addition, it was hoped that the labelling
profiles of the basal and columnar cells derived from the experiment would lead to a
better understanding of the cellular kinetics of this tissue.
A number of variables were introduced into this experiment to make possible the
comparison of data. Two different sets of antibodies were used and two different
methods of tracheal damage. Indeed, there was considerable variation in the data
derived from the different methods.
Firstly, there were differences between the results gained from the different sets of
antibodies. Profiles of labelling peaks and patterns observed through the use of
antibody set 1 were seen to occur at a later time point with antibody set 2. For
instance, polidocanol damaged tissue labelling peaked at day 6 with antibody set 1
but at day 21 with set 2 and the reduction in position 2 and 3 labelling was observed
with antibody set 1 at day 21 but not until day 95 with antibody set 2.
Considerable effort was made into providing both damage and immunohistochemical
controls for this experiment. In addition to the damaged animals, tissues from
animals which had received BrdU injections but no damage (termed "BND") and
animals which had received polidocanol damage but no BrdU (termed "PC") were
used to run along side the damaged tissues in the immunohistochemistry runs. The
BND tissues showed generally low levels of labelling (<4.0% with set ! antibodies
and <11% in set 2 antibodies). Basal cells were observed most commonly to be
stained in this group. The PC controls showed no false positive nuclear staining with
set number 1 antibody. In addition to these controls, a negative control serial section
was run when using antibody set number 2. Set 2 was found to be more sensitive
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than set 1, which sometimes resulted in high background runs. These slides were not
examined further. In addition, sporadic areas of very high nuclear and cytoplasmic
staining occurred. The pattern of this staining suggested that the secondary antibody
had bound without specificity to random areas of tissues. Again, these portions of
tissues were not counted.
This experiment fundamentally operates through the detection of BrdU labelled cells
and of equal importance, the failure to detect cells when the cellular BrdU content
drops as a consequence of cellular division. In this respect, it was important that the
method of detection had a finite degree of sensitivity. Moreover, this finite degree
would suit the time frame of the experiment.
Other possible sources of variation which may affect the data were restricted through
the use of similarly cut sections, the same areas for cell counting and examining the
slides in a blinded fashion.
Variation in labelling profiles arising from method of tracheal damage
The two methods of tracheal damage were observed to result in a different degree of
cellular labelling in the day +3 and day +6 animals. Taking average figures from all
three tracheal positions, the labelling index measured in SO? damaged animals was
up to 16 times larger than that measured in the polidocanol treated animals. This
difference may be perceived as being unexpected since both methods cause
considerable damage to the tracheal epithelium. To elucidate this observation the
pathology of damage and the conclusions presented from earlier in this chapter must
be further explored.
The pattern of damage caused by polidocanol was seen to differ from that of the
sulphur dioxide. Polidocanol was observed to remove columnar cells from the
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tracheal epithelium exposing the basal cells to the air. The effect of sulphur dioxide
was considerably more subtle. The pattern of damage appeared to be one of slower
cellular disruption. The consequence of which was that both columnar and basal
cells were observed to have received damage. It is additionally interesting to note the
development of tracheolytis obliterans in many of the polidocanol treated animals.
Can the difference in labelling index between the two methods of damage therefore
be explained as a consequence of the difference in cellular damage? Earlier in this
chapter, a theory was proposed that a subpopulation of basal cells were the main
cells of proliferative capacity in the mouse tracheal epithelium. On this platform, it is
possible to explain the differences in labelling indexes. In the polidocanol animals,
basal cells appear to resist damage. If a subpopulation of these cells have a strong
proliferative capacity they will be able to rebuild the tracheal epithelium very
quickly and with efficiency. When observed through the use of BrdU, this will result
in a generally low index since the window for cellular division would probably be
short and a small number of cells would be involved in division.
In the case of the S02 damaged animals, damage has occurred to both basal cells and
columnar cells. It is therefore likely that some of the highly proliferative basal cells
would be damaged through this process. Thus the system of epithelial regeneration
would be altered. The scenario can be envisaged that for epithelial repair to occur a
higher number of cells would have to divide and over a longer period of time than in
the polidocanol animals. This model would result in the S02 animals demonstrating a
higher labelling index than the polidocanol animals.
In conclusion, the differences observed in the labelling index of the SO? and the
polidocanol damaged tracheas is most likely as a consequence of the differences in
the cell types damaged. In the polidocanol animals, basal cells are retained. It is
proposed that as the basal cells are the main progenitor cell type in the mouse
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trachea, the profile of tissue repair differs between the two damage methods.
Polidocanol treated animals can undergo tissue repair much more quickly and
without such a high frequency of cell division than with the SCP treated animals.
This profile has the consequence of a lower degree of cellular labelling in the
polidocanol treated animals.
The 3 Zone Model Of Label Retaining Cells In The Mouse Trachea
At the later time points of this experiment (day 21 with antibody set 1 and day 95
with antibody set 2) LRCs were restricted to within or around the submucosal gland
ciliated ducts. The LRCs were observed to be of 3 different cell types and to occupy
three discrete zones. Zone 1 is a discrete niche of heavily labelled cells of poor
morphology situated towards the base of the ciliated duct. Zone 2 is from the upper
reaches of the ciliated duct out onto the neighbouring epithelium and contains
labelled basal cells. Zone 3 contains weakly labelled intermediate cells in an area
adjacent to zone 2 but further from the ductal opening.
The presence of labelled cells in this localised region while labelling in other regions
of the trachea is largely lost is of considerable kinetic interest. These data infer that
these cells are either derived from or are themselves cells of high proliferative
capacity and slow cellular turnover for the reasons described in the introduction to
this experiment. Such characteristics are associated with the properties of stem cells.
It is possible to define which of the LRCs may be stem cells and which are transit
amplifying cells (TACs) by property of their staining intensity. The higher up the
proliferative capacity hierarchy the cell is, the more heavily stained the cell should
be. This being due to the cell having a slower rate of cellular turnover.
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On this basis, cells in zone 1 are likely to be higher up a proliferative hierarchy than
those in zone 3. It is therefore likely, although no functional data is available at this
time, that the cells in zone 1 have the properties and perhaps are indeed stem cells.
These cells upon division, will produce the early TACs which are represented as the
cells in zone 2. The early TACs migrate from zone I out onto the epithelial surface
where they divide to produce zone 3 cells or late TACs.
This pattern of stem cell activity is in many ways similar to that observed in the
cornea (Cotsarelis, 1989). The stem cell niche is situated distant from where the
daughter cells will eventually become physiologically active. It is interesting to note
however, that zone 1. 2 and zone 3 all contain cell types which do not possess the
labelling retaining characteristics. This infers the route from stem cell through TACs
to mature cells is likely to include frequent asymmetric divisions as to produce
physiological functional cells as well as maintaining the population of migratory
proliferative cells.
Little is known about the identity of the labelled cells in zone 1. Their location and
structure show close resemblance to the "flask like cells" or "mitochondrial rich
cells" which have been observed in the human SMG (Meyrick, 1970, Engelhardt,
1992). It is exciting to note also that the flask-like cell have been observed in the
human to express CFTR (Engelhardt, 1992).
From these observations it is possible to generate a model which describes the role of






3 Zone Model For Area Of Label Retention
This figure presents the concept that the label retaining cells in the mouse trachea exist in a
region within and surrounding SMG ducts. The labelled cells occupy three zones, each zone
consisting of a different cell type and a different level of label intensity.
 
Evidence For Stem Cell Model In The "Steady State" Trachea
One possible way in which an experiment of this design could fail would be when
the damage induction results in a situation which does not represent the kinetics of
the steady state. Such a design obviously produces an artificial situation in as much
as the extent of epithelial damage and thus, recruitment of proliferative cells into
cellular division. However, the question will still remain whether the kinetics are
disturbed resulting in an "artificial" situation.
There are four main areas of evidence from steady state experiments which can be
seen to back up this model. Firstly, the cells from all three zones have been observed
to undergo cellular division in the steady state human bronchial SMGs (Leigh, 1995)
and from the control slides from this experiment. This suggests that the stem cells,
as proposed by this model, are not completely dormant during steady state.
The second piece of evidence is derived from the original definitions of what a stem
cell should like. As described in the introduction, stem cells are likely to be slow
cycling cells with very high proliferative potential. Furthermore, the stem cells are
likely to be poorly differentiated and occupy a cellular niche lying distant from the
most common sites of cellular damage (Cotsarelis, 1989). The zone I cells closely
match this description both having undifferentiated morphology (by light
microscopy) and lying in a pocket away from but closely connected to the tracheal
epithelium.
The third and most interesting piece of steady state evidence to back up this model is
from the aggregation chimaera studies of section 5.2. In that study, clonality of
SMGs was shown by studying reporter gene expression in the murine SMGs. From
the very same images (figure 5.2.5) it is interesting to note that the epithelium
surrounding a SMG which is expressing a reporter gene SMGs also express the
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reporter gene. The expression of transgene in the epithelium furthermore appears to
be restricted to a distance from the SMG duct similar to that of the extent of zone 3.
This provides interesting data to back up the notion that the stem cell activity as
observed in this experiment also occurs in steady state.
Lastly, an observation, which may be of importance in this argument, is that cultured
pulmonary epithelial cells from CF patients grow quicker than those from non-CF
patients (Randell, personal communication). An intriguing explanation for this may
be that as CF patients have more SMGs than non-CF patients (Yankaskas, personal
communication), there will be a higher frequency of zone 2 and zone 3 TACs in any
biopsy. In this scenario, the CF cultures will then have more cells of high
proliferative capacity than in non CF cultures and therefore, grow faster.
Spatially Restrictive role of tracheal stem cells in tissue maintenance
The finite nature of zone 3 cells suggests that the TACs derived from the tracheal
stem cells may not contribute to the kinetics of the entire tracheal epithelium. Indeed
the aggregation chimaera data supports the notion that the new cells arising from the
SMG positioned stem cell can only repopulate or maintain a relatively small area of
tissue. The question then arises of what of the rest of the remaining tracheal tissue. If
SMGs distribution is restricted in mice, how is the kinetics of the tissue regulated
when a SMG is not in the vicinity?
There are a number of possible solutions to this problem. Firstly, that as outlined in
section 7.2, the basal cells act as the main progenitor cell type in areas with few or
no SMGs. This explanation would seem to suggest that there are no cells possessing
classic stem cell features beyond the confines of the SMGs. A complementary
observation is the slight increase in the number of Clara cells in the distal trachea as
opposed to the proximal trachea (Pack, 1981). The proliferative capacity of Clara
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cells in the human bronchiole has been well characterised (Evans, 1976b) and
perhaps they too play a role in regulating cellular kinetics in the mouse trachea and
therefore are more common in areas with fewer SMGs. There is at this time no data
for this last notion. It would be very interesting to make an EM study of the epithelial
cell types lying between SMG ducts to see if there is an increase in Clara cells
beyond zone 3.
A Model For The Development And Kinetic Role Of SMGs
From the evidence presented in sections 7.3 and 5.2 can be used to present a model
of the development and kinetic role of SMGs in the mouse. This model is
particularly interesting in that two progenitor cell populations are present. Firstly, the
progenitor cell which goes to clonally produce SMGs and secondly the stem cells
which feed the local epithelium with new cells. Such a model presents much scope
for further examination of the regulation and control of phenotypic differentiation
and branching. This model is presented in figure 7.3.11.
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Figure 7.3.11
A Model Of Stem Cells And TAC Kinetics In And Surrounding Mouse Submucosal
Glands
1: Progenitor



















Implications For Gene Therapy: The Targeting Of The Stem Cell?
This chapter has described the existence of possible stem cells lying within the
ciliated ducts of murine SMGs. As were the arguments voiced in chapter 5, the
targeting of the tracheal stem cell for gene therapy would hopefully result in the long
term expression of the transgene in multiple cells (the stem cell's progeny).
Before the technical aspects of targeted gene therapy for the tracheal stem cell are
considered, it is worthwhile examining once more the fundamental assumption of
gene therapy for CF. That assumption being that genotypic correction of pulmonary
epithelial cells will result in a down stream reduction in disease phenotype in the CF
patient. The area of weakness in this argument is that the epithelium appears to
express CFTR at very low levels (Engelhardt, 1994) so may no necessarily be
important in the maintenance of the healthy lung. Targeting gene therapy at the
tracheal stem cell would also potentially suffer from this weakness although not to
the same extent as the MRC or "flask like cells" within zone 1 which are known to
express CFTR. Although the tracheal stem cells appear to lie in the same region as
these cells, their identity cannot be confirmed at this time.
Targeted gene therapy relies on their being a recognisable molecular marker on the
target cell. The most attractive candidate for such a marker for the tracheal stem cell
would most probably lie in the cytokeratin family. The cytokeratins are a family of
structural proteins whose members are often expressed in a cell type specific manner
(Randell, 1992). For instance, basal cells express cytokeratin 18 whilst columnar
cells express cytokeratin 14 (Shimizu, 1992). Recently Scott Randell's group,
University of North Carolina, generated a transgenic mouse in which the cytokeratin
5 promoter has been linked to the green fluorescent protein gene. Tissues normally
expressing cytokeratin 5 are seen to fluoresce. Preliminary data has shown that the
pattern of fluorescence in the tracheal epithelium is one of expression in a sub
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population of basal cells and also in the ciliated duct of the SMGs. This work is at
present unpublished but is very exciting since cytokeratin 5 could prove to be a
useful and possible marker for the tracheal stem cell population.
In conclusion, a population of heavily stained BrdU label retaining cells were
observed to lie in a discrete niche in the ciliated ducts of murine SMGs. Further
LRCs of weaker staining profile were observed higher in the ciliated ducts and on
the surrounding epithelium. These data when modelled against current stem cell
theory suggest that the LRCs in the ciliated ducts may have stem cell properties. It is
hoped that functional studies of isolated populations of these cells in the future may







A Summary Of The Findings Of This Thesis Is Presented Below
Chapter 2:
• SMGs are present in the mouse
• Murine SMGs show great similarity to those in the human with regard to cftr
expression, lysozyme production and cell types.
• Murine SMGs, unlike in humans, are spatially restricted to the more proximal
end of the trachea
Chapter 3:
• SMG distribution in SPF inbred mice can be significantly affected by the
genetic background of the mouse
• SMG distribution in SPF inbred mice can be significantly affected by CFTR
expression in the mouse
• The differences in SMG distribution led to the generation of a model which may
undermine the traditional conclusions derived from single point
electrophysiology measurements in the mouse trachea.
Chapter 4:
• Both human the mouse p-defensin-1 molecules show a salt sensitive pattern of
anti microbial activity with respect to the bacteria P. aeruginosa
• The clinical significance of this finding is unclear as the there have not been any
definitive results regarding chloride concentrations in the CF and non CF lung.
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Chapter 5:
• Murine SMG develop postnatally.
• Murine SMG are clonally derived from a single cell.
Chapter 6:
• Liposome mediated delivery of transgene to the mouse tracheal epithelium
resulted in transfection of epithelial cells and low levels of transgene expression.
• Liposome mediated gene therapy, unlike adenovirus mediated, does not show
increased tropism to damaged epithelium.
Chapter 7:
• The mouse tracheal epithelium is largely quiescent in steady state with respect to
cellular turnover.
• Little difference of statistical significance was observed in the rate of cell
proliferation in CF versus non CF mice and in mice from different housing
conditions suggesting that spontaneous lung disease in CF mice is limited.
• Basal cells are most likely to be the cell type of major proliferative capacity in
the mouse trachea.
• Cells with the characteristics of stem cells exist in the ciliated ducts of mouse
SMGs producing transit amplifying populations which migrate out and maintain




Modern CF research draws upon many different fields of science and clinical care.
Starting from the fundamentals, Pathologists observe what is abnormal in CF tissues.
In the molecular corner of the field, there is the research into the genetics of the
CFTR gene and the elusive promoter. The physiology researcher asks how CFTR
functions in the body, how it is regulated and how it interacts with other proteins.
As we approach more clinically orientated areas of research, the fields of
bacteriology becomes more prominent: what bacteria affect CF patients and why.
Further up this ladder, the patients are encountered and with this, clinical and
nursing staff in addition to physiotherapists, nutritionists and councillors become of
greater importance.
The paths to a possible cure are most commonly aimed at interrupting a specific step
of disease progression. However, such research most commonly draws upon the
wisdom from a many fields and often is seen to jump across the full extent of the
spectrum. It may not therefore be altogether surprising that the original notion that
gene therapy could bypass the prerequisite of understanding the underlying
pathophysiology of CF has been largely disproved.
Gene therapy research has now become spread through a wide range of fields one of
which is the kinetics of the target organ, the lung airway. This thesis aimed to further
the understanding of the kinetics of the tissues in the trachea with a view to making
possible more efficient systems of gene therapy. The mouse was chosen as a
candidate animal model for use throughout this experiment for both practical reasons
and also for the expertise and resources with respect to the transgenic CF mouse
models.
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In preparation for the more kinetic based experiments it was important to have first
established that the mouse would provide an adequate model for studying tracheal
kinetics. Although a number of previous studies had shown that the same cell types
were present in the mouse and the human trachea, they had also shown that these cell
types were present in different frequency. The largest number of uncertainties
regarding the suitability of the mouse as model were in connection to the SMGs.
Very little had been previously published on mouse SMGs and what there was
appeared to discount their physiological relevance on grounds of the sparcity of
SMGs in the mouse. It is widely thought that SMGs are considered important in the
pathophysiology of CF and therefore, it was of primary importance to examine for
the presence and nature of murine SMGs.
Mouse SMGs were found largely localised to the proximal end of the trachea of the
C57BL/6 and MF1/129 mice. This was in contrast to humans in which SMGs are
found distributed throughout the trachea and the bronchi but interestingly reflects
SMG distribution in human airway of similar diameter as the mouse (proximal
bronchioles). The mouse SMGs were observed to be similar to the human glands in
many important ways. Firstly, structurally, murine SMGs possess the same pattern of
ductal system and of cell types as in humans. Secondly, they too secrete mucus out
on the airway lumen and express lysozyme and CFTR from the serous cells. From
this evidence it was concluded that the mouse trachea could be used to adequately
model the pulmonary airways of the human for these studies.
It was interesting to re-examine the previous evidence that had led to the negative
reports concerning the mouse's suitability as a model for the human CF lung
(Widdicombe, 1994). It is argued that this is most likely due to sampling errors of the
mouse trachea as it is can be quite possible, through inadequate dissection, to miss
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the glandular region. It is hoped that the work presented in this thesis will act to
revitalise interest in the mouse as a model for CF lung disease.
Since early studies in the 1960's and 70's, it had been suggested that SMG
hyperplasia (increase in gland size) or hypertrophy (increase in number) may occur
in CF patients. This pattern has only recently been adequately numerically
demonstrated and confirmed (Yankaskas, unpublished). An investigation was
undertaken to analyse the differences, if any, in SMG biology in mice on different
genetic backgrounds. The restricted pattern of SMGs in the mouse provided a unique
opportunity to study the factors affecting SMG distribution. With respect to these
studies, it was possible to control the environmental influence on the data by using
mouse which were housed in a SPF facility. Furthermore, interfamilial variation was
restricted through the use of inbred mouse strains.
By a method of wholemount staining, SMG distribution was found to be
significantly affected by both mouse strain and genotype. Reduced CFTR expression
was observed to lead to more distal SMG distribution in the C57BL/6 and FVB mice
(the expansive wildtype SMG distribution of the BALB/c mice made the observation
in this animal difficult). This is an interesting observation that may suggest that
CFTR has in some way a developmental role to play in SMG development.
The exception to the protocol was the MFI/129 strain that was studied as it was the
original strain of the Cftr""'"GU mouse. This mouse is not housed under SPF
conditions and is on an outbred strain. However, this mouse showed the same pattern
as with the other mouse strains albeit in a pattern demonstrating greater variability
and less statistical significance. These data suggest that other modifier genes of
indeed environmental factors may also affect SMG distribution.
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It was quickly noted that the SMG distribution data closely reflected published
measurable differences in apparent CF phenotype in the different mouse strains.
Thus the screen for SMG distribution enlarged the scope of this line of investigation
from the examination of murine SMGs into the area of CF modifier genes. It can be
postulated, that the difference in gland number could in some way affect the
physiology of the trachea leading to the difference in CF phenotype. Yet, on further
investigation, these data led to the development of a model which suggested that the
method by which the differences in CF phenotype are measured (by single point
electrophysiology measurements) may be flawed. The model argues that the
electrophysiology technique is purely a reflection on SMG distribution. It has not
been adequately proven in this thesis that CFTR does have a direct developmental
influence on SMG therefore it cannot be said whether or not the SMG distribution,
which the electrophysiology measurements are likely to be measuring, is indeed a
measurement of CF phenotype.
In a collaborative effort with Dr. Donald Davidson, a study was made into one
possible theory of why bacteria so vigorously colonise the CF lung. This theory
describes the inactivation of antimicrobial defensin molecules in the CF lung as a
consequence of raised chloride levels in the ASF. This study may be seen as an aside
to the through strain of thought. However, as SMGs are the predominant site of
CFTR expression in the lung and therefore likely to contribute significantly to the
electrolyte maintenance of the ASF, this was considered an appropriate study to
make.
Raised chloride concentration was found to statistically limit the antimicrobial
activity of both the human p-defensin-1 peptide and its murine homologue against
the clinically relevant bacteria P. aeruginosa. However, the relevance of this theory
as one of major significance in the development of CF lung disease is under
question. From the further studies of this system conducted by Dr. Donald Davidson,
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of salt dependent activity of the defensins were not found to be applicable to all
bacterial types. Indeed, B. cepacia appeared to positively prefer the environment
found hostile to P. aeruginosa suggesting that the defensin inactivation is not likely
to be the only reason for increased bacterial tropism. The variations in salt
concentration was also seen to affect bacterial survival in control solutions.
Overlying these doubts is the unproved primary assumption that CF airway surface
fluid is more salty than non CF. This issue will be brought to a head in the 1998
North American CF conference where two prominent CF scientists are speaking
back to back on this very issue each with opposing points of view.
The finding that murine SMGs expressed CFTR and produced mucus led onto the
question of whether SMGs can be targeted for genotypic correction with gene
therapy. It was however considered unlikely that the traditional system of aerosol
delivered gene therapy would accomplish this due to the efflux of mucus from the
glands. One alternative approach was to investigate the development of SMGs,
through which, it was hoped, that a more accessible progenitor cell population could
be identified.
In order to study in vivo SMG development, aggregation chimaeric mice were
generated. The transgenic cell contribution to SMGs was studied which led to the
development of a model which suggested that murine SMGs are clonally derived
from a single cell type. This cell is most likely, on the basis of previous human and
ferret studies, to be located on the airway epithelium. Murine SMGs develop in early
postnatal life, this being in contrast to human SMGs which develop in the foetus. In
either species, the timing of SMG development presents an additional technical
problem. Although it would appear that the SMG progenitor cell population exists on
the airway epithelium, these cells would have to be targeted prior to SMG formation,
i.e. in the foetus. Although protocols for in utero gene therapy have been previously
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reported, attempts as repeat these results in this thesis using liposome vectors proved
largely unsuccessful.
Gene therapy delivery of a measurable transgene to the mature airway epithelium
was also conducted. This study was performed to firstly make a basic study of the
efficiency of liposome mediated in vivo gene therapy to the mouse lung and
secondly to investigate whether liposomes exhibited any particular tropism to cell
types which may prove useful in future cell targeting experiments. Liposomes were
found to successfully deliver transgenic DNA into the cells of the tracheal
epithelium however, levels of expression were low. After polidocanol induced
damage of the trachea, a protocol which removed the layer of columnar cells from
the epithelium but leaves basal cells, no increased levels of transfection of
expression were measured.
In a comprehensive study of the kinetics of the mouse trachea, data was produced
which described the varying proliferative roles of some of the main cell types found
in the mouse tracheal epithelium. In the steady state trachea in areas where SMGs
are not present, basal cells were found to be of greatest proliferative significance.
Evidence was provided to suggest that infact 2 types of basal cells are present. Type
1 basal cells produce only basal cells whilst type 2 basal cells produce the columnar
cell types. It was acknowledged that such studies are inherently difficult and prone to
statistical misinterpretation due to the quiescent nature of the tissue but efforts were
made to avoid the main areas of error, as highlighted by previous publications.
In collaboration with the CF Center in UNC-Chapel Hill, NC, USA, a study was
made to investigate whether cells possessing classic "stem-cell" features were
present in the mouse trachea. Stem cell are defined as cells of poor physiological
functionality but infinite proliferative capacity and have been identified in many
tissues including the skin, tongue, gut and the cornea. A classic way in which to
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study the presence of these cells is to examine a diverse population of cells in vivo
with respect to the way in which they retain nuclear labelling through detection
methods such as immunohistochemistry or autoradiography. The theory behind such
experiments is that if stem cells are nuclear labelled (BrdU or tritiated thymidine) at
the time of division, they will retain their labelling characteristics longer than other
labelled cells as stem cells divide or die less frequently. This experimental design
has been used successfully to identify stem cell populations in a variety of other
tissues but had not ever been used for studying the trachea. The main reason for this
is that the lung has a very slow rate of cellular turnover making it unlikely that a
stem cell population would not be dividing and thus, not marked by nuclear
labelling. This may seem to remove the trachea from the scope of this experimental
design but as a study on the cornea of rabbits demonstrated, the stem cell population
can be induced into cellular division by artificially damaging the tissue.
An experiment was therefore designed in which the trachea of mice were repeatedly
damaged over a 4 week period by either polidocanol solution of SCb inhalation. Over
this same period, mice repeatedly received injections of BrdU. Once this period had
ended, groups of mice were sacrificed at different time periods and the labelling
profiles of the trachea were examined.
This experiment provided data which suggested that a stem cell population existed in
a discrete niche in the base of the ciliated duct of submucosal glands. These stem
cells divide to produce populations of transit amplifying cells which migrate up onto
the epithelium thereby repopulating or maintaining the cellular population of the
tracheal epithelium. The area over which the stem cells were observed to function
was however finite and restricted to areas surrounding ciliated ducts. It may be that
in other regions, the basal cells may provide the source for new epithelial cells.
Evidence is also provided that this same system occurs in the steady state trachea.
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8.3
Thoughts for the Future
It is hoped that the work presented in this thesis will help to both re-vitalise some
pre-existing areas of research and generate some new areas of research.
With regard to pre-existing areas of research, the data reported with reference to the
SMGs of the mouse will hopefully regenerate interest in the mouse as a useful model
for studying the human lung and to reinforce the credibility of research using the CF
mouse models.
One areas of particular interest for future research is the observations regarding the
genetic factors affecting SMG distribution. It is very exciting to suggest that this
phenotype may demonstrate a novel link into the field of CF modifier genes. Firstly
though, the hypothesised link between single point electrophysiology results and
SMG distribution requires to be clarified. This will hopefully take place soon once
protocols are aligned so that the tracheal tissue can be used for both purposes.
Directly or independently to this, the role of SMG distribution in CF phenotype
requires to be addressed which will hopefully strengthen the link between SMG
biology and the study of CF. This work would further validate the case for
beginning to explore the modifier genes for SMG distribution question. It would
exciting to study whether the CF modifier genes as proposed by Rozmahel et al.
(1996)were associated with the SMG modifier genes.
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The suggestion from these data that CFTR is in somehow operating as a gene with
developmental influence suggests an exciting new area of research. This question
could be explored by developing CF aggregation chimaeras (as described in chapter
3) if mouse resources permitted.
It is interesting to now return to the original question of why do CF mice not
spontaneously develop CF lung disease? In the introduction, 5 possible scenarios
were presented which though not mutually exclusive, could be used as a the basis for
explaining the difference in murine-human CF pathophysiology. The evidence
presented in this thesis may in part answer the question of suitable homology
between SMGs but has highlighted the differences in SMG distribution. It is
puzzling to consider just how the mucus produced in the murine SMGs act in the
defence of the lung for it would appear that the mucus would only be present high up
in the trachea and not be present lower down where bacteria must also reach. If the
basis for this argument is true it would appear more likely that the mice with fewer
SMGs would be normally more susceptible to lung infections that those with more
distal SMG distribution although there is no experimental evidence to back this up.
It is not yet known from which cells the (3-defensin molecules are produced in the
mouse lung. It is very possible that if they are produced from epithelial cells and the
main cause of possible chloride imbalance in the lung is as a results of defective cftr
in the mouse SMGs that mice with few SMGs may not suffer from the same degree
of defensin inactivation as mice with many SMGs. This argument is in itself reliant
on the understanding of the movement of mucus through the lung airways: a field
which is also under much review at this time.
Therefore, just why the mouse deficient of cftr appears to develop lung disease in a
different fashion to that of the human still remains unclear. Indeed, the answer may
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lie far from this field, lying perhaps with the variation in alternative pulmonary
chloride channels observed between humans and mice.
It is hoped that through the data presented in this thesis, that the whole question of
the kinetics of the cartilaginous airway is slightly closer to answering. The data
regarding the significant proliferative role of basal cells in the mouse trachea may
lead directly to our further kinetic understanding of the tissue although reinforces the
need for studying the possible existence of 2 types of basal cells.
The proposed model of stem cell activity in the mouse trachea opens many far more
doors than it itself shut. Firstly, this experiment requires to be repeated, perhaps with
tritiated thymidine instead of BrdU to remove any doubt of the label retaining
characteristics of these cells. Then the question arises, what of these cells. What do
these cells look like? Can we characterise them further? Do molecular markers exist
for these cells? On the last point, there are studies underway which suggest that
cytokeratin 5 may be a reliable marker. It would also be very interesting to make a
closer study into the area of epithelium which is under stem cell control for it was
observed that the stem cell appears to only have the ability to control cellular
population over a small finite area of epithelium. It would be an interesting, if
technically difficult, study to examine local variations in cell type frequency between
SMG ducts to examine whether the stem cell regulated "islands" vary in cell type
than compared to the "water" between them. It is certainly true that a more
functional approach will eventually be required to classify these cells truly as stem
cells.
Isolation of the two types of progenitor cells found in the SMGs (tracheal stem cells
and SMG progenitor cells) would be an obvious extension to this study. This could
lead to the possibilities of ex vivo gene therapy approaches (as seen using the gut) or
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developmental studies into the regulation of SMG growth and branching as well as
studies into factor affection hypertrophy and hyperplasia.
Returning to the original aims of this thesis, the possibility of targeting progenitor
cell populations in the upper airways for gene therapy correction is slightly closer to
reality. Attempts were made (though not reported in this thesis) to deliver gene
therapy vectors to E12-E16 mouse embryos with the hope that transfection at this
early stage would target the developing submucosal gland precursor cells. The
experiments were largely unsuccessful showing only very low levels of transfection.
Progenitor cell populations have been at least shown to exist in the mouse trachea
although we still have many long paths to explore before we can turn this knowledge





The inbred mouse strains used in this thesis are a few of the 447 strains currently
recorded. Details of the inbred mice strains used are presented below.
CBA
Colour: Agouti
History: Developed in 1920 from a cross between a Bagg albino female and a DBA
male. Inbred at source for between 90-179 generations depending on substrain.




History: 3 major substrains (HeAn, J, Rl) trace back to before 1940 probably
diverging due to mutation or residual heterozygosity rather than genetic
contamination.
Phenotypes: Good breeding and long reproductive life-span .Low tumour incidence.




History: Founded 1937 as a substrain of the C57BL (founded 1921). Inbred for
more than 150 generations.
Phenotypes: High preference to alcohol, susceptible to aortic lesions, low plasma




History: Oldest of all inbred mice. Founded 1909 from stock segregated on coat
colour.
Phenotypes: High sensitivity to seizures.
FVB
Colour: albino
History: Originated in 1935 from outbred stocks and further selected for resistance to
histamine in 1966 prior to inbreeding.
Phenotypes: High reproductive performance producing large litters. Fertilised eggs
used widely for DNA microinjection.
311
Appendix 2
Numerical Data From Chapter 7.3
Ref set day position 1 position 2 position 3
b bm c cm b bm c cm b bm c cm
S5 1 3 - - - - - -
S6 1 3 43 62 21 106 39 104 3 78 54 143 16 100
S7 1 3 62 142 46 126 30 100 15 95 60 123 19 100
S8 1 3 34 104 16 66 35 115 6 86 16 76 5 85
P5 1 3 2 100 0 100 2 100 0 100 4 100 1 100
P6 1 3 3 100 1 100 4 100 0 100 1 100 1 100
P7 1 3 0 100 0 100 4 100 3 100 4 100 1 100
Pc2 1 3 0 100 0 100 0 100 0 100 0 100 0 100
Bnd2 1 3 4 100 0 100 2 100 2 100 3 100 4 100
S5 2 3 36 100 34 100 46 100 41 100 31 100 17 100
S6 2 3 42 100 46 100 31 100 26 100 27 100 24 100
S7 2 3 44 100 46 100 39 100 43 100 36 100 31 100
S8 2 3 26 100 30 100 18 100 14 100 21 100 16 100
P6 2 3 19 100 5 100 6 100 3 100 5 100 1 100
P7 2 3 7 100 2 100 9 100 7 100 1 100 1 100
Pc2 2 3 0 100 0 100 0 100 0 100 0 100 0 100
Bnd2 2 3 3 100 0 100 2 100 0 100 4 100 0 100
S9 1 6 32 100 17 100 35 100 13 100 29 100 1 100
S10 1 6 24 100 9 100 34 100 14 100 41 100 6 100
S11 1 6 40 100 21 100 42 100 16 100 37 100 7 100
S12 1 6 35 100 11 100 24 100 7 100 30 100 4 100
P9 1 6 3 100 0 100 5 100 1 100 1 100 0 100
P10 1 6 4 100 0 100 5 100 0 100 1 100 0 100
P11 1 6 7 100 0 100 3 100 0 100 0 100 0 100
P12 1 6 18 100 3 100 15 100 7 100 11 100 2 100
Pc3 1 6 0 100 0 100 0 100 0 100 0 100 0 100
Bnd3 1 6 2 100 0 100 0 100 0 100 0 100 0 100
S9 2 6 15 100 20 100 14 100 9 100 16 100 10 100
S10 2 6 31 100 17 100 27 100 10 100 25 100 11 100
S11 2 6 22 100 9 100 14 100 10 100 16 100 9 100
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